paclitaxel has been researched along with Local Neoplasm Recurrence in 1342 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 95 (7.08) | 18.2507 |
| 2000's | 487 (36.29) | 29.6817 |
| 2010's | 555 (41.36) | 24.3611 |
| 2020's | 205 (15.28) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, R; Bookman, MA; Coleman, RL; Fuh, KC; Herzog, TJ; Liu, JF; McIntyre, G; Monk, BJ; Moore, KN; Rangwala, R; Thaker, PH | 1 |
| Kang, JH; Ko, YT; Kwon, YJ; Lee, DS; Turabee, MH | 1 |
| Bēma, D; Bērziņš, J; Buiķis, I; Freivalds, T; Harju, L; Miķelsone, I; Patetko, L; Simsone, Z | 1 |
| Kirita, T; Kurita, H; Matsumura, T; Naruse, T; Okura, M; Ota, Y; Otsuru, M; Sasaki, M; Shintani, Y; Umeda, M; Yamada, SI; Yamakawa, N; Yanamoto, S | 1 |
| Alonso-Ovies, A; Cabezas-Camarero, S; Cabrera-Martín, MN; Merino-Menéndez, S; Pérez-Segura, P; Plaza-Hernández, JC | 1 |
| Abdeddaim, C; Clatot, F; Even, C; Guiard, E; Johnson, A; Perréard, M; Rambeau, A; Vauléon, E | 1 |
| Ak, R; Aksoy, S; Aktas, BY; Bas, O; Diker, O; Dizdar, O; Guven, DC; Kertmen, N; Koylu, B; Oksuzoglu, B; Olgun, P; Taban, H | 1 |
| Chiu, CC; Hou, MF; Hsieh, TH; Hsu, CY; Kan, JY; Liang, SS; Ou-Yang, F; Tsai, EM; Wang, TN; Yang, PJ | 1 |
| Chen, Y; Ding, X; Feng, G; Huang, Y; Lin, L; Ma, S; Wang, R; Xu, R; Yang, Y; Zhang, C; Zhang, L; Zhou, T | 1 |
| Barrios, C; Bondarenko, I; Dent, RA; Hinton, H; Isakoff, SJ; Kim, SB; Kovic, B; Lian, Q; Mani, A; Nowecki, Z; O'Shaughnessy, J; Oliveira, M; Reilly, SJ; Saji, S; Turner, N; Wongchenko, MJ | 1 |
| Feng, T; Li, C; Mei, Y; Shi, M; Yan, C; Yan, M; Yuan, H; Zhang, J; Zhu, Z | 1 |
| Fiegl, H; Hackl, H; Haschka, MD; Karbon, G; Parson, W; Rocamora-Reverte, L; Soratroi, C; Villunger, A | 1 |
| Chen, J; Liu, A; Shi, B; Shi, Y | 1 |
| Chen, T; Chen, X; Cheng, W; Huang, Y; Jiang, Y; Nie, X; Zhong, Y | 1 |
| Clarke, A; Day, E; de la Rosa, CN; Fiorentino, F; Krell, J; Reddi, M; Webber, L | 1 |
| Bellon, JR; Burstein, HJ; Dang, CT; DeMeo, M; Isakoff, SJ; Krop, IE; Partridge, AH; Tayob, N; Tolaney, SM; Tralins, J; Winer, EP; Yang, DD | 1 |
| Inoue, Y; Ito, H; Kato, T; Oba, A; Ono, Y; Sato, T; Shigematsu, Y; Suzuki, T; Takahashi, Y; Ushida, Y | 1 |
| Hwang, WY; Kim, JH; Kim, K; Kim, YB; Lee, M; No, JH; Suh, DH | 1 |
| Alvisi, MF; Benedetti Panici, P; Biagioli, E; Bologna, A; Carlucci, L; Colombo, N; DeCensi, A; Fossati, R; Lapresa, M; Lissoni, AA; Mancari, R; Nicoletto, MO; Palaia, I; Poli, D; Rulli, E; Tasca, G; Tettamanzi, F; Tognon, G; Tomao, F; Torri, V | 1 |
| Arak, H; Bayram, S; Besen, AA; Bilici, A; Bozkurt, O; Coskun, HS; Dae, SA; Geredeli, C; Goktas Aydin, S; Ilhan, Y; Inanc, M; Kaplan, MA; Karaagac, M; Kargi, A; Korkmaz, M; Kose, F; Onder, AH; Oruc, Z; Ozdogan, M; Ozturk, B; Selvi, O; Sezgin Goksu, S; Tatli, AM; Teker, F | 1 |
| Hagiwara, Y; Hyodo, I; Ikoma, T; Kajiwara, T; Kurioka, Y; Matsumoto, T; Moriwaki, T; Nakasya, A; Nishina, T; Tsuduki, T; Yamamoto, Y; Yamashita, N | 1 |
| Fukuda, S; Fukumitsu, K; Horiuchi, M; Ito, Y; Kagawa, Y; Kanemitsu, Y; Maeno, K; Niimi, A; Oguri, T; Ohkubo, H; Sone, K; Tajiri, T; Takakuwa, O; Takemura, M; Uemura, T | 1 |
| Al-Wahsh, H; Ferraiuolo, RM; Fifield, BA; Gupta, R; Hamm, C; Hussein, A; Kay, A; Kulkarni, S; Mailloux, E; Mathews, J; Porter, LA | 1 |
| Adamchuk, GA; Fadeeva, NV; Kalloli, M; Kryukov, F; Matrosova, MP; Nagarkar, R; Roy, B; Shelepen, KG; Shustova, MS; Stroyakovskiy, DL; Voevodin, GD; Zhuravleva, D | 1 |
| Chen, T; Chen, X; Cheng, W; Jiang, Y; Nie, X; Zhong, Y | 1 |
| Kataoka, K; Kimura, T; Kondoh, Y; Matsuda, T; Morise, M; Oi, H; Yamano, Y; Yokoyama, T | 1 |
| Fu, C; Yang, X | 1 |
| Arai, R; Ikeda, N; Inoue, T; Kushima, Y; Masawa, M; Nakamura, Y; Niho, S; Okutomi, H; Shimizu, Y; Soda, S; Takemasa, A; Uchida, N | 1 |
| Badau, LM; Ciocoiu, AD; Gheju, A; Oprean, CM; Segarceanu, NA; Vlaicu, B | 1 |
| Cao, KJ; Chen, MY; Chen, QY; Chen, ZJ; Guo, L; Guo, X; Hu, D; Hua, YJ; Huang, PY; Ke, LR; Li, WZ; Liang, H; Liu, GY; Liu, T; Lu, N; Luo, DH; Lv, SH; Lv, X; Mai, HQ; Mo, HY; Qian, CN; Qiu, F; Sun, R; Tang, LQ; Tang, WB; Tong, LH; Wang, DS; Wang, L; Xia, WX; Xiang, YQ; Yang, W; Ye, YF; Yuan, TZ; Zhang, HX; Zhao, C | 1 |
| Di Fabio, F; Filippini, DM; Mosca, M; Rihawi, K; Rojas, FL; Tober, N | 1 |
| Sugarbaker, PH | 1 |
| de la Rosa, CN; Fiorentino, F; Krell, J; Webber, L | 1 |
| Augustin, D; Braun, M; Christgen, M; Fischer, HH; Forstbauer, H; Gluz, O; Graeser, M; Grischke, EM; Harbeck, N; Kates, R; Krauss, K; Kreipe, HH; Kuemmel, S; Nitz, U; Pelz, E; Potenberg, J; Reimer, T; Schumacher, C; Stefek, A; Wuerstlein, R; Zu Eulenburg, C | 1 |
| Fan, R; Li, J; Song, S; Sun, W; Tian, Y; Wang, R; Zhang, H; Zhang, T; Zheng, A | 1 |
| Bhatia, AK; Burtness, B; Deshpande, H; Forman, R | 1 |
| Baldassarre, G; Belletti, B; Manfioletti, G; Pegoraro, S; Pellarin, I; Piazza, S; Ros, G; Sgarra, R; Sgubin, M | 1 |
| Grabsch, HI; Guan, J; Masuda, M; Miyagi, Y; Oshima, T; Rino, Y; Sakamoto, J; Tan, P; Tanaka, S; Tsuburaya, A; Yoshida, K; Yoshikawa, T | 1 |
| Chang, TC; Chao, CC; Huang, SL; Kohli, A; Sun, NK | 1 |
| Eng, C; Jácome, AA; Morris, VK | 1 |
| Allard, M; Bastida-Ruiz, D; Cohen, M; Dietrich, PY; Petignat, P; Yart, L | 1 |
| Camejo, HS; Heffernan, K; Knott, C; Nikitas, FS; Shukla, U | 1 |
| Hara, H; Hashimoto, K; Jiromaru, R; Komune, N; Kuratomi, Y; Manako, T; Masuda, M; Matsuo, M; Nakagawa, T; Nishimura, E; Takeuchi, T; Toh, S; Wakasaki, T; Yamauchi, M; Yasumatsu, R | 1 |
| Berger, J; Boisen, M; Buckanovich, R; Coffman, LG; Courtney-Brooks, M; Edwards, RP; Frisbie, LG; Griffith, K; Lesnock, J; Liu, T; Mahdi, H; McLean, K; Normolle, D; Olawaiye, A; Orellana, TJ; Sukumvanich, P; Taylor, SE; Uppal, S | 1 |
| Cai, J; Chen, L; Huang, Y; Sun, S; Wang, Z; Xiong, Z; Yang, L; Zhao, J | 1 |
| Agar, N; Blessing, WA; Colby, AH; Colson, YL; Digesu, CS; Grinstaff, MW; Hachey, KJ; Korunes-Miller, JT; Kumar, A; Liu, R; Mahvi, DA; Raut, CP; Regan, MS; Shih, A; Tal-Mason, A | 1 |
| Kii, T; Sakuma, K; Tanaka, A; Yoda, M | 1 |
| Aoyama, T; Chin, K; Hama, T; Kawaguchi, M; Kawakami, K; Takahari, D; Tomomatsu, T; Yamaguchi, K; Yamaguchi, M | 1 |
| Chen, JR; Hung, SM | 1 |
| De Cuypere, M; Gennigens, C; Jerusalem, G; Kridelka, F; Lapaille, L; Ray-Coquard, I; Streel, S | 1 |
| Chen, M; Ge, X; Liu, J; Ma, Q; Tang, Y; Wen, Q; Zhang, L; Zhao, M; Zhu, L | 1 |
| Gao, X; Guan, W; Li, X; Liu, H; Wang, C; Wang, F; Xu, G; Xu, X; Yuan, J; Zhang, J | 1 |
| Choi, KH; Kim, CW; Kim, SM; Kim, SY; Lee, JH; Lim, JH; Pan, CH; Park, K; Park, KC; Weicker, R; Yun, HJ | 1 |
| Hiranuma, O; Iwasaku, M; Katayama, Y; Matsui, Y; Morimoto, K; Morimoto, Y; Shiotsu, S; Takayama, K; Takeda, T; Tamiya, N; Tokuda, S; Yamada, T | 1 |
| Besch, BM; Henson, C; Hsieh, ML; Peterson, JEG | 1 |
| Andou, M; Furuse, J; Kitamura, H; Nagashima, F; Nakazawa, J | 1 |
| Aoki, D; Makker, V; Monk, BJ; Nogueira-Rodrigues, A; Rubinstein, M; Sehouli, J; Shen, S; Tan, DSP | 1 |
| Chen, JL; Gao, FF; Liu, NF; Sui, XC; Tang, YD; Zhang, TT; Zhang, XL | 1 |
| Akhmedzhanov, F; Brink, AL; Carter, B; Coleman, RL; Fu, S; Gershenson, D; Gong, J; Hong, DS; Jazaeri, A; Leung, CH; Lin, H; McQuinn, L; Meric-Bernstam, F; Naing, A; Pant, S; Piha-Paul, S; Shah, J; Sood, AK; Tsimberidou, A; Westin, SN; Yilmaz, B | 1 |
| Caner, A; Cumaoğlu, A; Önal, MG; Sezer, G | 1 |
| Bhosale, P; Chisholm, GB; Flores-Legarreta, A; Frumovitz, M; Gonzales, NR; Hillman, RT; Jhingran, A; Ramalingam, P; Salvo, G | 1 |
| Ao, X; Cui, L; He, ZM; Jiang, M; Jin, H; Li, HS; Liang, HL; Qiu, N; Xia, HM; Zhan, YT; Zhou, J | 1 |
| Duarte, D; Nunes, M; Ricardo, S; Vale, N | 1 |
| Bodiwala, K; Khadela, A; Mansuri, M; Sureja, D; Vyas, B | 1 |
| Dasanu, CA; Goff, CB | 1 |
| Albers, D; Kasper, S; Kostbade, K; Laue, K; Liffers, ST; Markus, M; Markus, P; Maßmann, M; Mende, B; Pogorzelski, M; Reissig, TM; Roehrle, J; Rosery, V; Schildhaus, HU; Schmid, K; Schuler, M; Schumacher, B; Siveke, JT; Ting, S; Treckmann, JW; Virchow, I; Wendling, J; Wiesweg, M; Zaun, G | 1 |
| Asaka, S; Kono, T; Kuhara, K; Nishiguchi, R; Ohigashi, S; Okayama, S; Shimakawa, T; Shimojima, Y; Shiozawa, S; Usui, T; Yokomizo, H | 1 |
| Armstrong, DK; Arranz, JA; Coleman, RL; Fujiwara, K; Gabra, H; Ghamande, SA; González-Martín, A; Hanna, R; Herzog, TJ; Jia, Y; Monk, BJ; Pignata, S; Ramsay, L; Rubio, MJ; Scambia, G; Sehouli, J; Slomovitz, B; Tewari, KS; Ushijima, K; Vergote, IB; Vulsteke, C; Weil, SC; Wenham, RM; Zamagni, C | 1 |
| Boitano, TKL; Scarinci, IC | 1 |
| Albain, KS; Barroso-Sousa, R; Burstein, HJ; Carey, LA; Dang, CT; DeMeo, M; DiLullo, M; Ellis, MJ; Graham, N; Hudis, CA; Krop, IE; Marcom, PK; Moy, B; Parè, L; Partridge, AH; Prat, A; Rugo, HS; Shapira, I; Tarantino, P; Tayob, N; Tolaney, SM; Villacampa, G; Villagrasa, P; Wagle, N; Waks, AG; Weiss, J; Winer, EP; Wolff, AC; Yardley, DA; Zanudo, JGT | 1 |
| Christensen, L; Jones-Miller, S; Shammas, G; Shammas, NW | 1 |
| Auranen, A; Black, D; Boere, I; Buscema, J; Chase, DM; Cibula, D; Coleman, RL; Copeland, LJ; dePont Christensen, R; Gilbert, L; Gill, SE; Gold, MA; Hanker, LC; He, Z; Herzog, TJ; Landrum, LM; McCourt, C; Mirza, MR; Monk, BJ; Novák, Z; Pothuri, B; Powell, MA; Raspagliesi, F; Shahin, MS; Sharma, S; Slomovitz, BM; Stevens, S; Stuckey, A; Tian, M; Valabrega, G; Zografos, E | 1 |
| Bao, T; Dreyfus, N; Galantino, M; Kot, KL; Lessing, A; Li, S; Piulson, L; Zhi, WI | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shinohara, Y; Shirakawa, T; Taguchi, H; Ueda, Y; Ueno, S; Ureshino, N | 1 |
| Geng, A; Wang, Z; Wu, C; Yang, H | 1 |
| Erthal, LCS; Gobbo, OL; Ruiz-Hernandez, E; Shi, Y; Sweeney, KJ | 1 |
| Ishikawa, M; Kataoka, T; Kobayashi, H; Satoh, T; Shibata, T; Takekuma, M; Yaegashi, N | 1 |
| Asama, H; Hashimoto, M; Hikichi, T; Imamura, H; Irie, H; Kato, T; Konno, N; Nakamura, J; Noguchi, Y; Ohira, H; Okubo, Y; Sato, Y; Shibukawa, G; Sugimoto, M; Suzuki, R; Takagi, T; Watanabe, K; Yanagita, T | 1 |
| Aldana, M; Brunette-Masi, LL; Ciccone, MA; Dong, T; Facio, G; Garcia, AA; Garcia-Sayre, J; Groshen, SG; Lin, YG; Louie, S; Matsuo, K; Mhawech-Fauceglia, P; Muderspach, LI; Pham, HQ; Roman, LD; Tsao-Wei, DD; Yessaian, AA | 1 |
| Aksoy, S; Arslan, C; Basaran, G; Bilici, A; Cakar, B; Cicin, I; Cubukcu, E; Demirci, U; Erdem, D; Gumus, M; Harputluoglu, H; Kaplan, MA; Karadag, I; Karadurmus, N; Oksuzoglu, B; Olmez, OF; Selcukbiricik, F; Sendur, MAN; Sezer, A; Sezgin Goksu, S; Shbair, ATM; Sumbul, AT | 1 |
| Brem, H; Chakroun, RW; Chen, D; Chen, Z; Cui, H; Gorelick, N; Guan, Y; Hanes, J; Huang, Q; Monroe, MK; Serra, R; Su, H; Suk, JS; Sun, M; Tyler, B; Wang, F; Wang, H; Wang, Z; Zheng, M | 1 |
| Chang, TC; Huang, SL; Sun, NK | 1 |
| Braicu, EI; Casado, A; Debruyne, PR; Falcó, E; Ferrero, A; García-Martinez, E; Gennigens, C; Guerra-Alia, E; Kerger, J; Laenen, A; Lorusso, D; Muallem, MZ; Pignata, S; Rubio, MJ; Sehouli, J; Van Gorp, T; Van Nieuwenhuysen, E; Vergote, I; Wimberger, P; Zola, P | 1 |
| Akamatsu, H; Asao, T; Goto, Y; Ikeda, S; Kaira, K; Ko, R; Mimori, T; Mizutani, H; Mori, K; Shukuya, T; Sugawara, S; Suzuki, T; Tachihara, M; Takahashi, K; Takayama, K; Tanaka, H; Tanizaki, J; Tsubata, Y; Zenke, Y | 1 |
| Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ | 1 |
| Choi, KU; Kim, D; Kim, DK; Kim, JH; Kim, JS; Lee, SY; Shin, MJ; Suh, DS | 1 |
| Fukuda, N; Mitani, H; Nakano, K; Oki, R; Ono, M; Sato, Y; Suto, H; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yunokawa, M | 1 |
| Chen, L; Gelblum, D; Han, J; Hesse, J; Kang, JJ; Lee, NY; McBride, SM; Michel, L; Raab, G; Riaz, N; Shamseddine, A; Sherman, EJ; Tsai, CJ; Wong, RJ; Yu, Y; Zakeri, K | 1 |
| Bando, M; Fukuizumi, A; Gemma, A; Homma, S; Isobe, K; Izumi, S; Kishi, K; Koyama, R; Minegishi, Y; Omori, M; Sugiyama, H; Sugiyama, Y; Takahashi, K; Uruga, H | 1 |
| Akhlaghipour, I; Maharati, A; Moghbeli, M; Samsami, Y; Taghehchian, N | 1 |
| Kohn, N; Locke, M; Seetharamu, N | 1 |
| Akers, KG; Cortes, J; Fasching, PA; Frederickson, AM; Haiderali, A; Huang, M; O'Shaughnessy, J; Pan, W; Park, JE; Schmid, P | 1 |
| Akamatsu, H; Hida, T; Inui, N; Kang, JH; Kim, HR; Lee, JS; Lee, KH; Nakagawa, K; Nishio, M; Ohe, Y; Sugawara, S; Takahashi, S; Tamura, T; Tanaka, H; Yamamoto, N; Yang, CT; Yoshida, T; Yu, CJ | 1 |
| Bosiers, M; Bosiers, MJ; Callaert, J; De Donato, G; Deloose, K; Eckstein, HH; Giaquinta, A; Hendriks, J; Keirse, K; Maene, L; Navarro, T; Scheinert, D; Silveira, PG; Teβarek, J; Torsello, G; van den Eynde, W; Verbist, J; Veroux, P | 1 |
| Deng, X; Guo, S; Liu, L; Yang, S | 1 |
| Nara, K; Seto, Y; Suzuki, H; Takada, T; Yagi, K; Yamamoto, T; Yamashita, H | 1 |
| Maowulieti, G; Yuan, H; Zhao, M; Zhao, S | 1 |
| Enokida, T; Fujisawa, T; Hoshi, Y; Ishii, G; Okano, S; Onaga, R; Sakashita, S; Sato, M; Tahara, M; Takeshita, N; Tanaka, H; Tanaka, N; Wada, A | 1 |
| Dawson, MR; Ghosh, D; Hsu, J; Mejia Peña, C; Schechter, I; Skipper, TA | 1 |
| Akiyama, H; Endo, I; Kasahara, K; Kondo, H; Kosaka, T; Kunisaki, C; Sato, S; Sato, T; Tamura, Y; Yago, A | 1 |
| Schwendeman, SP | 1 |
| Biglietto, M; Calabrese, F; Caterino, M; Ciardiello, F; Conzo, G; De Vita, F; Laterza, MM; Molino, C; Orditura, M; Pappalardo, A; Petrillo, A; Pompella, L; Tirino, G; Ventriglia, A | 1 |
| Menon, R; Mensing, S; Nuthalapati, S; Ratajczak, CK; Shepherd, SP; Stodtmann, S; Xiong, H | 1 |
| Gou, M; Huang, M; Huang, Y; Kang, T; Li, Y; Liu, J; Wang, S; Wang, Y; Wei, X; Xiong, M; Yang, L; Zhu, J | 1 |
| Ando, K; Iwata, T; Mishima, H | 1 |
| Chen, J; Gu, W; Yao, H; Yin, W | 1 |
| Chen, H; Chen, K; Chen, Y; Fu, Z; Niu, Y; Shen, HM; Shi, Y; Sun, W; Wang, L; Wu, Y; Xia, D; Zhang, H; Zhu, J | 1 |
| Banerjee, S; Kelly, G; Khalique, S; Lord, CJ; Natrajan, R; Pettitt, SJ; Tunariu, N | 1 |
| Bennink, RJ; Biermann, K; Doukas, M; Gisbertz, SS; Krishnadath, KK; Lagarde, SM; Luyer, M; Meijer, SL; Neijenhuis, LKA; Nieboer, D; Nieuwenhuijzen, GAP; Nikkessen, S; Noordman, BJ; Oostenbrug, LE; Riedl, RG; Roef, MJ; Schoon, EJ; Sosef, MN; Spaander, MCW; Valkema, R; van Berge Henegouwen, MI; van der Gaast, A; van der Wilk, BJ; van Lanschot, JJB; van Lijnschoten, I; Wijnhoven, BPL | 1 |
| Adkins, DR; Daly, M; Gay, HA; Jackson, R; Johnson, KCC; Ley, J; Lu, J; Oppelt, P; Paniello, RC; Pipkorn, P; Rich, J; Thorstad, W; Zevallos, J | 1 |
| Arcieri, M; Ergasti, R; Fagotti, A; Marchetti, C; Palluzzi, E; Pietragalla, A; Rosati, A; Scaletta, G; Scambia, G | 1 |
| Chumsri, S; Colon-Otero, G; Gavin, PG; Li, Z; Mashadi-Hossein, A; Moreno-Aspitia, A; Paik, S; Perez, EA; Pogue-Geile, KL; Serie, DJ; Song, N; Thompson, EA | 1 |
| Farinas-Madrid, L; Grau, JF; Oaknin, A | 1 |
| Badola, S; Bahamon, B; Baik, C; Bedford, L; Belani, CP; Bryant, M; Byers, L; Chiang, AC; Chiappori, A; Chouaid, C; Csoszi, T; Czebe, K; Ecsedy, JA; Jaime, JC; Jones, S; Joy, AA; Kolek, V; Kong, EF; Leonard, EJ; Li, C; Majem, M; Mark, Z; Nackaerts, K; Niu, H; Ostoros, G; Owonikoko, TK; Patel, MR; Roubec, J; Santos, ES; Sheldon-Waniga, E; Shin, H; Simmons, J; Speranza, G; Spigel, DR; Ullmann, CD; Williams, M | 1 |
| Breda, E; Cecere, SC; Cinieri, S; Colombo, N; Conte, C; Ferrandina, G; Lapresa, MT; Lombardi, D; Lorusso, D; Maltese, G; Pietragalla, A; Pignata, S; Pisano, C; Sabatucci, I; Sabbatini, R; Savarese, A; Scambia, G; Sonetto, C; Tagliaferri, P | 1 |
| Lu, J; Song, J; Yang, P | 1 |
| Alvarez Secord, A; Armstrong, DK; Basen-Engquist, K; Brady, MF; Casey, AC; Chan, JK; Cohn, DE; Coleman, RL; Davidson, SA; DiSilvestro, P; Enserro, D; Fujiwara, K; Herzog, TJ; Huang, HQ; Kim, BG; Kim, JW; Mannel, RS; Nam, JH; Park, SY; Rubin, S; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL | 1 |
| Lassaletta, A; Madero, L; Moreno-Tejero, ML; Pelaez, I; Perez-Somarriba, M; Rozas, MI | 1 |
| Bajorin, D; Bellmunt, J; Enokida, H; Frenkl, T; Fujimoto, K; Fukasawa, S; Imai, K; Nishimura, K; Nishiyama, H; Perini, R; Sassa, N; Shimamoto, T; Takahashi, K; Tanaka, Y; Yamamoto, Y; Yokoyama, M | 1 |
| Ahmed, M; Bissessur, R; Kabir, A; Nazeer, N | 1 |
| Faggioni, L; Gadducci, A; Manassero, F; Selli, C; Tognarelli, A | 1 |
| Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B | 1 |
| Biasoni, D; Bisogno, G; Boldrini, R; Conte, M; Crocoli, A; D'Angelo, P; Dall'Igna, P; De Pasquale, MD; Inserra, A; Miele, E; Siracusa, F; Spreafico, F; Terenziani, M | 1 |
| Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D | 1 |
| Chang, HK; Chang, SJ; Han, SS; Kim, DY; Kim, HS; Kim, J; Kim, S; Lee, JW; Lee, KH; Park, SJ; Park, SY; Shim, SH | 1 |
| Bivona, C; Grauer, D; Henry, D; Mahmoudjafari, Z; Martin, G; Murphy, M | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Burger, R; Coleman, RL; Handley, KF; Molin, GZD; Moore, KN; Sood, AK; Stagg, R | 1 |
| Barra, F; Bifulco, G; Della Corte, L; Evangelisti, G; Ferrero, S; Foreste, V; Giampaolino, P | 1 |
| Chang, TC; Chen, WC; Chou, HH; Huang, HJ | 1 |
| Bae, DS; Bae, JH; Choi, CH; Choi, HJ; Kim, BG; Kim, TJ; Lee, JW; Lee, YY | 1 |
| Marnitz, S; Waltar, T | 1 |
| Adorni, M; Cosio, S; Ferrero, AM; Gadducci, A; Landoni, F; Lissoni, AA; Sartori, E; Zizioli, V | 1 |
| Bun, S; Kato, MK; Kato, T; Miyasaka, N; Shimoi, T; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
| Aleohin, N; Elyashiv, O; Levy, T; Migdan, Z; Peled, O; Tal, O | 1 |
| Sadamitsu, T; Tanaka, T; Ueda, T; Yokoyama, T; Yoshimura, A | 1 |
| Chino, S; Chuman, M; Ema, A; Hiki, N; Kondo, Y; Kubo, H; Naito, M; Nakamura, K; Nishi, Y; Takahashi, Y; Tokito, T; Ushiku, H | 1 |
| Li, Q; Liao, W; Wang, F; Wang, X; Wu, Q; Zhang, M | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Asano, H; Ihira, K; Kato, T; Kobayashi, N; Konno, Y; Kudo, M; Mayama, M; Mitamura, T; Nomura, E; Nozaki, A; Takeda, M; Watari, H | 1 |
| Ardizzoni, A; Barbieri, F; Boni, L; Brocchi, S; Cavanna, L; Cinieri, S; Colantonio, I; Dazzi, C; Delmonte, A; Frassoldati, A; Gelsomino, F; Lamberti, G; Longo, L; Riccardi, F; Sperandi, F; Tiseo, M; Tofani, L | 1 |
| Jin, Y; Li, S; Li, Y; Ma, Z; Sun, R; Yan, H; Zhao, K; Zhao, W | 1 |
| Eguchi, H; Hayashi, N; Kuroda, Y; Masuda, T; Mimori, K; Natsugoe, S; Noda, M; Otsu, H; Tanaka, F; Tsuruda, Y | 1 |
| Hata, T; Imada, A; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Murakami, K; Murata, K; Ohmura, Y; Sakamoto, T; Takase, K; Takeda, Y; Takeno, A; Toya, K; Yukawa, Y | 1 |
| Kosaka, M; Sakaguchi, K; Yamazaki, Y | 1 |
| Economos, K; Friedman, M; Gorelick, C; Heyman, T; Kanis, MJ; Lee, YC; McEachron, J; Shanahan, L; Singhal, PK; Tran, V | 1 |
| Abdelkhalek, S; Abdelmoety, D; Aboelnaga, E; Baraka, R; Elemam, O; Zeeneldine, A | 1 |
| Chen, N; Kassir, N; Li, Y; Palmisano, M; Wang, X; Zhou, S | 1 |
| André, F; Frischhut, N; Nguyen, VA; Schmuth, M; Skvortsov, S; Walder, A | 1 |
| Ihira, K; Kaneuchi, M; Kato, T; Kobayashi, N; Konno, Y; Mitamura, T; Murakami, G; Nozaki, A; Sakuragi, N; Shimada, C; Todo, Y; Umazume, T; Watari, H | 1 |
| Akiyama, Y; Baba, S; Endo, F; Fujisawa, R; Koeda, K; Nikai, H; Sasaki, A | 1 |
| Chambers, L; Chichura, A; Costales, AB; Debernardo, R; Mahdi, H; Michener, CM; Rose, PG; Yao, M | 1 |
| Abdelghany, O; Azodi, M; Backes, FJ; Bellone, S; Buza, N; Celano, P; Chambers, S; Edraki, B; ElSahwi, K; Fader, AN; Havrilesky, L; Hui, P; Litkouhi, B; Lowery, W; Nevadunsky, N; O'Malley, DM; Pikaart, D; Ratner, E; Roque, DM; Santin, AD; Schwartz, PE; Secord, AA; Siegel, E; Silasi, DA | 1 |
| Burges, A; Cron, N; Degregorio, N; Harter, P; Heitz, F; Kurzeder, C; Ledermann, J; Lindemann, K; Lorusso, D; Marme, F; Paoletti, X; Pautier, P; Petru, E; Redondo, A; Reuss, A; Sehouli, J; Van Nieuwenhuysen, E; Wimberger, P | 1 |
| Chen, WY; Hwang, YC; Ke, FY; Kuo, KT; Lin, MC; Wu, HC | 1 |
| Berjon, A; Brenes, J; Casado, G; Castelo, B; Espinosa, E; Feliu, J; Gallego, A; Hardisson, D; Hernandez, A; Mendiola, M; Ramon-Patino, J; Redondo, A | 1 |
| Hagio, K; Nara, M; Oshino, T; Takazaki, E; Yamashita, H | 1 |
| Fujii, T; Fujiwara, K; Fukuhara, T; Koyama, S; Morisaki, T; Nakamura, Y; Takeuchi, H | 1 |
| Fujisawa, T; Ishikawa, T; Kashiwaba, M; Kawaguchi, H; Kondo, N; Mashino, K; Morita, S; Nakamura, R; Nakayama, T; Ohno, S; Ohtani, S; Takahashi, M; Takano, T; Tanino, Y; Toh, U; Toi, M; Toyama, T; Tsugawa, K; Yamamoto, Y; Yamashiro, H | 1 |
| Colombo, N; Donica, M; Dreosti, L; Estevez-Diz, M; Gonzalez-Martín, A; Irahara, N; Joly, F; Lorusso, D; McCormack, M; Nogueira-Rodrigues, A; Redondo, A; Ruff, P; Scambia, G; Schenker, M | 1 |
| Di, GH; Fan, L; He, M; He, PQ; Hou, YF; Lin, XY; Liu, GY; Ma, D; Mo, M; Ricci, F; Shao, ZM; Shen, ZZ; Song, CG; Toss, A; Wang, C; Wang, J; Wu, J; Wu, KJ; Ye, FG; Yu, KD; Zeng, XH; Zhuang, ZG | 1 |
| Kajiyama, H; Kikkawa, F; Nakamura, T; Tamauchi, S; Yoshihara, M | 1 |
| Byrom, M; Gomes Dos Reis, L; Ong, HX; Traini, D; Williamson, J; Xu, J; Young, PM | 1 |
| Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A | 1 |
| Abramson, VG; Axelrod, ML; Balko, JM; Bergman, RE; Donaldson, J; Garrido-Castro, AC; Gonzalez-Ericsson, PI; Jansen, VM; Krop, IE; Loi, S; Mackay, S; Mallal, S; Marotti, JD; Mayer, IA; McDonnell, WJ; Miller, TW; Nixon, MJ; Opalenik, SR; Pilkinton, MA; Rexer, BN; Salgado, R; Sanchez, V; Sanders, ME; Shee, K; Tolaney, SM; Zhou, J | 1 |
| Aibe, H; Hattori, M; Masuda, M; Mori, D; Nishihara, Y; Sakai, M; Sassa, Y; Shirahane, K | 1 |
| Ackermann, CJ; Adderley, H; Califano, R; Khan, A; Ortega-Franco, A; Reck, M | 1 |
| Andreetta, C; Bartoletti, M; Bonotto, M; Bortot, L; Corsetti, S; De Scordilli, M; De Vivo, R; Del Fabro, A; Fasola, G; Giorda, G; Mazzeo, R; Meacci, ML; Nicoloso, MS; Puglisi, F; Scalone, S; Sopracordevole, F; Sorio, R; Vitale, MG | 1 |
| Brocard, F; Chevalier-Place, A; Dalban, C; De Giorgi, U; Floquet, A; Fujiwara, K; Gladieff, L; Harter, P; Heudel, PE; Lorusso, D; Lück, HJ; Mangili, G; Pautier, P; Pignata, S; Provansal, M; Ray-Coquard, I; Schnelzer, A; Sehouli, J; Selle, F; Vergote, I | 1 |
| Ge, LP; Gou, ZC; Jiang, W; Jiang, YZ; Liu, XY; Ma, D; Shao, ZM; Xu, XE; Yang, YS | 1 |
| Ahlström, H; Botling, J; Dahlstrand, H; Koliadi, A; Öberg, K; Tholander, B; Ullenhag, GJ; Von Heideman, A | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Bas, O; Ceylan, F; Dizdar, O; Guven, DC; Kilickap, S; Yildirim, HC | 1 |
| Aoki, D; Enomoto, T; Fujiwara, K; Kimura, E; Kondo, E; Kotera, Y; Okamoto, A; Sugiyama, T; Sumi, T; Suzuki, N; Tabata, T; Terauchi, F; Tokuyama, O; Yaegashi, N; Yahata, H | 1 |
| de Vincenzo, R; Fagotti, A; Fanfani, F; Ferrandina, G; Gallotta, V; Gui, B; Ricci, C; Scambia, G | 1 |
| du Bois, A; Mirza, MR; Pignata, S; Ray-Coquard, I; Romero, I; Walther, A | 1 |
| Chang Lee, R; Hsieh, AH; Moldovan, M; Price, T; Tomita, Y; Townsend, A | 1 |
| Fujiwara, Y; Fukuda, N; Hayashi, N; Nakano, K; Ohmoto, A; Ono, M; Sato, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yunokawa, M | 1 |
| Fujimoto, A; Ichinose, Y; Matsuura, K; Nukui, A; Osaki, A; Saeki, T | 1 |
| Chen, R; Cui, Y; Guo, S; Li, F; Ma, S; Wang, H; Wang, Y; Wang, Z; Wei, Y; Zhang, K | 1 |
| Chosokabe, M; Deura, I; Kawamoto, H; Koike, J; Kondo, H; Kuji, S; Maeda, I; Migita, O; Ohara, T; Suzuki, N; Tozawa-Ono, A; Tsugawa, K | 1 |
| Fariñas, L; Grau, F; Oaknin, A; Perez-Fidalgo, JA | 1 |
| Chan, JCH; Chang, CC; Chen, TW; Endo, M; Farid, M; Goh, WL; Hirose, T; Kawai, A; Leung, AKC; Loong, HH; Maw, MM; Mingmalairak, S; Ngan, RKC; Pang, A; Puhaindran, ME; Quek, R; Sriuranpong, V; Tan, SH | 1 |
| Batman, S; Bohn, J; Bruegl, A; Caughey, A; Hersh, A; Weisenberger, MW; Winter, W | 1 |
| Slater, H | 1 |
| Bidard, FC; Borg, C; Cabel, L; Kim, S; Spehner, L | 1 |
| Akaike, H; Amemiya, H; Furuya, S; Higuchi, Y; Hosomura, N; Ichikawa, D; Kawaguchi, Y; Kawaida, H; Kono, H; Nakata, Y; Nakayama, T; Saito, R; Shoda, K; Sudo, M; Tsukahara, I | 1 |
| Itoh, R; Miyamoto, K; Tadano, Y | 1 |
| Ishikawa, S; Kano, S; Kayahara, M; Makita, N; Munemoto, M; Oonishi, I; Yagi, Y | 1 |
| Chino, S; Chuman, M; Hiki, N; Kondo, Y; Maruyama, M; Naito, M; Nakamura, K; Nishi, Y; Takahashi, Y; Tokito, T; Ushiku, H; Yamazaki, H | 1 |
| Cabezas-Camarero, S; Cabrera-Martin, MN; Perez-Segura, P; Saiz-Pardo Sanz, M | 1 |
| Aghajanian, C; Casablanca, Y; Cosgrove, C; Devor, EJ; Dewdney, S; Filiaci, VL; Jackson, A; Lankes, H; Leslie, KK; Levine, DA; Mallen, AR; Mathews, C; McDonald, ME; McHale, M; Moxley, K; Mutch, D; Richardson, D; Rose, PG; Secord, AA; Tewari, KS; Thiel, KW; Zhou, X | 1 |
| Adkins, D; Atiq, O; Gitau, M; Ley, J; Liu, J; Oppelt, P; Palka, K; Powell, S; Rigden, C; Spanos, WC | 1 |
| Bischoff, F; Bodurka, D; Coleman, RL; Fellman, BM; Garcia, ME; Hu, W; Meyer, LA; Nick, A; Palancia, J; Ram, P; Ramirez, PT; Schmeler, K; Soliman, P; Sood, AK; Westin, SN; Yuan, Y; Zhu, Z | 1 |
| Anjanappa, M; Ma, C; Nakshatri, H; Pandurangi, RS; Paulmurugan, R; Rajput, S; Tomasetti, M; Verapazham, ST | 1 |
| Abderrahim, E; Bacha, M; Ben Abdallah, T; Ben Hamida, F; Chargui, S; Hajji, M; Harzallah, A; Hedri, H; Ounissi, M | 1 |
| Blom, GJ; Bogers, JA; Bouwense, SAW; Braam, PM; de Jong, MA; de Vos-Geelen, J; Geurts, SME; Hoebers, FJP; Jeene, PM; Kasperts, N; Muijs, CT; Nieuwenhuijzen, GAP; Rozema, T; Tjan-Heijnen, VCG; Valkenburg-van Iersel, LBJ; Voncken, FEM | 1 |
| Alméciga, A; Amaro, K; Aragona, A; Borges Garnica, A; Calderaro di Ruggiero, F; Chavez, C; De Padua, C; Estrada, E; Greif, D; Hoegl, J; Laufer, J; Lopez, A; Pareja, R; Rendón, G; Rodriguez, J; Scasso, S; Serrano, O; Taranto, F | 1 |
| Bay, JO; Chatelut, E; Chevreau, C; Ciccolini, J; Culine, S; Delva, R; Filleron, T; Fizazi, K; Flechon, A; Gallois, Y; Gravis, G; Gross-Goupil, M; Guitton, J; Lelièvre, B; Lotz, JP; Massard, C; Moeung, S; Mourey, L; Olivier, P; Paci, A; Thomas, F | 1 |
| Amini, A; Chen, J; Chen, Y; Fan, M; Hamaji, M; Haque, W; Jeong, BK; Jia, H; Li, J; Li, L; Li, Y; Lin, Q; Lu, S; Mo, M; Nie, Y; Rivin Del Campo, E; Shridhar, R; Simone, CB; Tang, H; Wang, J; Wu, C; Wu, S; Xia, Y; Ye, J; Zhang, Z; Zhao, K; Zhao, W; Zhou, J; Zhu, H; Zhu, Z | 1 |
| Aoyama, Y; Harada, H; Hoshino, K; Kagami, S; Kinjo, Y; Kuradome, Y; Murakami, M; Ueda, T; Yoshino, K | 1 |
| Brown, R; Chiu, DS; Choi, H; Hoppe, MM; Huntsman, DG; Jaynes, P; Jeyasekharan, AD; Karnezis, A; Kaye, SB; Leung, S; Lie, S; Lim, DGZ; Lim, S; P S Yeong, J; Pang, BNK; Patel, NR; Pitt, JJ; Sato, K; Scott, CL; Sedukhina, AS; Tan, DSP; Tan, TZ; Topp, MD; Upadhyayula, SS; Wardyn, JD | 1 |
| Chen, C; Chen, KN; Dai, L; Du, M; Fang, Y; Gong, L; Hou, Y; Jiang, H; Jiao, J; Li, H; Li, K; Li, W; Li, Z; Lian, C; Liao, Y; Liu, J; Shen, Y; Tan, L; Tang, H; Wang, H; Wu, H; Xie, D; Yin, J; Zeng, Z; Zhao, Q; Zheng, B; Zhu, J | 1 |
| Francis, KE; Friedlander, M; Gebski, V; Lee, CK; Lord, SJ; Pujade-Lauraine, E | 1 |
| Beppu, S; Hanai, N; Kadowaki, S; Motai, R; Nishikawa, D; Sasaki, E; Sawabe, M; Suzuki, H; Terada, H | 1 |
| Fukuda, K; Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Havelund, BM; Kronborg, CS; Serup-Hansen, E; Spindler, KG; Storm, KS; Truelsen, CG | 1 |
| Battista, R; Coluccio, V; Grandi, G; Guidotti, I; Monari, F; Moscetti, L; Neri, I; Piombino, C; Torcetta, F; Toss, A | 1 |
| Alfonsi, M; Chevalier, T; Daste, A; Dupuis, C; Fakhry, N; Fayette, J; Huguet, F; Lambert, T; Le Tourneau, C; Loundou, A; Peyrade, F; Peyraud, F; Reure, J; Saada-Bouzid, E; Salas, S; Toullec, C | 1 |
| Hori, K; Ito, K; Kasamatsu, Y; Kondo, E; Nishio, S; Takehara, K; Ushijima, K | 1 |
| Ackroyd, SA; Huang, ES; Kurnit, KC; Lee, NK | 1 |
| Chang, YJ; Chou, CW; Huang, CY; Huang, YM; Hung, CS | 1 |
| Kim, HS; Lee, M; Lee, N; Lee, S; Paik, H; Park, SJ; Yim, GW | 1 |
| Akamatsu, H; Hida, T; Inui, N; Kang, JH; Kim, HR; Lee, JS; Lee, KH; Nakagawa, K; Namba, Y; Nishio, M; Ohe, Y; Sugawara, S; Sumiyoshi, N; Tamura, T; Tanaka, H; Yamamoto, N; Yang, CT; Yoshida, T; Yu, CJ | 1 |
| Fuyama, S; Higashi, T; Mase, K; Mizutani, M; Moriya, T; Ozawa, K; Takagi, S; Takei, S; Takeshita, A; Yokoyama, M | 1 |
| Adriaenssens, E; Angrand, PO; Bidan, N; Chopin, V; Lagadec, C; Le Bourhis, X; Meignan, S; Toillon, RA; Völkel, P; Winter, M | 1 |
| Koukourakis, IM; Koukourakis, MI; Kouloulias, V; Zygogianni, A | 1 |
| Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 2 |
| Abert, I; Andric, Z; Bashir, Z; Bondarenko, IN; Dvorkin, M; Fu, D; Galic, K; Galiulin, R; Jones, S; Kassalow, LM; Kuchava, V; Sriuranpong, V; Syrigos, K; Trukhin, D; Zhavrid, E | 1 |
| Fujisaki, K; Miyoshi, T; Ootsubo, Y; Sai, G; Shiina, N; Wakabayashi, Y; Yokomizo, J | 1 |
| Barsotti, C; Cosio, S; Fabrini, MG; Fanucchi, A; Gadducci, A; Laliscia, C; Tana, R | 1 |
| Janssen, S; Manig, L; Rades, D; Schild, SE | 1 |
| Brown, JM; Brundage, MD; Cook, A; Embleton, AC; Kaplan, RS; Ledermann, JA; Qian, W; Raja, FA; Stark, DP; Swart, AMW; Velikova, G | 1 |
| Anderegg, MCJ; Gisbertz, SS; Hulshof, MCCM; Los, M; Mohammed, NH; Ruurda, JP; van Berge Henegouwen, MI; van der Sluis, PC; van Hillegersberg, R; van Laarhoven, HWM; van Vulpen, M; Wiezer, MJ | 1 |
| Armstrong, DK; Ashfaq, R; Basen-Engquist, K; Brady, MF; Chan, JK; Coleman, RL; Davidson, SA; DiSilvestro, P; Fujiwara, K; Herzog, TJ; Huang, H; Kim, BG; Mannel, RS; O'Malley, DM; Rubin, SC; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL | 1 |
| Hazama, S; Inoue, Y; Kanekiyo, S; Kubo, H; Maeda, N; Matsui, H; Nagano, H; Nagashima, Y; Oka, M; Sakamoto, K; Sato, Y; Shindo, Y; Suzuki, N; Takeda, S; Ueno, T; Yamamoto, S; Yoshino, S | 1 |
| Guerra, I; McCormack, M; Munk, VC; Nogueira-Rodrigues, A; Rosen, VM; Sasse, A; Shang, A | 1 |
| Bergzoll, C; Eva, L; Jamieson, A; Simcock, B; Sykes, P | 1 |
| Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y | 1 |
| Baeksgaard, L; Corkhill, AK; Crosby, T; Cuffe, S; Cunnane, M; Cunningham, M; Dermott, RM; Dib, M; Donohoe, CL; Griffin, SM; Hanna, G; Hennessy, B; Hofland, K; Illsley, M; Johnson, C; Jones, G; Lawner, P; Lee, K; Leonard, G; Marchesin, V; Mariette, C; Mellor, J; Muldoon, C; O'Dowd, G; O'Neill, B; O'Reilly, S; O'Toole, D; Parker, I; Preston, SR; Ravi, N; Reynolds, JV; Scott, K; Svendsen, LB; Warren, S | 1 |
| Bonnetain, F; de la Motte Rouge, T; Kalbacher, E; Lesoin, A; Pautier, P | 1 |
| Kong, L; Mo, R; Ping, Q; Shen, S; Sun, H; Wang, L; Wei, Z; Wen, Y; Xue, J; Xue, L; Zhang, C; Zhang, L; Zhao, Z | 1 |
| Bournakis, E; Dimopoulos, MA; Gazouli, M; Karageorgopoulou, S; Kostakis, ID; Markaki, S; Papadimitriou, CA; Papadimitriou, M | 1 |
| Barshack, I; Ben-Shushan, D; Caspi, R; Dekel, B; Eldar-Boock, A; Harari-Steinberg, O; Markovsky, E; Pode-Shakked, N; Satchi-Fainaro, R; Shukrun, R; Vax, E; Yeini, E | 1 |
| Aleman, BMP; Grootscholten, C; Sikorska, K; Snaebjornsson, P; van der Kaaij, RT; van Dieren, JM; van Sandick, JW; van Werkhoven, E; Voncken, FEM | 1 |
| Brunette, LL; Ciccone, MA; Machida, H; Matsuo, K; Moeini, A; Mostofizadeh, S; Roman, LD; Takiuchi, T | 1 |
| Denkert, C; Forstbauer, H; Hoffmann, G; Karn, T; Kohls, A; Köhne, CH; Linn, SC; Loibl, S; Marmé, F; Möbus, VJ; Nekljudova, V; Schem, C; Schmatloch, S; Schouten, PC; Solbach, C; Thomssen, C; van Rossum, AGJ; von Minckwitz, G; Weber, KE | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Asato, T; Cho, EK; Hara, K; Hayashi, H; Hida, T; Ichinose, Y; Kaneda, H; Kato, T; Kubota, K; Lee, KH; Lin, CB; Nakagawa, K; Oshita, F; Park, K; Tanaka, H; Yamada, K; Yang, JC; Yoh, K; Yoshioka, H | 1 |
| Fukushima, H; Kawabata, K; Marshall, S; Mitani, H; Nakano, K; Sasaki, T; Sato, Y; Shimbashi, W; Taira, S; Takahashi, S; Tomomatsu, J; Yonekawa, H | 1 |
| Airoldi, M; Bossi, P; Caldara, A; Caponigro, F; Denaro, N; Ferrari, D; Ferrau, F; Hollander, L; Licitra, L; Lo Vullo, S; Locati, LD; Miceli, R; Moretti, G; Moro, C; Nolè, F; Rinaldi, G; Sponghini, A; Tettamanzi, F; Vaccher, E; Vecchio, S | 1 |
| Baxi, SS; Dunn, LA; Fury, MG; Haque, S; Ho, AL; Katabi, N; Korte, S; Pfister, C; Pfister, DG; Sherman, EJ; Xiao, H | 1 |
| Bonetti, A; Giuliani, J | 1 |
| Boisgerault, N; Coffey, M; Diaz, RM; Evgin, L; Harrington, K; Ilett, E; Kottke, T; Melcher, A; Pandha, H; Rommelfanger, D; Selby, P; Shim, KG; Thompson, J; Vile, R; Zaidi, S | 1 |
| Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML | 1 |
| Baehner, FL; Butler, SM; Cherbavaz, DB; Costantino, JP; Jamshidian, F; Jeong, JH; Julian, TB; Kim, SR; Lawrence Wickerham, D; Lembersky, BC; Liu, Q; Mamounas, EP; Paik, S; Shak, S; Sing, AP; Tang, G; Wolmark, N | 1 |
| Boulinguez, S; Chira, C; Godillot, C; Meyer, N; Paul, C; Riffaud, L; Sibaud, V; Tournier, E | 1 |
| Aghajanian, C; Alvarez Secord, A; Carney, ME; Coleman, RL; Gray, HJ; Hanjani, P; Hu, W; Kehoe, SM; Landrum, LM; Lankes, HA; Pearl, ML; Richardson, DL; Sill, MW; Sood, AK; Van Le, L; Zhou, XC | 1 |
| Bartscht, T; Hakim, SG; Idel, C; Rades, D | 1 |
| Tutt, A | 1 |
| Bando, H; Doi, T; Fukuoka, S; Kawazoe, A; Kojima, T; Kuboki, Y; Matsumoto, H; Ohtsu, A; Shimada, K; Shitara, K; Yoshino, T | 1 |
| de Melo, AC; de Moraes Lino da Silva, F; Fontes Dias, MS; Ingles Garces, ÁH; Moreira, E; Paulino, E; Saramago, M; Thuler, LCS | 1 |
| Chen, G; Chen, J; Guo, Z; Li, X; Liu, J; Ren, D; Wei, S; Xu, S | 1 |
| Choi, YS; Jo, DY; Kim, JM; Ko, YB; Lee, HJ; Ryu, H; Song, IC; Yun, HJ | 1 |
| Capurso, G; Delle Fave, G; Panzeri, V; Passacantilli, I; Sette, C; Terracciano, F | 1 |
| Borel, C; Burgy, M; Leblanc, J | 1 |
| Cho, JY; Cho, SH; Jo, YW; Kang, MJ; Kang, SY; Kang, YK; Kim, JG; Kim, JW; Nam, BH; Oh, SC; Park, SH; Park, SR; Park, YI; Rha, SY; Roh, SY; Ryoo, BY; Ryu, MH; Yoon, KE | 1 |
| Banerjee, S; Chen, J; Colombo, N; Gore, M; Gorla, S; Hirte, H; Kaye, S; Naumann, RW; Oza, A; Poondru, S; Sessa, C; Singh, M; Steinberg, J; Van Tornout, J; Yuen, G | 1 |
| Attianese, D; Cosio, S; Fabrini, MG; Ferrero, A; Gadducci, A; Guerrieri, ME; Laliscia, C; Rossi, A | 1 |
| Kudlowitz, D; Muggia, F; Musa, F; Velastegui, A | 1 |
| Ebara, S; Edamura, K; Hanamoto, M; Hayashi, N; Hirata, T; Ogura, K; Saika, T; Takamura, K | 1 |
| Duan, Z; Gao, P; Garbutt, C; Hornicek, FJ; Kan, Q; Ma, H; Shi, H; Wang, J | 1 |
| Ahn, HJ; Jang, YS; Lee, J; Risnayanti, C | 1 |
| Aghajanian, C; Bender, DP; Carlson, JW; Dao, F; Dizon, DS; Filiaci, V; Gao, J; Lankes, HA; Levine, DA; Moore, K; O'Malley, DM; Powell, MA; Secord, AA; Soslow, RA; Stuckey, A; Tewari, KS | 1 |
| Agyemang-Prempeh, K; Barna, O; Kullmann, T; Pintér, T; Sipőcz, I | 1 |
| Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T | 1 |
| Benedetti Panici, P; Tomao, F; Tomao, S | 2 |
| Coleman, RL; Richardson, DL; Sill, MW | 1 |
| Arakawa, A; Asai-Sato, M; Hongo, A; Inokuchi, Y; Kamiura, S; Kato, K; Komiyama, S; Matsumoto, T; Sugiyama, T; Tabata, T; Takano, H; Takeshima, N | 1 |
| Brown, L; Chen, AM; Ganju, RG; Hoover, A; Jewell, A; Tawfik, O; TenNapel, M | 1 |
| Bae, DS; Choi, CH; Choi, HJ; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Paik, ES | 1 |
| Al-Batran, SE; Alsina, M; Bang, YJ; Boku, N; Chung, HC; Conti, I; Evesque, L; Hallwachs, R; Hong, J; Lee, KW; Lichinitser, M; Moehler, MH; Park, SH; Ruiz, EY; Ryu, MH; Schenker, M; Taieb, J; Van Cutsem, E; Wyrwicz, L; Xiong, H | 1 |
| Alpaugh, K; Dang, CT; Miller, KD; Northfelt, DW; O'Neill, A; Sledge, GW; Sparano, J; Wolff, AC | 1 |
| Concin, N; Manso, L; Sessa, C; Van Nieuwenhuysen, E; Vergote, I; von Moos, R | 1 |
| Kitanaka, C; Okada, M; Sanomachi, T; Seino, S; Suzuki, S; Togashi, K; Yamamoto, M; Yamashita, H | 1 |
| Baltezor, M; Bechtel, SM; Bryan, JN; Decedue, C; Espinosa, J; Flesner, BK; Henry, CJ; Rajewski, L; Selting, KA; Tate, D | 1 |
| Itasaka, S; Matsuoka, T; Nakashima, T; Okumura, N; Takahashi, A; Yamanashi, K; Yokoyama, T | 1 |
| Hirasawa, T; Iida, T; Ikeda, M; Kajiwara, H; Machida, H; Mikami, M; Shida, M | 1 |
| Hirasawa, T; Iida, T; Ikeda, M; Machida, H; Mikami, M; Shida, M | 1 |
| Hu, WH; Jin, T; Li, PJ; Luo, DH; Mo, HY | 1 |
| Amant, F; Annibali, D; Goffin, F; Han, S; Nooij, L; van den Bulck, H; van Rompuy, AS | 1 |
| Fiorino, L; Kumar, A; O'Dwyer, H; Tinker, AV | 1 |
| Chiba, Y; Hiraki, Y; Imano, M; Iwama, M; Kato, H; Kimura, Y; Nishida, S; Shinkai, M; Shiraisi, O; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Chiba, Y; Hiraki, Y; Imano, M; Iwama, M; Kato, H; Kimura, Y; Nishida, S; Shinkai, M; Shiraishi, O; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Jung, YH; Lee, SH; Park, HJ; Yoo, JY | 1 |
| Choi, N; Deist, T; Liao, Z; Mohan, R; Paganetti, H; Tucker, SL; Verma, V; Xu, T | 1 |
| Chang, HM; Hwang, I; Ip, HNN; Jeong, JH; Kang, J; Kim, KP; Ryoo, BY; Yoo, C | 1 |
| Behbakht, K; Buscema, J; Coleman, RL; Duska, LR; Fabbro, M; Falchook, G; Fu, S; Ghamande, S; Goff, B; Gray, HJ; Kurzrock, R; Leonard, EJ; Lesoin, A; Lin, HM; Lortholary, A; Martin, LP; Matulonis, U; Ray-Coquard, I; Roszak, A; Sawrycki, P; Schilder, RJ; Schwartz, PE; Sheldon-Waniga, E; Tew, W; Venkatakrishnan, K; Zhou, X | 1 |
| Adams, S; Chang, CW; Diamond, JR; Foster, PG; Funke, R; Hamilton, E; Iizuka, K; Molinero, L; Pohlmann, PR; Powderly, J; Tolaney, SM; Zhang, W | 1 |
| Choi, MC; Jeong, DH; Kang, S; Kim, JW; Kim, KH; Kim, TH; Kim, YB; Kim, YM; Lee, IH; Lee, JW; Lee, JY; Lee, KB; Lee, YJ; Park, JY; Park, SY; Pujade-Lauraine, E | 1 |
| Nugent, E; Smith, JA; Tomasino, T; Tran, AT; Zhong, L | 1 |
| Daido, W; Funaishi, K; Hattori, N; Kawamoto, K; Matsumoto, N; Matsumoto, Y; Ohashi, N; Taniwaki, M; Yamasaki, M | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Chen, QY; Guo, L; Guo, SS; Li, XY; Liang, YJ; Lin, C; Lin, HX; Liu, LT; Liu, SL; Mai, HQ; Sun, XS; Tang, LQ; Tang, QN; Wen, YF; Xie, HJ; Yan, JJ; Yang, ZC | 1 |
| Aghajanian, C; Bender, DP; Carlson, JW; Crane, EK; Darus, CJ; Makker, V; Mannel, RS; Matulonis, UA; Mutch, DG; Sill, MW | 1 |
| Chen, Y; Chen, ZS; Gao, W; Jiang, Y; Lin, Z; Wang, B; Wu, S; Yang, X | 1 |
| Kim, JC; Kim, JH; Kim, YM; Yoon, YS | 1 |
| Antonia, SJ; Bepler, G; Chen, DT; Chiappori, AA; Creelan, BC; Gabrilovich, DI; Gray, JE; Haura, EB; Simon, GR; Tanvetyanon, T; Thapa, R; Williams, CC | 1 |
| Blumenschein, GR; Garden, AS; Ginsberg, LE; Glisson, BS; Gold, KA; Haddad, RI; Hutcheson, K; Johnson, FM; Kies, MS; Lee, JJ; Lewis, J; Lin, HY; Massarelli, E; Myers, J; Papadimitrakopoulou, V; Pharaon, RR; Pickering, C; Rabinowits, G; Tishler, RB; William, WN; Williams, MD | 1 |
| Armstrong, DK; Bender, DP; Bookman, MA; Burger, RA; Copeland, LJ; Friedlander, ML; Geller, MA; Guntupalli, SR; Hamilton, CA; Java, JJ; Lee, RB; Markman, M; Method, MW; Muggia, FM; Mutch, DG; Rose, PG; Salani, R; Secord, AA; Tewari, KS; Van Le, L; Wenham, RM | 1 |
| Chen, J; Han, C; Jiao, S; Kong, W; Liu, T; Song, D; Zhang, T | 1 |
| Duran, GE; Sikic, BI | 1 |
| Akaishi, T; Hakamada, K; Hara, Y; Kubo, N; Mitsuhashi, Y; Muroya, T; Ogasawara, H; Sato, K; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yoshida, E; Yoshida, T | 1 |
| Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okamoto, K; Okazaki, M; Sakai, S; Tajima, H; Takamura, H; Terai, S | 1 |
| Kim, S; Kim, SW; Kim, YT; Lee, J; Li, LY; Nam, EJ | 1 |
| Aoyama, T; Hayashi, T; Inoue, H; Kamiya, M; Masuda, M; Morinaga, S; Murakawa, M; Numata, M; Ohshima, T; Rino, Y; Shiozawa, M; Yamada, T; Yamamoto, N; Yotsumoto, H | 1 |
| Chen, L; Chen, LQ; Chu, XY; Gao, CH; Gao, CS; Gao, ZG; Ge, C; Huang, W; Jin, MJ; Meng, LW; Wang, YL | 1 |
| Chumsri, S; Colon-Otero, G; Knutson, KL; Li, Z; Lou, Y; Mashadi-Hossein, A; Moreno-Aspitia, A; Perez, EA; Pogue-Geile, KL; Serie, DJ; Soyano-Muller, AE; Thompson, EA; Warren, S | 1 |
| Bakowsky, U; Bosakova, Z; Cerna, T; Franek, M; Hampejsova, Z; Hobzova, R; Hrabeta, J; Jedelska, J; Kovarova, J; Lhotka, M; Michalek, J; Sirc, J; Steinhart, M; Vaculin, S; Venclikova, K | 1 |
| Nakatsumi, H; Nakayama, KI; Shimizu, H; Takeishi, S | 1 |
| Arai, A; Hirano, S; Kinoshita, S; Konishi, E; Mitsuda, J; Mori, D; Ozawa, S; Saburi, S; Takenaka, M; Tsujikawa, T; Yoshimura, K | 1 |
| Alarcón, E; Armstrong, AC; Cheung, SYA; Corcoran, C; Cullberg, M; Davies, BR; de Bruin, EC; Foxley, A; Gómez Villanueva, A; Lindemann, JPO; López Chuken, YA; Maudsley, R; Moschetta, M; Oliveira, M; Outhwaite, E; Pass, M; Pérez-Fidalgo, JA; Philco, M; Rugman, P; Sablin, MP; Schiavon, G; Tamura, K; Turner, NC | 1 |
| Chon, HJ; Chung, HC; Jung, M; Kang, B; Kim, C; Kim, HS; Kim, JH; Nam, CM; Rha, SY | 1 |
| Das, CK; Dracham, CB; Elangovan, A; Gupta, S | 1 |
| DiSilvestro, PA | 1 |
| Burges, A; Colomban, O; Du Bois, A; Freyer, G; Hardy-Bessard, AC; Kurzeder, C; Leary, A; Lortholary, A; Péron, J; Pfisterer, J; Ray-Coquard, I; Tod, M; You, B | 1 |
| Hanayama, H; Hayase, S; Kono, K; Monma, T; Nirei, A; Ohki, S; Saze, Z; Tada, T; Ujiie, D; Yamada, L | 1 |
| Albain, KS; Barry, WT; Bellon, JR; Burstein, HJ; Carey, LA; Dang, CT; Ellis, M; Guo, H; Hudis, CA; Krop, I; Marcom, PK; Moy, B; Overmoyer, BA; Partridge, AH; Rugo, HS; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, DA | 1 |
| Brady, WE; Christensen, H; Dark, G; Feeney, A; Frumovitz, M; Ganesan, R; Gershenson, DM; Gore, M; Hackshaw, A; Kehoe, S; Ledermann, J; Lord, R; Mackean, M; McCluggage, WG; Montes, A; Penson, RT; Perren, T; Reed, N; Rustin, G; Summers, J; Wilkinson, N; Zaino, R | 1 |
| Coleman, RL; Falchook, G; Schilder, RJ | 1 |
| Bajorin, DF; Bellmunt, J; Choueiri, TK; Climent, MA; Culine, S; de Wit, R; Fong, L; Fradet, Y; Frenkl, TL; Gerritsen, W; Gurney, H; Lee, JL; Nam, K; Necchi, A; Perini, RF; Petrylak, DP; Quinn, DI; Sternberg, CN; Vaughn, DJ; Vogelzang, NJ | 1 |
| Komune, N; Matsuo, M; Nakagawa, T; Taura, M; Uchi, R; Wakasaki, T; Yasumatsu, R | 1 |
| Ishigaki, A; Kainuma, O; Kato, M; Kuwayama, N; Maruyama, T; Matsumoto, Y; Miyazaki, A; Mizumoto, H; Natsume, T; Note, H; Oshima, S; Sato, Y; Shimizu, S; Suzuki, K; Tanaka, H; Yoshioka, T | 1 |
| Azuma, M; Hamano, K; Harada, E; Iida, M; Kanekiyo, S; Minami, Y; Miyazaki, K; Nagano, H; Okamoto, T; Sakaida, I; Suzuki, N; Takeda, S; Yoshino, S | 1 |
| Amano, R; Fukuoka, T; Hirakawa, K; Kimura, K; Maeda, K; Muguruma, K; Nagahara, H; Ohira, G; Ohira, M; Shibutani, M; Tamura, T; Tanaka, H; Toyokawa, T; Tsujio, G; Yamazoe, S; Yashiro, M | 1 |
| Harada, D; Kageyama, A; Kawakubo, T; Kitamura, M; Mitsumori, N; Nakazawa, Y | 1 |
| Harper, NW; Hodges, KB; Huang, B; O'Connor, KL; Romond, EH; Stewart, RL; Wu, J | 1 |
| Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S | 1 |
| Cai, G; Cao, L; Chen, JY; Feng, Y; Kirova, YM | 1 |
| Jimi, T; Kitai, M; Matsuoka, K; Nagao, S; Shibutani, T; Shiozaki, T; Suzuki, K; Yamaguchi, S; Yamamoto, K; Yano, H | 1 |
| Bozzato, E; Danhier, F; Gallez, B; Ghiassinejad, S; Joudiou, N; Préat, V; Zhao, M | 1 |
| Atsumi, K; Azuma, A; Fukuizumi, A; Gemma, A; Hisakane, K; Kobayashi, K; Kubota, K; Minegishi, Y; Noro, R; Omori, M; Seike, M; Sugano, T; Takahashi, S; Takano, N; Takeuchi, S | 1 |
| Bilal, H; Chae, YK; Lin, X; Park, LC; Roh, Y; Saleem, N; Sheikh, MM; Sukhadia, B; Viveiros, P | 1 |
| Buckner, CA; Conlon, MS; Lafrenie, RM; Pawelec, G; Shipp, C; Speigl, L | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Axelrod, RS; Bradley, JD; Buyyounouski, MK; Komaki, R; Langer, C; Lawrence, YR; Machtay, M; Movsas, B; Paulus, R; Smith, C; Wasserman, T; Werner-Wasik, M | 1 |
| Han, W; Im, SA; Moon, HG; Moon, WK; Noh, DY; Park, IA; Park, SJ; Shin, HC | 1 |
| Fang, J; Li, S; Lv, C; Ma, Y; Sun, Y; Wu, N; Yan, S; Yang, Y; Zheng, Q | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Amm, HM; Buchsbaum, DJ; DellaManna, D; Egger, ME; Eltoum, IE; Frederick, PJ; Grizzle, WE; Kerr, EH; McNally, LR; Oelschlager, DK; Sellers, J; Stockard, CR; Straughn, JM | 1 |
| Alves, FV; de Melo, AC; do Carmo, CC; Fernandes, AC; Garces, ÁH; Grazziotin, R; Mora, PA; Nogueira-Rodrigues, A | 1 |
| Allen, P; Buchholz, TA; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Kim, MM; Kuerer, HM; Litton, JK; Meric-Bernstam, F; Mittendorf, EA; Woodward, WA | 1 |
| Cai, RG; Li, Q; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yin, Y; Yuan, P; Zhang, BL; Zhang, P | 1 |
| Aghajanian, CA; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B | 1 |
| Kang, SB; Kim, JH; Kim, KT; Kim, SM; Kim, YM; Kim, YT; Lee, JM; Lee, TS; Park, BJ | 1 |
| Khemapech, N; Lertkhachonsuk, R; Oranratanaphan, S; Termrungruanglert, W; Vasurattana, A | 1 |
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Fu, JH; Gao, Z; Ren, CC; Shi, YG | 1 |
| Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
| Álvarez, I; Andrés, R; Antón, A; Barnadas, A; Calvo, L; Carabantes, FJ; Carrasco, E; Chacón, JI; Crespo, C; Dorca Ribugent, J; Espinosa, E; González, S; Hernando, B; Jara, C; Lluch, A; López-Vega, JM; Margelí Vila, M; Martín, M; Mendiola Fernández, C; Muñoz-Mateu, M; Plazaola, A; Ribelles, N; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz Borrego, M; Ruiz, A; Salvador Bofill, J; Sánchez-Rovira, P; Seguí-Palmer, MA; Servitja, S | 1 |
| Fukuda, S; Furuya, T; Hazama, S; Kawaoka, T; Nishimura, T; Oka, M; Ozasa, H; Shimizu, R; Yoshino, S | 1 |
| Akagi, Y; Ishikawa, H; Kinugasa, T; Mizobe, T; Ohshima, K; Oka, Y; Setojima, K; Shiratsuchi, I; Shirouzu, K | 1 |
| Bains, MS; Gerber, N; Goodman, KA; Ilson, DH; Janjigian, YY; Kelsen, DP; Rizk, N; Rusch, VW; Wu, AJ; Zhang, Z; Zheng, J | 1 |
| Altundağ, Ö; Ayhan, A; Dizdar, O; Dursun, P; Kucukoztas, N; Ozen, O; Rahatli, S; Reyhan, NH; Tarhan, C; Yalcin, S; Yildiz, F | 1 |
| Kim, JH; Kim, JW; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ; Yim, GW | 1 |
| Ishizuna, K; Kawashima, M; Kojima, M; Ninomiya, J; Nozaki, M; Oya, M; Ueda, Y; Yamagishi, H | 1 |
| Isohashi, F; Ito, K; Kimura, T; Mabuchi, S; Ogata, T; Ogawa, K; Takahashi, R; Tsutui, T; Yokoi, T; Yoshioka, Y | 1 |
| Fagotti, A; Fanfani, F; Ferrandina, G; Margariti, PA; Nero, C; Pedone, AL; Petrillo, M; Scambia, G; Vizzielli, G | 1 |
| Beukema, JC; Burgerhof, JG; Güler, S; Hospers, GA; Mul, VE; Plukker, JT; Smit, JK | 1 |
| Niu, L; Ohlfest, JR; Panyam, J; Roger, E; Swaminathan, SK; Toti, U | 1 |
| Chen, Q; Fan, L; Jiang, J; Qi, X; Wang, S; Yang, X; Zhang, Y | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Barbieri, E; Bettelli, S; Conte, PF; Dieci, MV; Ficarra, G; Guarneri, V; Omarini, C; Piacentini, F | 1 |
| Gao, YT; Li, M; Li, N; Li, XG; Sun, YC; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Cai, Y; Conzen, SD; Goyal, A; Hall, BA; Kocherginsky, M; Skor, MN; Wonder, EL | 1 |
| Aksoy, S; Altundag, K; Sendur, MA; Zengin, N | 1 |
| Al-Sakaff, N; Bell, R; Chang, J; Feng, FY; Heinzmann, D; Jassem, J; Láng, I; Lopez, RI; Semiglazov, V | 1 |
| Aquino-Parsons, C; Hoskins, P; Jutzi, L; Kwon, JS; Lim, P; Tinker, A | 1 |
| Kruitwagen, RF; Massuger, LF; Ottevanger, PB; van de Laar, R; Van Gorp, T; Zusterzeel, PL | 1 |
| Fujiwara, K; Kigawa, J; Michimae, H; Nagao, S; Nishio, S; Okada, S; Otsuki, T; Suzuki, M; Tanabe, H; Tanioka, M | 1 |
| Ozdemir, O; Ozdemir, P; Ozhan, MH; Uluer, H; Veral, A | 1 |
| Li, J; Shi, Y; Xing, P | 1 |
| Amadio, G; Masciullo, V; Scambia, G; Stefano, L | 1 |
| Biasoni, D; Catanzaro, M; Farè, E; Giannatempo, P; Gianni, AM; Lo Vullo, S; Mariani, L; Milani, A; Necchi, A; Nicolai, N; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Torelli, T | 1 |
| Clark, JI; Kucuk, O; Malhotra, B; Moon, J; Urba, SG; Wolf, GT; Worden, FP | 1 |
| Chen, XF; Han, JH; Ji, FZ; Ji, J; Pu, J; Shen, WY; Su, XL; Tao, GZ; Wang, CS; Xu, YM; Yi, JG; Zhou, XL; Zhu, WG; Zong, CD; Zuo, YS | 1 |
| Leminen, A; Puistola, U | 1 |
| Dobrodeev, AIu; Musabaeva, LI; Tyzikov, SA; Zav'ialov, AA | 1 |
| Bookman, MA | 1 |
| González-Martín, A | 1 |
| Calvo, A; El-Nikhely, N; Larzabal, L; Redrado, M; Savai, R; Seeger, W | 1 |
| Amiri-Kordestani, L; Liewehr, DJ; Lin, NU; Palmieri, D; Steeg, PS | 1 |
| Feng, ZY; Liao, QP; Liu, TY; Ma, K; Wen, HW; Yang, X; Yang, YH | 1 |
| Jiang, Y; Yang, L; Yuan, Z; Zhang, Y; Zhao, Q | 1 |
| Fujimoto, T; Ito, K; Kagabu, M; Kigawa, J; Kurachi, H; Matsumoto, T; Mizunuma, H; Nagase, S; Nakahara, K; Niikura, H; Nishiyama, H; Otsuki, T; Sato, N; Sato, S; Shimada, M; Shoji, T; Soeda, S; Sugiyama, T; Takano, T; Tase, T; Terada, Y; Tokunaga, H; Toyoshima, M; Utsunomiya, H; Yaegashi, N; Yamada, H; Yokoyama, Y | 1 |
| Beukema, JC; Hulshof, MC; Oppedijk, V; Reinders, JG; Richel, DJ; Rütten, H; Spruit, PH; van Berge Henegouwen, MI; van der Gaast, A; van der Sangen, MJ; van Hagen, P; van Lanschot, JJ; van Os, R; van Rij, CM | 1 |
| Baldassarre, G; Barbareschi, M; Croce, CM; Fassan, M; Galligioni, E; Gasparini, P; Ishii, H; Lovat, F; Schiappacassi, M; Vecchione, A | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY | 1 |
| Chalapati, W; Suprasert, P | 1 |
| Bergman, JJ; Geijsen, D; Haj Mohammad, N; Hulshof, MC; van Berge Henegouwen, MI; van Laarhoven, HW; Wilmink, JW | 1 |
| Barni, S; Coinu, A; Lorusso, D; Petrelli, F; Raspagliesi, F | 1 |
| González Ruiz de la Herrán, F; Haya Palazuelo, J; López de la Manzanara Cano, C; Martín Fernández, J; Padilla Valverde, D; Pascual-Ramírez, J; Sánchez García, S; Villarejo Campos, P | 1 |
| Markman, M | 3 |
| Brower, SL; Krivak, TC; Leath, CA; Lele, S; Moore, RG; Richard, S; Secord, AA; Tian, C | 1 |
| Christopoulou, A; Emmanouilidis, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Koinis, F; Papadimitraki, E; Polyzos, A; Samonis, G; Zafeiriou, Z | 1 |
| Du, ZG; Gao, WC; Li, QQ; Ma, ZY; Yin, B; Zhao, ZH; Zhou, ZW | 1 |
| Huang, H; Landrum, LM; Leitao, MM; Long, HJ; Michael, HE; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Sill, MW; Tewari, KS | 1 |
| Hurvitz, SA; Megerdichian, C; Olimpiadi, Y | 1 |
| Chen, J; Feng, Y; Liu, Y; Shao, N; Wang, Y; Zhang, L | 1 |
| Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ | 1 |
| Athanasopoulos, A; Daladimos, T; Dimitriadis, G; Gekas, C; Kosmas, C; Lydakis, D; Magiorkinis, E; Miltiadous, C; Mylonakis, N; Zilakos, M; Ziras, N | 1 |
| Baxley, A; Khawandanah, M; Pant, S | 1 |
| Bamias, A; Bollag, D; Follana, P; Hilpert, F; Kristensen, G; Mirza, MR; Oaknin, A; Pereira, D; Poveda, A; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Sorio, R; Vergote, I; Weber, B; Wimberger, P; Witteveen, P | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; O'Malley, DM; Salani, R | 1 |
| Deng, W; Guan, Z; Huang, M; Huang, W; Jiang, W; Kang, T; Li, L; Li, S; Liu, Q; Liu, R; Pan, C; Tan, W; Thomas, GR; Wu, J; Ye, W; Ying, X; Zeng, M; Zhang, L | 1 |
| Markham, MJ; Murphy, MC | 1 |
| Ellenrieder, V; Michl, P; Neesse, A; Tuveson, DA | 1 |
| Ki, KD; Lee, JM; Seol, HJ; Ulak, R | 1 |
| Goto, M; Hara, T; Koizumi, W; Miyata, Y; Muro, K; Nishina, T; Sasaki, Y; Toh, Y; Tsuji, A; Yasui, H | 1 |
| Geijsen, ED; Hulshof, MC; van Berge Henegouwen, MI; van Hooft, JE; van Laarhoven, HW; van Os, RM; Versteijne, E | 1 |
| Cho, J; Choi, NC; Sharp, GC; Shusharina, N | 1 |
| Colomban, O; Freyer, G; Hénin, E; Oza, A; Pujade-Lauraine, E; Tod, M; Wilbaux, M; You, B | 1 |
| Chen, L; Huang, MJ; Lu, Y; Song, LL; Wang, YS; Xiong, WJ; Xue, JX; Zhang, XX | 1 |
| Fujimoto, M; Fujisawa, Y; Kadono, T; Miyagawa, T; Nakamura, Y; Yoshino, K | 1 |
| Arima, H; Eguchi, Y; Hirata, M; Ijichi, T; Ishigami, S; Kijima, Y; Kurahara, H; Nakajo, A; Natsugoe, S; Okumura, H; Shinden, Y; Uenosono, Y; Yoshinaka, H | 1 |
| Aisner, J; Aisner, S; Dahlberg, SE; DiPaola, RS; Pillai, RN; Ramalingam, SS; Rogers, JS; Schiller, JH | 1 |
| Guan, Y; Liu, J; Liu, S; Liu, X; Niu, Y; Wang, L; Wang, Y; Zhang, W | 1 |
| Abubaker, K; Ahmed, N; Burns, CJ; Findlay, JK; Luwor, RB; McNally, O; Quinn, MA; Thompson, EW; Zhu, H | 1 |
| Becker, HP; Berry, DA; Burstein, HJ; Cirrincione, CT; Hudis, CA; Kimmick, G; Martino, S; Muss, H; Norton, L; O'Regan, R; Perez, EA; Schneider, CJ; Shapiro, CL; Shulman, LN; Winer, EP | 1 |
| Bae, DS; Bamias, A; Brize, A; Coleman, RL; Fabbro, M; Fujiwara, K; Herzog, TJ; Karlan, BY; Lhommé, C; Marth, C; Monk, BJ; Navale, L; Oaknin, A; Oza, AM; Poveda, A; Provencher, DM; Raspagliesi, F; Ray-Coquard, I; Redondo, A; Richardson, G; Rincón, DG; Tassoudji, M; Vergote, I; Warner, DJ | 1 |
| Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Eskander, RN; Tewari, KS | 1 |
| Cho, CH; Cho, H; Kang, SB; Kim, BG; Kim, JH; Kim, SM; Nam, BH; Ryu, HS | 1 |
| Cai, XY; Chen, XX; Guo, GF; He, WZ; Jiang, C; Liao, FX; Qiu, HJ; Rong, YM; Xia, LP; Yang, Q; Yin, CX; Zhang, B | 1 |
| Ichioka, D; Joraku, A; Kandori, S; Kawai, K; Kojima, T; Kurobe, M; Miyazaki, J; Nishiyama, H; Oikawa, T; Suetomi, T; Takaoka, E | 1 |
| Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 2 |
| Cascales-Campos, PA; Feliciangeli, E; Gil, E; Gil, J; González-Gil, A; López, V; Nieto, A; Parrilla, JJ; Parrilla, P; Ruiz-Pardo, J | 1 |
| Emoto, S; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H | 1 |
| Alvero, AB; Graham, E; Joo, WD; Montagna, MK; Mor, G; Sumi, NJ | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
| Ferrero, A; Friedlander, M; Gebski, V; Grunewald, T; Hardy-Bessard, AC; Harter, P; Heywood, M; Lee, CK; Lord, S; Pujade-Lauraine, E; Scambia, G; Schauer, C; Sehouli, J; Vergote, I; Woie, K | 1 |
| Cracchiolo, BM; DiPaola, RS; Gibbon, DG; Hellmann, M; Nieves-Neira, W; Rodriguez-Rodriguez, L; Shih, WJ; Song, M; Vaidya, A; Wagreich, AR | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Nahta, R; O'Regan, RM; Paplomata, E | 1 |
| Abe, A; Kato, K; Kondo, E; Matoda, M; Nomura, H; Okamoto, S; Omatsu, K; Sueoka, K; Takeshima, N; Umayahara, K; Usami, T; Yamamoto, A | 1 |
| Chang, GJ; Crane, CH; Das, P; Eng, C; Ohinata, A; Pathak, P; Phillips, JK; Rodriguez-Bigas, M; Rogers, JE; Sethi, S; Vauthey, JN; Wolff, RA; Xing, Y; You, YN | 1 |
| Ansaloni, L; Campanati, L; Catena, F; Ceni, V; Ceresoli, M; Coccolini, F; De Iaco, P; Frigerio, L; Jimenez Cruz, J; Lotti, M; Magnone, S; Napoli, J; Pinna, A; Rossetti, D; Runnebaum, I | 1 |
| Fujihara, A; Hongo, F; Kamoi, K; Miki, T; Nakamura, T; Nakanishi, H; Naya, Y; Oishi, M; Okihara, K; Ueda, T | 1 |
| Chen, Z; Erin, N; Gorczynski, RM; Khatri, I; Podnos, A | 1 |
| Badreldin, W; Berney, D; Chowdhury, S; Frampton, AE; Harding, V; Harland, SJ; Krell, J; Mazhar, D; Shamash, J; Stebbing, J; Wilson, P | 1 |
| Fujiwara, Y; Furuta, K; Horinouchi, H; Kanda, S; Katsui Taniyama, T; Kitazono, S; Kohno, T; Mizugaki, H; Nakamichi, S; Nokihara, H; Shiraishi, K; Sumi, M; Tamura, T; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Dragun, AE; Dunlap, NE; Jain, D; Meena, RA; Quillo, AR; Riley, EC; Shaughnessy, JN | 1 |
| Bos, MM; Boven, E; Braun, JJ; de Groot, SM; Honkoop, AH; Jager, A; Kroep, JR; Lam, SW; Linn, SC; ten Tije, AJ; van den Bosch, J; van Tinteren, H | 1 |
| Frankel, P; Kirschenbaum, M; Kruper, L; Luu, T; Shaw, S; Shinde, AM; Somlo, G; Vito, C; Vora, NL; Yim, JH; Yu, KW; Zhai, J | 1 |
| Barrett, JC; Benzaquen, AO; Cibula, D; Colombo, N; Dougherty, B; Friedlander, M; Hirte, H; Lowe, ES; Mackay, H; Mahner, S; Mathijssen, RH; Oza, AM; Plante, M; Poole, C; Rowbottom, J; Schmalfeldt, B; Sonke, GS; Špaček, J; Vuylsteke, P | 1 |
| Drake, R; Escobar, PF; Nutter, B; Rasool, N; Rose, PG; Simpkins, F | 1 |
| Koizumi, W; Morita, S; Sakata, Y | 1 |
| Borani, N; Karalök, MA; Keskin, HL; Köse, MF; Özgül, N; Tulunay, HG; Turan, AT; Üreyen, I | 1 |
| Aldairy, W; Borin, MT; Chen, M; Chittenden, J; Mocci, S; Rubets, I; Stroh, M | 1 |
| Endo, M; Imai, H; Kenmotsu, H; Ko, R; Mori, K; Murakami, H; Naito, T; Ono, A; Taira, T; Takahashi, T; Wakuda, K | 1 |
| Albain, KS; Barry, WT; Burstein, HJ; Carey, LA; Dang, CT; Ellis, M; Guo, H; Hudis, CA; Krop, IE; Marcom, PK; Moy, B; Overmoyer, BA; Partridge, AH; Rugo, HS; Shapira, I; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, DA | 1 |
| Jansaka, N; Suprasert, P | 1 |
| Azodi, M; Damast, S; Higgins, SA; Mani, S; Ratner, E; Rutherford, T; Schwartz, PE; Silasi, DA; Young, MR; Yu, JB | 1 |
| Kadalayil, L; KhoshZaban, M; Kuku, S; Ledermann, J; Loddo, M; McCormack, M; Proctor, I | 1 |
| Barton, S; Edwards, SJ; Thurgar, E; Trevor, N | 1 |
| Huang, HQ; Landrum, LM; Leitao, MM; Long, HJ; Method, M; Michael, H; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Stockman, S; Tewari, KS; Wenzel, LB | 1 |
| Krill, LS; Tewari, KS | 1 |
| Hasegawa, T; Kobayashi, D; Kuribayashi, K; Tanaka, M; Watanabe, N; Yanagihara, N | 1 |
| Du, XL; Li, HQ; Lu, CH; Pan, CX; Sheng, XG; Wang, C; Yin, YJ | 1 |
| Chang-Halpenny, C; Hwang-Graziano, J; Lu, SM | 1 |
| Mahdi, H; Rizzo, A; Rose, PG | 1 |
| Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P | 1 |
| Kamura, T; Kasamatsu, T; Katsumata, N; Kitagawa, R; Nakanishi, T; Nishimura, S; Satoh, T; Shibata, T; Takano, M; Ushijima, K; Yoshikawa, H | 1 |
| Bareggi, C; Blundo, C; Galassi, B; Gambini, D; Locatelli, E; Runza, L; Sosnovskikh, I; Tomirotti, M; Visintin, R | 1 |
| Bono, P; Diéras, V; Dirix, LY; Gonçalves, A; Guastalla, JP; Hurvitz, SA; Jassem, J; Jerusalem, G; Lakshmaiah, KC; Li, A; Limentani, SA; Pickett, CA; Pienkowski, T; Roché, H; Romieu, G; Sánchez-Rovira, P; Seguí Palmer, MÁ; Slamon, DJ; Sun, YN; Wildiers, H | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Ding, T; Liu, XH; Lv, QY; Song, J; Wang, SH; Wang, Y; Wei, MH; Wu, MD; Yang, QH; Zhou, J; Zhou, YF | 1 |
| Li, Y; Shang, YM; Yang, Y; Zheng, H | 1 |
| Hiura, K; Iwaki-Egawa, S; Komori, H; Shiraishi, A; Suzuki, C; Takamura, K; Watanabe, Y; Yamamoto, M | 1 |
| Bonanno, L; Canova, F; Carli, P; Conte, P; Favaretto, A; Pasello, G; Polo, V; Urso, L; Zago, G | 1 |
| Lheureux, S; Oza, AM | 1 |
| Arcangeli, V; Brandes, AA; Cecere, SC; Cinieri, S; Daniele, G; Di Maio, M; Di Napoli, M; Gallo, C; Lorusso, D; Maltese, G; Mosconi, AM; Orditura, M; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Ricci, C; Salutari, V; Sambataro, D; Scambia, G; Tamberi, S | 1 |
| Goldstein, BH; Micha, JP; Sassoon, AF; Wong, H | 1 |
| Gao, C; Gao, Y; He, W; Qu, W; Yu, Y; Zhang, S; Zhang, Y; Zhu, S | 1 |
| Han, JH; Kim, DY; Kim, JH; Kim, YM; Kim, YT; Lee, SW; Nam, JH; Park, JY | 1 |
| Baracat, EC; Carvalho, JP; da Costa Miranda, V; Estevez Diz, Mdel P; Favero, G; Fukushima, JT; Köhler, C; Macerox, N; Pfiffer, T | 1 |
| Moore, KN; Rowland, MR | 1 |
| Chen, G; Cheng, G; Feng, J; Han, B; He, J; Hu, C; Jiang, G; Liu, X; Lu, S; Lu, Y; Pan, H; Song, X; Wang, J; Wu, YL; Yin, AY; Zhang, H; Zheng, W; Zhou, C; Zhu, Y | 1 |
| Hidaka, T; Ishiguro, Y; Kameda, T; Kamiunten, A; Kawabata, T; Kitanaka, A; Kubuki, Y; Miyaushiro, S; Sekine, M; Shide, K; Shimoda, K; Umekita, Y | 1 |
| Huang, CB; Huang, LL; Lin, SJ; Pan, JJ; Qiu, SF; Xu, YJ; Zheng, W; Zong, JF | 1 |
| Cohen, JG; Li, AJ; Tran, AQ | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yoon, SJ; Yun, T | 1 |
| Barry, WT; Carey, LA; Cirrincione, C; Hudis, C; Leung, E; Lyss, AP; Mayer, EL; Moreno-Aspitia, A; Naughton, M; Perez, EA; Rugo, HS; Toppmeyer, D; Winer, EP | 1 |
| Fujiwara, K; Hasegawa, T; Hasumi, Y; Kigawa, J; Matsumoto, T; Nagao, S; Nakamura, K; Nishio, S; Okada, S; Otsuki, T; Shimada, M; Suzuki, M; Takano, M; Takei, Y; Takekuma, M; Tanabe, H | 1 |
| Bang, YJ; Cho, JY; Im, SA; Jung, JA; Kim, JW; Koh, SA; Lee, KH; Lee, KW; Park, YI; Shin, DB; Yu, KS; Zang, DY | 1 |
| Barry, WT; Berry, D; Cirrincione, CT; Citron, M; Ellis, M; Gradishar, W; Hudis, CA; Ingle, JN; Ligibel, JA; Liu, M; Mardis, E; Martino, S; Michaelson, R; Perou, CM; Sikov, W; Winer, E | 1 |
| Chen, S; Deng, Q; Jing, S; Li, J; Li, X; Ma, S; Tang, R; Wu, K; Wu, Z; Zheng, Z | 1 |
| Koo, YJ; Lim, KT | 1 |
| Aloisi, A; Angioli, R; Capriglione, S; De Cicco Nardone, C; Laraud, F; Miranda, A; Montera, R; Plotti, F; Scaletta, G; Terranova, C | 1 |
| Dartigues, P | 1 |
| Chu, C; Lin, LL; Rubin, S; Xu, MJ | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kamide, Y; Koga, Y; Kuwako, T; Masuda, T; Ono, A; Sunaga, N; Yamada, M | 1 |
| Bamias, A; Hilpert, F; Mitchell, L; Poveda, AM; Pujade-Lauraine, E; Reuss, A; Savarese, A; Scotto, N; Selle, F; Vergote, I; Witteveen, P | 1 |
| Bang, YJ; Cho, JY; Chun, HG; Fielding, A; Hodgson, D; Im, SA; Kim, WH; Kim, YH; Lee, KH; Lee, KW; O'Connor, MJ; Park, JO; Rowbottom, J; Song, EK; Yin, X; Zang, DY | 1 |
| Arend, RC; Leath, CA; Smith, HJ; Straughn, JM; Walters Haygood, CL | 1 |
| Hao, YZ; Lan, WG; Ma, LB; Wang, P; Xu, DH; Zhou, YL | 1 |
| Rexer, H | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Amagai, K; Boku, N; Gotoh, M; Hamamoto, Y; Kawai, H; Mizusawa, J; Nakamura, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shirao, K; Yamaguchi, K; Yasui, H | 1 |
| Bhamarapravatana, K; Mairaing, K; Piyawang, W; Poomtavorn, Y; Suwannarurk, K; Tangtiang, K; Thaweekul, Y | 1 |
| Ando, N; Harada, K; Inozume, T; Kawamura, T; Matsuzawa, M; Onuma, T; Sano, S; Shimada, S | 1 |
| Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G | 1 |
| Aloisi, A; Angioli, R; Capriglione, S; Fiore, L; Luvero, D; Montera, R; Panici, PB; Plotti, F; Scaletta, G; Terranova, C | 1 |
| Baselga, J; Chen, MF; Comen, EA; D'Andrea, GM; Dang, CT; Drullinsky, PR; Fornier, MN; Gajria, D; Goldfarb, SB; Hudis, CA; Iyengar, NM; Lacouture, ME; Lake, DE; Modi, S; Norton, L; Patil, S; Sugarman, SM; Theodoulou, M; Traina, TA; Troso-Sandoval, TA | 1 |
| Im, YH; Kim, M; Kim, S; Lee, J; Lee, SJ; Park, SH; Park, YH | 1 |
| Banerjee, S; Carty, K; Davidson, S; Dive, C; Flubacher, M; Gourley, C; Hudson, E; Jackson, D; Jankowska, P; Lord, R; McCartney, E; McCormack, M; Paul, J; Powell, M; Rai, D; Reed, N; Symonds, RP; West, CML | 1 |
| Tewari, KS | 1 |
| Zhu, Z | 1 |
| Bi, Y; Chen, X; Chen, Y; Cheng, C; Cheng, X; Cui, H; Cui, Y; Guo, J; Guo, S; Hu, X; Jia, J; Jia, Z; Kong, P; Li, G; Li, H; Li, Q; Li, Y; Liang, J; Liu, H; Liu, J; Qian, Y; Shi, R; Song, B; Wang, C; Wang, F; Wang, J; Wang, T; Xi, Y; Xu, E; Yan, T; Yang, B; Yang, J; Zhan, Q; Zhang, L; Zhang, Y; Zhao, Z; Zhou, Y | 1 |
| Győrffy, B; Lisanti, MP; Peiris-Pagès, M; Smith, DL; Sotgia, F | 1 |
| Fujitake, S; Ishigure, K; Ishiyama, A; Ito, S; Kobayashi, D; Kodera, Y; Kojima, H; Mochizuki, Y; Morita, S; Nakanishi, K; Shikano, T | 1 |
| Chen, Y; Cheng, K; Du, Y; Gou, HF; Li, C; Liu, JY; Wu, J; Xu, F; Yang, Y; Yuan, L | 1 |
| Afsar, CU; Duman, BB; Ercolak, V; Gunaldi, M; Sahin, B | 1 |
| Holmes, D | 1 |
| Arjona-Sánchez, Á; Briceño, FJ; Casado-Adam, Á; Medina-Fernández, FJ; Muñoz-Casares, FC; Muñoz-Villanueva, MC; Ortega-Salas, R; Rubio, MJ; Rufián-Peña, S; Sánchez-Hidalgo, JM | 1 |
| Cho, HJ; Kim, DK; Kim, HR; Kim, YH; Park, SI; Park, YS | 1 |
| Kim, JH; Lee, EJ; Lee, TJ; Nguyen, TM; Park, J; Park, MS; Shin, IW | 1 |
| Dobelbower, MC; Dreicer, R; George, A; Heney, NM; Kaufman, DS; Mitin, T; Sandler, HM; Shipley, WU; Souhami, L; Uzzo, RG; Wallace, HJ; Zietman, AL | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Sumi, M; Tamura, T; Yamamoto, N | 1 |
| Audibert, LF; Cagney, JM; Christos, PJ; Saxena, A; Scheff, RJ; Schneider, BJ | 1 |
| Jeong, K; Lee, SR; Park, S | 1 |
| Bacon, CL; Bracken-Clarke, D; Browne, PV; Conneally, E; Daly, PA; Flynn, C; Gardiner, N; Hayden, PJ; Kennedy, MJ; Lee, G; McCaffrey, J; Ni Chonghaile, M; O'Donnell, DM; O'Kane, G; Power, D; Vandenberghe, E | 1 |
| Albers, P; Niegisch, G; Retz, M; Siener, R | 1 |
| Cheng, H; Ding, H; Han, X; Li, A; Liu, Y; Lv, J; Shao, L; Si, X; Sun, L; Sun, Y; Yang, N; Yang, Y; Zhang, XA; Zhu, D | 1 |
| Bach, BA; Bamias, A; Brize, A; Coleman, RL; DeCensi, A; Fabbro, M; Fujiwara, K; Lhommé, C; Monk, BJ; Oaknin, A; Provencher, D; Raspagliesi, F; Ray-Coquard, I; Vergote, I; Vogl, FD; Zhang, K | 1 |
| Boupaijit, K; Suprasert, P | 1 |
| Beriwal, S; Boisen, MM; Edwards, RP; Kelley, JL; Lesnock, JL; Richard, SD; Zorn, KK | 1 |
| Frank, H; Kitzwögerer, M; Moser, M; Wiedemann, D | 1 |
| Ezendam, NP; Frielink, LM; Pijlman, BM; Pijnenborg, JM | 1 |
| Gunnarsson, O; Hwang, WT; Narayan, V; Nathanson, KL; Squillante, CM; Stadtmauer, EA; Vaughn, DJ | 1 |
| Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N | 1 |
| Abdi, R; Alikhasi, A; Amouzegar-Hashemi, F; Esmati, E; Kalaghchi, B | 1 |
| Cosio, S; Fanucchi, A; Gadducci, A; Lanfredini, N; Menichetti, A; Notarnicola, M | 1 |
| Pugliano, L; Ryan, C; Tsoi, D; White, M; Woodward, N | 1 |
| Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ | 1 |
| Gill, HS; Mody, MD; Saba, NF | 1 |
| Fei, Z; Jin, X; Li, L; Lin, B; Pan, Q; Su, H; Xie, C; Xue, S; Zhang, X; Zhao, H; Zhao, L | 1 |
| Bisagni, G; Ciccarese, M; Fontanella, C; Gamucci, T; Leo, L; Marchetti, P; Molino, A; Puglisi, F; Silva, RR | 1 |
| Anghel, R; Beslija, S; Brodowicz, T; Dank, M; Eniu, A; Greil, R; Inbar, M; Kahán, Z; Láng, I; Melichar, B; Messinger, D; Nisenbaum, B; Petruzelka, L; Pienkowski, T; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Boku, N; Iwasa, S; Kitagawa, Y; Kodera, Y; Masuishi, T; Miki, A; Miwa, H; Morita, S; Nishida, Y; Nishikawa, K; Noshiro, H; Saji, S; Sakamoto, J; Takahashi, T; Takaishi, H; Yamada, Y; Yoshida, K; Yoshikawa, T | 1 |
| Bach, BA; Bae, DS; Bamias, A; Brize, A; Coleman, RL; Fabbro, M; Fujiwara, K; Karlan, BY; Lhommé, C; Ma, H; Marth, C; Monk, BJ; Oaknin, A; Oza, AM; Poveda, A; Provencher, DM; Raspagliesi, F; Ray-Coquard, I; Redondo, A; Richardson, G; Rincón, DG; Vergote, I; Vogl, FD | 1 |
| Kamura, T; Kitagawa, R; Konishi, I; Nishio, S; Shibata, T; Ushijima, K; Yoshikawa, H | 1 |
| Abell, F; Apt, D; Chan, S; Fehrenbacher, L; Gendreau, S; Huizing, M; Laing, R; Petrakova, K; Rooney, I; Roylance, R; Singel, S; Vuylsteke, P; Zhou, J | 1 |
| Ahn, KJ; An, IS; An, S; Bae, S; Choi, YM; Kim, TJ; Lee, J; Lee, JH | 1 |
| Otsuka, I; Shoji, K | 1 |
| Beyer, J; Lorch, A | 1 |
| Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Michel, L; Nussenbaum, B; Paniello, R; Rich, J; Thorstad, W; Trinkaus, K; Uppaluri, R; Wildes, TM | 1 |
| Bo, L; Cui, H; Fang, Z; Qun, T; Xia, C | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Bergmann, JJ; Geijsen, ED; Hulshof, MC; Jeene, PM; Muller, K; van Berge Henegouwen, MI; van Laarhoven, HW; Versteijne, E | 1 |
| Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A | 1 |
| Amant, F; Annibali, D; Cuppens, T; Depreeuw, J; Koskas, M; Lambrechts, D; Moens, S; Moerman, P | 1 |
| Brown, J; Burzawa, JK; Byers, LA; Coleman, RL; Frumovitz, M; Munsell, MF; Ramalingam, P | 1 |
| Adansa Klain, JC; Berrocal, A; Caballero Daroqui, J; Cruz-Hernández, JJ; Del Barco Morillo, E; González-Rivas, C; Martínez-Galán, J; Martínez-Trufero, J; Mesía, R; Pastor Borgoñon, M; Vázquez Fernández, S; Vera, R | 1 |
| Chai, Y; He, B; Liu, Z; Wang, T; Zhou, Z | 1 |
| Coeffic, D; García, Y; Gebski, V; Gibbs, E; González-Martín, A; Hilpert, F; Huizing, M; Kaern, J; Kristensen, G; Lee, CK; Levaché, CB; Lück, HJ; Pujade-Lauraine, E; Roemer-Becuwe, C; Sorio, R; Witteveen, P; Zagouri, F | 1 |
| Juszczak, M; Paschke, L; Slupski, M | 1 |
| Baik, CS; Baker, KK; Chow, LQM; Eaton, KD; Goulart, B; Lee, SM; Martins, R; Pellini Ferreira, B; Redman, M; Rodriguez, CP; Santana-Davila, R | 1 |
| Aghajanian, C; Bell-McGuinn, KM; Brady, WE; Carter, JS; Cohn, DE; Di Silvestro, PA; Dizon, DS; Duan, W; Fracasso, PM; Jelovac, D; Lankes, HA; Mannel, RS; Mutch, DG; Resnick, KE; Salani, R; Thaker, PH | 1 |
| Augspurger, ME; Bogart, JA; Bosch, W; Bradley, JD; Choy, H; Chun, SG; Dobelbower, MC; Galvin, JM; Hu, C; Iyengar, P; Kavadi, VS; Komaki, RU; MacRae, RM; Narayan, S; Paulus, R; Raben, A; Robinson, CG; Schild, SE; Timmerman, RD; Wynn, RB | 1 |
| Adkins, D; Daly, K; Ley, J; Oppelt, P; Wildes, TM | 1 |
| Arenare, L; Bergamini, A; Cecere, SC; Della Pepa, C; Di Napoli, M; Facchini, G; Gargiulo, P; Mangili, G; Pignata, S; Pisano, C; Rossetti, S; Tambaro, R | 1 |
| Baehner, FL; Butler, SM; Cherbavaz, DB; Costantino, JP; Jamshidian, F; Jeong, JH; Julian, TB; Kim, SR; Lembersky, BC; Liu, Q; Mamounas, EP; Paik, S; Shak, S; Sing, AP; Tang, G; Wickerham, DL; Wolmark, N | 1 |
| Aimone, P; Alyasova, A; Barone, C; Chakravartty, A; Chol, M; Dechaphunkul, A; Erfán, J; Faivre, S; Hirawat, S; Karpenko, A; Kasper, S; Kim, SB; Kiss, LA; Li, SH; Licitra, L; Lin, JC; Mesía, R; Nagarkar, R; Ochsenreither, S; Remenár, É; Soulières, D; Tamás, L; Turri, S | 1 |
| Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
| Anderson, CB; DeCastro, GJ; Ghandour, R; Matulay, JT; McKiernan, JM; Robins, DJ; Sui, W | 1 |
| Ali, S; Moslemi-Kebria, M; Rose, PG; Simpkins, F | 1 |
| Bajorin, DF; Bellmunt, J; Choueiri, TK; Climent, MA; Culine, S; de Wit, R; Fong, L; Fradet, Y; Gerritsen, W; Gurney, H; Lee, JL; Mai, Y; Necchi, A; Perini, RF; Petrylak, DP; Poehlein, CH; Quinn, DI; Sternberg, CN; Vaughn, DJ; Vogelzang, NJ | 1 |
| Jiang, H; Li, J; Liu, X; Yuan, Z; Zhu, X | 1 |
| Duan, Y; Fan, X; Gong, Z; Gulina, K; Hou, Y; Jiang, Z; Li, J; Li, X; Li, Z; Liu, Y; Peng, Y; Sun, L; Tan, G; Xie, B; Yin, L; Yu, X; Yuan, B; Zhu, Q | 1 |
| Bachelot, T; Blay, JY; Dufresne, A | 1 |
| Bogardus, C; Canfield, V; Hancock, SB; Kaneaster, SK; Kojouri, K; Krempl, GA; Medina, JE | 1 |
| Ameshima, S; Demura, Y; Ishizaki, T; Mizuno, S; Morikawa, M; Okazawa, H | 1 |
| Chu, SC; Kao, RH; Li, CC; Wang, TF; Yao, CY | 1 |
| Economopoulos, T; Panayiotides, J; Papachristodoulou, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Sykiotis, C; Tountas, N; Xiros, N | 1 |
| Ajani, JA; Arora, R; Bhutani, MS; Correa, AM; Hofstetter, WL; Izzo, JG; Javeri, H; Lee, JH; Liao, Z; Maru, D; McAleer, MF; Swisher, SG | 1 |
| Hamaguchi, T; Hirashima, Y; Kato, K; Matsubara, J; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y | 1 |
| Eisenkop, SM; McAlpine, JN; Spirtos, NM | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Papadimitriou, CA; Pectasides, D | 1 |
| Kamposioras, K; Papaxoinis, G; Pectasides, D; Pectasides, E | 1 |
| Chen, YL; Chu, CN; Liu, YQ; Tang, DH | 1 |
| Bokemeyer, C; Kollmannsberger, C | 1 |
| Hakenberg, OW; Klebingat, HJ; Protzel, C | 1 |
| Abu-Rustum, NR; Aghajanian, CA; Alektiar, KM; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q | 1 |
| Konishi, I; Sugiyama, T | 1 |
| Asaishi, K; Doi, T; Inaba, M; Kimura, M; Nishimura, R; Okamoto, Y; Okuyama, N; Takeuchi, H; Tamaki, N; Tominaga, T; Yanagita, Y | 1 |
| Blay, JY; Hartmann, JT; Hogendoorn, PC; Judson, I; Marreaud, S; Reichardt, P; Schlemmer, M; Thyss, A; Van Glabbeke, M; Verweij, J | 1 |
| An, N; Gao, M; Gao, YN; Jiang, GQ; Yan, X | 1 |
| Vasey, PA | 1 |
| Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Souda, M; Tanaka, K; Yamamoto, Y | 1 |
| Choi, IS; Choi, JH; Chung, HC; Hong, YS; Kang, WK; Kim, SY; Lee, JJ; Lee, KH; Lee, YY; Song, HS; Woo, IS | 1 |
| Adler, L; O'Malley, D; Sabbatini, P; Secord, AA; Sill, MW | 1 |
| Bachelot, T; Colin, C; Fournel, C; Ganne, C; Jacquin, JP; Jaisson-Hot, I; Lenoir, VT; Marechal, F; Mechin-Cretinon, I; Orfeuvre, H; Peaud, PY; Poncet, B; Salles, B; Tigaud, JD; Trillet-Lenoir, V | 1 |
| Chen, CA; Hsiao, SM; Hsieh, CY; Lin, HH; Wei, LH | 1 |
| Aizawa, H; Azuma, K; Hattori, S; Ikeda, J; Itoh, K; Kage, M; Kawahara, A; Kuwano, M; Sasada, T; Takamori, S; Yamada, A | 1 |
| Horiguchi, J; Iino, Y; Ishikawa, Y; Kikuchi, M; Koibuchi, Y; Nagaoka, R; Odawara, H; Rokutanda, N; Sato, A; Takeyoshi, I; Tokiniwa, H | 1 |
| Kushimoto, T; Misawa, A; Nagao, M; Yasuda, M | 1 |
| Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Mochizuki, Y; Uemura, T | 1 |
| El-Saghir, NS; Farhat, MH; Shamseddine, AI | 1 |
| Ando, M; Fujiwara, Y; Hasegawa, T; Hashizume, K; Hatanaka, Y; Katsumata, N; Kinoshita, T; Kouno, T; Ono, M; Shimizu, C; Tamura, K; Tsuta, K; Yonemori, K | 1 |
| Foad, I; Hussein, T; Margergis, M; Mostafa, E; Sharawy, I | 1 |
| Cai, RG; Li, Q; Wang, JY; Wu, WH; Xu, BH; Yuan, P; Zhang, P; Zhao, LM; Zhou, AP | 1 |
| Berek, J; McGuire, W; Nicodemus, CF; Schultes, B; Smith, LM; Taylor, P | 1 |
| Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM | 1 |
| Gao, M; Gao, YN; Jiang, GQ; Wang, W; Yan, X; Zheng, H | 1 |
| Halle, J; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Cho, BC; Choi, HJ; Kim, H; Kim, JH; Kim, KJ; Lee, YJ; Shin, S | 1 |
| Amano, S; Enomoto, K; Kitajima, A; Sakurai, K; Shiono, M; Tani, M | 1 |
| De Benedictis, E; Fasolo, A; Gianni, L; Mariani, G | 1 |
| Ebina, Y; Hosaka, M; Mitamura, T; Moriwaki, M; Ohba, Y; Sakuragi, N; Takeda, M; Todo, Y; Watari, H | 1 |
| Axtell, AE; Bottsford-Miller, J; Drake, RD; Fader, AN; Gehrig, PA; Gibbons, H; Havrilesky, LJ; Huh, WK; Kelley, JL; Moore, KN; Nagel, C; O'Malley, DM; Rose, PG; Secord, AA; Tuller, E; Walsh, CS; Zanotti, KM | 1 |
| Chin, SN; Dodge, J; Mackay, H; Murphy, J; Oza, A; Pinto, V; Rosen, B | 1 |
| Chauffert, B; Combe, M; Delroeux, D; Demarchi, M; Guardiola, E; Heyd, B; Lorgis, V; Pivot, X; Royer, B; Stein, U | 1 |
| Asmar, L; Boehm, KA; Crozier, M; Encarnacion, C; Hancock, K; Messing, MJ; Teneriello, MG; Tseng, PC; Williams, A | 1 |
| Güth, U; Holzgreve, W; Huang, DJ; Kann, SR; Schötzau, A; Wight, E | 1 |
| Marquez, A; Perez-Ruiz, E; Ribelles, N; Roman, A; Sanchez-Muñoz, A | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Mabuchi, S; Morishige, K; Sakata, M; Tsutsui, T | 1 |
| Hirabayashi, N; Ishikura, S; Kimura, M; Kodera, Y; Miyashita, Y; Nagata, N; Oba, K; Sakamoto, J; Takahashi, N; Tsuburaya, A; Yoshida, K; Yoshikawa, T | 1 |
| Hagen, R; Hoppe, F; Pfreundner, L; Relic, A; Scheich, M; Stapf, J; Voelter, C | 1 |
| Carpenter, PM; Marshall, J; Mehta, RS; Schubbert, T | 1 |
| Bordin, V; Bozzoni, S; Caldiera, S; Codecà, C; Di Maria, G; Ferrari, D; Fiore, J; Floriani, I; Foa, P; Luciani, A; Zonato, S | 1 |
| Carey, MS; D'Souza, DP; Hammond, JA; Harle, IA; Kwon, JS; Lupe, K; Radwan, JS | 1 |
| du Bois, A; Gropp, M; Kimmig, R; Kuhn, W; Lück, HJ; Meier, W; Olbricht, S; Pfisterer, J; Reuss, A; Richter, B | 1 |
| Anan, K; Ishikawa, M; Iwakuma, N; Mitsuyama, S; Takamatsu, Y; Tamura, K; Umeda, S | 1 |
| Coens, C; Demonty, G; Guerra, C; Reed, N; Scarabeli, C; van der Velden, J; Vergote, I; Witteveen, PO | 1 |
| Altaras, M; Ben-Harim, Z; Bruchim, I; Fishman, A; Shechter-Maor, G | 1 |
| Economopoulos, T; Fountzilas, G; Koumarianou, A; Panayiotides, J; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N | 1 |
| Bentley, JR; Miller, WH; Oza, A; Pouliot, JF; Power, P; Provencher, D; Stuart, G | 1 |
| Sivanesaratnam, V | 1 |
| Ji, W; Lü, JM; Ou, GF; Ren, H; Wang, LH; Wang, XZ; Yin, WB; Zhou, ZM | 1 |
| A'Hern, R; Ang, JE; Blake, P; Coombes, I; Everard, M; Gabra, H; Gore, ME; Hall, G; Jenkins, A; Jones, RL; Kaye, SB; Keyzor, C; Shah, RN; Thomas, K | 1 |
| Eifel, PJ; Gershenson, DM; Jhingran, A; Klopp, AH; Lu, K; Ramondetta, L | 1 |
| Blumenschein, G; Esmaeli, B; Ginsberg, LE; Phan, L; Phan, R; Williams, MD | 1 |
| Igarashi, T; Kitagawa, Y; Kumagai, K; Nakamura, R; Saikawa, Y; Takahashi, T; Takeuchi, Y | 1 |
| Fridrichová, P; Malírová, E; Melichar, B; Tomsová, M | 1 |
| Basu, S; Faber, LP; Kim, AW; Liptay, MJ; Miller, C; Milman, S; Warren, WH | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW | 1 |
| Akrivos, T; Daladimos, T; Kalinoglou, N; Karabelis, A; Karvounis, N; Kosmas, C; Malamos, N; Mylonakis, N; Tsakonas, G; Tsavaris, N; Vorgias, G | 1 |
| Hatta, M; Kamigaki, S; Masuda, N; Nakayama, T; Sakamoto, J; Taguchi, T; Yamamura, J | 1 |
| Ishii, T; Kai, K; Kashima, K; Kira, N; Narahara, H; Nasu, K; Takai, N | 1 |
| Ozols, RF | 3 |
| Hoekstra, AV; Hurteau, JA; Kirschner, CV; Rodriguez, GC | 1 |
| Heintz, AP; van der Graaf, Y; Vernooij, F; Verweij, E; Witteveen, PO | 1 |
| Cohn, DE; Copeland, LJ; Eisenhauer, E; Fowler, JF; Hurt, JD; O'Malley, DM; Richardson, DL; Salani, R; Seamon, LG | 1 |
| Bahleda, R; Cadranel, J; Ferte, C; Gomez-Roca, C; Loriot, Y; Moldovan, C; Soria, JC; Wislez, M | 1 |
| Akiya, T; Higuchi, K; Koizumi, W; Nakayama, N; Sakuyama, T; Sasaki, T; Sato, A; Sekikawa, T; Tanabe, S; Yamaguchi, K | 1 |
| Monk, BJ; Tewari, KS | 2 |
| Goto, T; Inoue, H; Kato, M; Kikuchi, Y; Kita, T; Miyamoto, M; Ohbayashi, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Akagi, Y; Fujita, K; Ito, A; Ito, K; Kagemoto, M; Kashiwado, K; Kimura, T; Matsuura, K; Monzen, Y; Mori, M; Murakami, Y; Nagata, Y; Wadasaki, K; Yuki, S | 1 |
| Blanch, JL; Caballero, M; Grau, JJ; Monzó, M; Verger, E | 1 |
| Amour, E; Beckendorf, V; Bossard, N; Douillard, JY; Girard, N; Grunenwald, D; Milleron, B; Mornex, F; Quoix, E | 1 |
| Candeloro, G; Di Orio, F; Guerriero, G; Piazze, J; Rea, S; Recchia, F | 1 |
| Gu, J; Han, HB; Hu, MH; Li, JY; Wang, Y; Xie, Y; Xing, BC; Xu, XL; Xu, ZL; Zhang, ZQ; Zhao, W | 1 |
| Auner, V; Horvat, R; Oskay-Oezcelik, G; Sehouli, J; Speiser, P; Zeillinger, R | 1 |
| Blank, SV; Caputo, TA; Christos, PJ; Einstein, MH; Goldberg, GL; Goldman, N; Hershman, D; Ivy, PS; Kim, M; Kuo, DY; Muggia, F; Pothuri, B; Runowicz, CD | 1 |
| Bell, J; Chan, JK; Herzog, T; Kapp, DS; Monk, BJ; Teoh, D; Tian, C | 1 |
| Balleyguier, C; Duvillard, P; Even, C; Gouy, S; Lhommé, C; Morice, P; Pautier, P; Petrella, M; Uzan, C | 1 |
| Chirieac, LR; Colson, YL; Grinstaff, MW; Liu, R; Southard, E; Walpole, J; Wolinsky, JB | 1 |
| Hou, JL; Li, XG; Liu, LY; Wu, LY; Yao, HW; Yuan, GW | 1 |
| Santarpia, L; Sarlis, NJ; Sherman, SI; Skarulis, MC; Tulloch-Reid, M | 1 |
| Ansari, RH; Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Aizawa, N; Hayashi, N; Hayashida, H; Higaki, N; Ichihara, T; Ikeda, T; Kan, K; Murakami, M; Nakano, K; Niju, T; Saito, N; Sakon, M; Soma, I | 1 |
| Fukushima, Y; Hashimoto, K; Hiraki, M; Matsumoto, S; Matsuyama, J; Morimoto, T; Morita, S; Naitou, A; Nishishou, I; Nomura, T; Sasaki, Y; Yokoyama, S | 1 |
| Akitake, H; Ebisui, C; Fujimoto, T; Hama, N; Kashiwazaki, M; Konishi, M; Maekawa, T; Ookubo, K; Ootsuka, M; Taniguchi, M; Tsujie, M; Yoshioka, S | 1 |
| Baba, K; Hasegawa, Y; Ichikawa, M; Imaizumi, K; Kataoka, K; Kondo, M; Kume, H; Matsumoto, S; Noda, Y; Shindo, Y; Shindoh, J; Suzuki, K; Suzuki, R; Takagi, K; Taniguchi, H; Tanikawa, Y | 1 |
| Hama, Y; Nakagawa, K | 1 |
| Fujitani, K; Furukawa, H; Kimura, Y; Machida, H; Shimokawa, T; Takiuchi, H; Tominaga, K; Tsujinaka, T; Yamamoto, M; Yano, H | 1 |
| Aebert, H; Al-Kamash, F; Bamberg, M; Budach, W; Dippon, J; Eschmann, SM; Friedel, G; Hehr, T; Kimmich, M; Kohlhaeufl, M; Kyriss, T; Pfannenberg, C; Spengler, W; Steger, V; Veit, S; Walles, T | 1 |
| Im, DD; Matsuo, K; Rosenshein, NB | 1 |
| Bachelot, T; Chabaud, S; Favier, B; Fayette, J; Girodet, D; Montbarbon, X; Montella, A; Pommier, P; Racadot, S; Zrounba, P | 1 |
| Godoy, H; Kesterson, JP; Lele, S | 1 |
| Jiang, ZF; Shao, ZM; Xu, BH | 1 |
| Bae, SH; Baek, JH; Chae, YS; Do, YR; Kim, JG; Kim, JY; Kim, MK; Lee, KH; Park, KU; Ryoo, HM; Song, HS | 1 |
| Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T | 1 |
| Abbruzzi, A; Chen, C; Come, S; Dang, C; Hudis, C; Lin, N; Morris, P; Moy, B; Norton, L; Patil, S; Steingart, R; Sugarman, S; Winer, E | 1 |
| Chu, P; Ghatage, P; Lucero, CA; Nation, J; Nelson, G | 1 |
| Fang, Q; Li, P; Ou, W; Sun, HB; Wang, SY; Yang, H; Ye, X; Zhang, BB | 1 |
| Bepler, G; Cognetti, F; Conti, F; Di Lauro, L; Fabi, A; Giannarelli, D; Lopez, M; Metro, G; Sergi, D; Tomao, F; Vici, P | 1 |
| Chang, TC; Chen, CK; Chou, HH; Hong, JH; Hsueh, S; Huang, YT; Lai, CH; Lee, SP; Tsai, CS; Wang, CC | 1 |
| Egawa-Takata, T; Enomoto, T; Fujita, M; Kimura, T; Matsuzaki, S; Miyake, T; Miyatake, T; Ueda, Y; Yokoyama, T; Yoshino, K | 1 |
| Bryan, M; Pavlick, AC; Pliner, L; Pulte, ED; Saunders, T; Toomey, KC; Wieder, R | 1 |
| Baird, RD; Kaye, SB; Tan, DS | 1 |
| Dahlberg, S; Hambleton, J; Johnson, DH; Kolb, MM; Sandler, A; Schiller, J; Wang, L; Yi, J | 1 |
| Aoki, D; Hatae, M; Hiura, M; Jobo, T; Katsumata, N; Konishi, I; Nomura, H; Takahashi, F; Watanabe, Y; Yaegashi, N | 1 |
| Amano, N; Hamamoto, Y; Hironaka, S; Imamoto, H; Kato, K; Muro, K; Seriu, T; Tahara, M; Takiuchi, H | 1 |
| Chung, HH; Kang, SB; Kim, HJ; Kim, HS; Kim, JW; Kim, JY; Kim, K; Kim, YB; Park, NH; Song, YS | 1 |
| Liu, J; Matulonis, UA | 1 |
| Li, M; Li, XG; Li, YF; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| DeCamp, MM; Flickinger, JC; Medford-Davis, LN; Recht, A; Schaefer, E; Varlotto, JM | 1 |
| An, HY; Cao, XF; Ji, L; Lü, J; Tao, L; Wang, DD; Wang, S; Wu, BC; Zhu, B | 1 |
| Aragane, H; Ichikawa, D; Itokawa, Y; Kakihara, N; Koizumi, K; Morii, J; Morita, S; Nishi, H; Okamoto, K; Otsuji, E; Sakamoto, J; Shimotsuma, M; Taniguchi, F; Ueda, Y; Yamagishi, H; Yamashita, T | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, D; Huang, HQ; McMeekin, DS; Monk, BJ; Ramondetta, L; Wenzel, L | 1 |
| Bast, RC; Markman, M | 1 |
| Adams, S; Bauer, JA; Chakravarthy, AB; Donach, M; Formenti, SC; Goldberg, JD; Hochman, T; Lymberis, S; Muggia, F; Pietenpol, JA; Schneider, RJ; Singh, B; Spicer, D | 1 |
| Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK | 1 |
| Andreopoulou, E; Blank, S; Borgato, L; Boyd, L; Curtin, J; Levinson, B; Muggia, F; Pothuri, B; Safra, T; Tiersten, A | 1 |
| Angleitner-Boubenizek, L; Dirschlmayer, W; Marth, C; Medl, M; Petru, E; Reinthaller, A; Schauer, C; Sevelda, P; Stummvoll, W; Zeimet, A | 1 |
| Coleman, RL; Fujita, H; Itani, Y; Ito, K; Kuroboshi, H; Nobunaga, T; Tsubamoto, H | 1 |
| Hayashi, N; Igawa, S; Iida, Y; Katono, K; Kimura, Y; Maki, S; Makita, S; Masuda, N; Onoda, S; Otani, S; Takakura, A; Yamamoto, M; Yanagisawa, N | 1 |
| Ansari, R; Bechar, N; Bedano, P; Bhatia, S; Einhorn, L; Govindan, R; Hanna, N; Jalal, S; Koneru, K; Schneider, B; Wu, J; Yu, M | 1 |
| Hirabayashi, N; Kitano, M; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Guan, Z; Jiang, Z; Shen, Z; Xu, B; Zhang, X | 1 |
| Argenta, PA; Carson, LF; Chura, JC; Downs, LS; Geller, MA; Ghebre, R; Judson, PL | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Fujii, M; Hasegawa, Y; Kurono, Y; Minami, H; Nibu, K; Onozawa, Y; Sagae, D; Seriu, T; Tahara, M; Tomita, K; Tsukuda, M; Watanabe, A | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| DI, GH; Hu, XC; Li, JJ; Liu, GY; Lu, JS; Shao, ZM; Wang, Y; Wang, ZH; Wu, J; Yang, WT | 1 |
| Chen, C; Chen, P; Jin, ZL; Li, K; Li, N; Zhang, CC | 1 |
| Amano, S; Enomoto, K; Sakurai, K | 1 |
| Fukuda, S; Hiraki, S; Kawaoka, T; Matsukuma, S; Nagashima, A | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Kaneko, J; Katsuta, E; Maejima, S; Ohkubo, T; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Ishikawa, H; Iwazaki, S; Izumi, M; Kakinuma, S; Kawate, S; Kobayashi, J; Kobayashi, M; Koyano, T; Makita, F; Nakagami, K; Nakamura, S; Ogawa, T; Ohya, T; Roppongi, T; Sakamoto, I; Sato, Y; Sunose, Y; Takeyoshi, I; Tanahashi, Y; Tomizawa, N; Yamada, T | 1 |
| Bepler, G; Chen, DT; Chiappori, A; Dilling, TJ; Greenberg, H; Haura, E; Hazelton, T; Simon, G; Stevens, C; Tanvetyanon, T; Wagner, H; Walsh, F; Williams, C | 1 |
| Chen, JS; Cheng, JC; Chuang, TH; Hsu, CH; Hsu, HH; Huang, PM; Kuo, SW; Lee, JM; Lee, YC; Lin, CC; Shun, CT; Wang, YH; Wu, MT; Yang, PW; Yang, SY | 1 |
| Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H | 1 |
| Kato, K; Ushijima, M; Yamakawa, Y | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Rheaume, PS; Richardson, DL; Salani, R | 1 |
| Iishi, H; Imamoto, H; Kakutani, C; Morimoto, T; Morita, S; Nakamura, M; Narahara, H; Oba, K; Oriuchi, N; Sakamoto, J; Shiozaki, H; Yumiba, T | 1 |
| Lee, DW; Lee, HN; Lee, KH; Lee, YS; Park, EK; Park, JS | 1 |
| Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Nagawa, H; Yamaguchi, H; Yamashita, H | 1 |
| Brown, C; Buck, M; Dorum, A; Elit, L; Floquet, A; Kaminsky, MC; Kimmig, R; Kurtz, JE; Petru, E; Pujade-Lauraine, E; Reed, N; Scambia, G; Varsellona, N; Veillard, AS | 1 |
| Adewoye, H; Adrover, E; Alba, E; Almel, S; Baños, A; Cabaribere, D; Crown, J; Eiermann, W; Hei, YJ; Hurvitz, S; Jagiełło-Gruszfeld, A; Kennedy, MJ; Lang, I; Latreille, J; Lemmerick, Y; Lindsay, MA; Mackey, JR; Martin, M; Moroose, R; Munoz, M; Pienkowski, T; Pinter, T; Priou, F; Provencher, L; Ramos, M; Roche, H; Rolski, J; Rupin, M; Snyder, R | 1 |
| Atkinson, EN; Brown, J; Burke, TW; Coleman, RL; Euscher, E; Gano, JB; Lacour, RA; Ramirez, PT; Ramondetta, LM; Sun, CC | 1 |
| Atkinson, MA; Ferguson, SE; Helpman, L; Le, L; Mackay, H; Mackean, M; Rana, A; Rogerson, A | 1 |
| Colson, YL; Grinstaff, MW; Griset, AP; Khullar, OV; Liu, R; Wade, JE; Zubris, KA | 1 |
| Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
| Galic, VL; Herzog, TJ; Lewin, SN; Wright, JD | 1 |
| Aletti, GD; Bakkum-Gamez, JN; Cliby, WA; Keeney, GL; O'Malley, DM; Powless, CA; Richardson, DL; Seamon, LG | 1 |
| Blessing, JA; McMeekin, S; Miller, DS; Muller, CY; Rotmensch, J; Schilder, RJ; Shahin, MS; Tewari, KS; Warshal, DP | 1 |
| Brady, WE; Coleman, RL; Hoffman, JS; Lentz, SS; McMeekin, DS; Rose, PG; Shahin, MS; Soper, JT | 1 |
| Ajani, JA; Hofstetter, WL; Komaki, RU; Konski, AA; Swisher, SG; Willett, CG; Winter, KA; Wu, TT | 1 |
| Brady, MF; Cohn, DE; Degeest, K; Hanjani, P; Hiura, M; Kohn, EC; Lee, R; Mannel, RS; Michael, H; Monk, BJ | 1 |
| He, L; Huang, L; Huang, X; Li, JD; Liu, JH; Ren, YF; Wang, HY; Xiong, Y; Zheng, M | 1 |
| Chougule, P; DiSiena, MR; Koness, RJ; McRae, RG; Nigri, PT; Radie-Keane, K; Rathore, R; Ready, N; Wanebo, HJ | 1 |
| Alexandre, J; Dauba, J; Durando, X; Gladieff, L; Largillier, R; Lortholary, A; Paraiso, D; Pujade-Lauraine, E; Slama, B; Weber, B | 1 |
| Boman, K; Dell'Anna, T; Donoghoe, M; Fabbro, M; Ferrandina, G; Huober, J; Joly, F; Pujade-Lauraine, E; Ray-Coquard, I; Reinthaller, A; Sugimoto, A; Vaughan, M; Vergote, I | 1 |
| Hwang, JH; Lee, JK; Lee, KW; Lee, NW; Shin, BK; Song, SH | 1 |
| Bollet, MA; Campana, F; Chira, C; Derhem, N; Fourquet, A; Jacob, J; Kirova, YM; Marchand, V; Pierga, JY | 1 |
| Blasco, A; Cabrera, A; Camps, C; Carrato, A; Gil, M; Gómez-Aldaraví, L; González-Larriba, JL; Guijarro, R; Iranzo, V; Jantus, E; Massuti, B; Provencio, M; Rossell, R; Sanmartín, E; Sirera, R; Velasco, A | 1 |
| Abdel-Hady Hemida, R; Abdel-Hady, el-S; El-Shamey, M; Gamal, A | 1 |
| Beck, T; Bromund, J; Brufsky, A; Frontiera, M; Hainsworth, J; Hoelzer, K; Keaton, M; Krill-Jackson, E; Kroener, J; Marciniak, MD; Middleman, E; Nadella, P; Obasaju, C; Orlando, M; Panella, T; Paul, D; Tai, F; Whorf, R; Zhao, L | 1 |
| Chin, K; Esaki, T; Hamaguchi, T; Ikeda, R; Kato, K; Kimura, M; Matsumura, Y; Sakai, K; Shimada, Y; Tsuji, Y; Yamaguchi, K; Yoshikawa, T | 1 |
| Bidoli, E; Capobianco, G; Dessole, F; Lombardi, D; Miolo, G; Santeufemia, DA; Scalone, S; Sorio, R; Spazzapan, S; Tabaro, G; Veronesi, A | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Ghiringhelli, F; Ladoire, S; Pfitzenmeyer, P; Quipourt, V; Rambach, L | 1 |
| Catalano, PJ; Chirieac, LR; Colson, YL; Grinstaff, MW; Liu, R; Raut, CP; Wagner, AJ; Wolinsky, JB | 1 |
| Ceccacci, I; Maneschi, F; Manicone, A; Pane, C; Perugini, A; Simeone, A | 1 |
| Blair, EA; Cohen, EE; Haraf, DJ; Pederson, AW; Portugal, L; Salama, JK; Seiwert, T; Stenson, KM; Villaflor, VM; Vokes, EE; Witt, ME | 1 |
| An, X; He, Y; Li, Y; Wang, F; Wang, Z; Xu, R; Zhou, N | 1 |
| Amant, F; Capoen, A; Coenegrachts, L; Moerman, P; Vandenput, I; Verbist, G; Vergote, I | 1 |
| Droz, JP; Fizazi, K; Fléchon, A; Massard, C | 1 |
| Akazawa, K; Ishihara, H; Kim, SJ; Matsushima, T; Nakayama, S; Noguchi, S; Shibayama, M; Shimazu, K; Tamaki, Y; Torikoshi, Y; Tsukamoto, F | 1 |
| Ikeda, O; Kitajima, Y; Miyoshi, A; Noshiro, H; Satoh, S; Yakabe, T | 1 |
| Borsellino, N; Cinieri, S; Colucci, G; Febbraro, A; Galetta, D; Gebbia, V; Maiello, E; Marzano, N; Montrone, M; Pappagallo, GL; Pisconti, S; Rinaldi, A; Rizzo, P; Sasso, N | 1 |
| Daladimos, T; Kalinoglou, N; Karabelis, A; Kosmas, C; Moschovis, D; Mylonakis, N; Panagiotidi, E; Papachrysanthou, T; Politis, P; Tsakonas, G; Tsavaris, N; Vorgias, G | 1 |
| Cortes-Funes, H; Cruz-Hernandez, JJ; García-Sáenz, JA; Grau, JJ; Hitt, R; Irigoyen, A | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Barinoff, J; du Bois, A; Grabowski, J; Harter, P; Heitz, F; Hilpert, F; Kurzeder, C; Mahner, S; Pfisterer, J | 1 |
| Choi, HL; Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yun, T | 1 |
| Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, S; Park, SH; Park, YS | 1 |
| Berman, ML; Dalmar, A; Lentz, SE; Mahdavi, A; Tajalli, TR; Vasilev, SA | 1 |
| Hiramatsu, Y; Hongo, A; Imafuku, N; Joja, I; Kodama, J; Nakamura, K; Nishida, T; Niwa, I | 1 |
| Bahleda, R; Bosq, J; Hartl, DM; Hollebecque, A; Massard, C; Soria, JC | 1 |
| Arihiro, K; Emi, A; Haruta, R; Kadoya, T; Kajitani, K; Kataoka, T; Kobayashi, Y; Masumoto, N; Oda, M; Okada, M; Sasada, T; Shigematsu, H | 1 |
| Endo, D; Hosaka, M; Kato, T; Kikawa, S; Konno, Y; Mitamura, T; Odagiri, T; Sakuragi, N; Suzuki, Y; Watari, H | 1 |
| Beriwal, S; Edwards, RP; Krivak, TC; Lesnock, JL; McBee, WC; Richard, SD; Skaznik-Wikiel, ME; Zorn, KK | 1 |
| Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T | 1 |
| Choong, N; Firat, S; Kharofa, J; Sadasiwan, C; Schultz, C; Wang, D; Wong, S | 1 |
| Alam, S; Layman, R; Lustberg, M; Reinbolt, RE; Shapiro, C | 1 |
| Brown, JV; Buck, M; Chambers, SK; Covens, A; Davy, M; Ghatage, P; Hansen, VL; Karlan, BY; Leath, CA; Nagarkar, RV; Nguyen, H; Oza, AM; Pippitt, CH; Provencher, DM; Richardson, GE; Stepan, DE; Sun, YN; Tassoudji, M; Vergote, IB; Weinreich, DM | 1 |
| Bafaloukos, D; Batistatou, A; Bobos, M; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Kosmidis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Stathopoulos, GP; Timotheadou, E | 1 |
| Beyer, J; Griffin, S; Kanjanavaikoon, P; Robinson, WR | 1 |
| Karlan, BY; Kuchimanchi, M; Lu, JF; Melara, R; Navale, L; Rasmussen, E; Stepan, DE; Sun, YN; Vergote, IB; Weinreich, DM | 1 |
| Bacoyiannis, C; Bafaloukos, D; Boukovinas, I; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Pavlidis, N; Pectasides, D; Skarlos, D; Syrigos, K | 1 |
| Heth, JA; Wilson, TJ | 1 |
| Antsaklis, A; Bamia, C; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Karadimou, A; Rodolakis, A; Soupos, N; Thomakos, N; Vlahos, G; Zagouri, F | 1 |
| Alcalde, J; Aristu, J; Cambeiro, M; Gaztañaga, M; Martínez-Monge, R; Montesdeoca, N; Pagola, M; Rodriguez Ruiz, ME | 1 |
| Zvaríková, M | 1 |
| Cai, XY; Cai, YC; Cao, Y; Jiang, WQ; Jin, Y; Shi, YX; Tan, YT | 1 |
| Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Mitsuhashi, N; Ozawa, S; Saito, M; Suzuki, T | 1 |
| Brown, C; Brundage, M; Eisenhauer, E; Ferrero, A; Gebski, V; Gropp, M; Lund, B; Mann, K; Mefti, F; Pignata, S; Pujade-Lauraine, E; Reed, N; Wolfram, G | 1 |
| Henderson, M; Hui, A; Skandarajah, A; Speakman, D | 1 |
| Amant, F; Berteloot, P; Cadron, I; Leunen, K; Torfs, S; Vergote, I | 1 |
| Ando, M; Fujiwara, Y; Kamura, T; Katsumata, N; Kitagawa, R; Nakanishi, T; Satoh, T; Shimizu, C; Ushijima, K; Yoshikawa, H | 1 |
| Thigpen, T | 2 |
| Enomoto, T; Fujita, M; Hamasaki, T; Hisamatsu, T; Kimura, T; Mabuchi, S; Yoshino, K | 1 |
| Blank, S; Lordick, F; Lorenzen, S; Ott, K; Siewert, JR | 1 |
| Iitsuka, C; Iwase, H; Nomura, H; Omatsu, K; Sakamoto, K; Takada, T; Takeshima, N; Takizawa, K | 1 |
| Agelidou, M; Emmanouilidis, C; Georgoulias, V; Hatzidaki, D; Karachaliou, N; Kontopodis, E; Kotsakis, A; Mountzios, G; Popis, E; Vardakis, N | 1 |
| Amant, F; Neven, P; Vandenput, I; Vergote, I | 1 |
| Boran, N; Celik, B; Hizli, D; Isikdogan, Z; Karabuk, E; Kose, MF; Tulunay, G; Turan, T; Yilmaz, S | 1 |
| Ito, Y; Kajiyama, H; Kato, S; Kikkawa, F; Morikawa, S; Nawa, A | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Aynaoglu, G; Kahraman, K; Kankaya, D; Ortac, F | 1 |
| Cariello, A; Casanova, C; Cruciani, G; Dazzi, C; Freier, E; Gamboni, A; Leoni, M; Mazza, V; Milandri, C; Montanari, M; Papi, M; Papiani, G; Verlicchi, A; Vertogen, B | 1 |
| Mould, T | 1 |
| Amant, F; Han, SN; Vergote, I | 1 |
| Agnoletti, V; Amadori, A; Ansaloni, L; Catena, F; Cavaliere, D; Coccolini, F; De Iaco, P; Di Battista, M; Framarini, M; Gazzotti, F; Ghermandi, C; Kopf, B; Pinna, AD; Saponara, M; Tauceri, F; Vallicelli, C; Verdecchia, GM | 1 |
| Arakawa, A; Furukawa, N; Hirashima, Y; Itani, Y; Ito, K; Murakoshi, H; Tabata, T; Takekuma, M; Takeuchi, S; Tsubamoto, H | 1 |
| Lim, L; Powles, T; Rashid, S | 1 |
| Aghajanian, C; Powell, MA; Secord, AA; Sill, MW; Steinhoff, M | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Buiret, G; Ceruse, P; Chabaud, S; Favier, B; Fayette, J; Girodet, D; Lavergne, E; Péron, J; Pham, BN; Ramade, A; Zrounba, P | 1 |
| Fury, MG; Haque, S; Ho, A; Katabi, N; Kelly, KW; Nwankwo, O; Pfister, DG; Sherman, E; Sima, C | 1 |
| Campos, S; Esselen, KM; Growdon, W; Horowitz, NS; Krasner, C; Rodriguez, N | 1 |
| Celano, P; Crowley, E; Damstrup, L; Dizon, DS; Finkler, NJ; Glasspool, R; Knoblach, P; Lassen, U; Lichenstein, HS; Penson, RT | 1 |
| Chiantera, V; Köhler, C; Mangler, M; Piek, JM; Schneider, A; Speiser, D; Vercellino, GF | 1 |
| Gong, Y; Huang, M; Li, N; Liu, Y; Peng, F; Wang, J; Xu, Y; Zhang, J; Zhou, L; Zhu, J | 1 |
| Kang, S; Lim, MC; Lim, S; Park, JY; Park, SY; Seo, SS; Yoo, HJ | 1 |
| Barry, WT; Berchuck, A; Broadwater, G; Havrilesky, LJ; Lancaster, J; Lee, PS; Secord, AA; Teoh, DK; Wenham, RM; Yu, M | 1 |
| Chang, AC; Hayman, JA; Lee, JS; Merajver, SD; Orringer, MB; Pan, CC; Pickens, A; Schneider, BJ; Urba, SG | 1 |
| Bondarde, S; Gradishar, WJ; Jain, M; Kaklamani, V; Lokanatha, D; Lokker, NA; Raina, V; Ro, SK; Sahoo, TP; Schwartzberg, L | 1 |
| Boaz, M; Golan, A; Levy, T; Menczer, J; Shem, EB; Weiser, R | 1 |
| Lowe, MP; Schwartzberg, LS; Stepanski, EJ; Tillmanns, TD; Walker, MS | 1 |
| Cosio, S; Fuso, L; Gadducci, A; Landoni, F; Maggino, T; Sartori, E; Zola, P | 1 |
| Alberts, DS; Blessing, JA; Bonebrake, AJ; Landrum, LM; Martin, LP; Ramondetta, LM; Rose, SL; Warshal, DP | 1 |
| Iida, K; Ishibashi, T; Ishikawa, M; Katagiri, A; Katagiri, H; Miyazaki, K; Nakayama, K; Nakayama, S; Otsuki, Y; Rahman, M; Rahman, MT | 1 |
| Abdulkadir, L; Amant, F; Berteloot, P; Cadron, I; Despierre, E; Leunen, K; Neven, P; Vergote, I | 1 |
| Cornes, P; Flubacher, M; Forrest, JL; Scatchard, K; Williams, C | 1 |
| Baumann, K; Belau, A; Bentley, J; Berton-Rigaud, D; Brown, C; Canzler, U; Friedlander, M; Gebski, V; Kristensen, G; Kurzeder, C; Ledermann, JA; Lee, CK; Lord, SJ; Nankivell, M; Parma, G; Pfisterer, J; Pisano, C; Plante, M; Pujade-Lauraine, E; Schauer, C; Simes, RJ; Skeie-Jensen, T; Swart, AM; Vergote, I | 1 |
| Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H | 1 |
| Catalano, PJ; Colson, YL; Gilmore, D; Grinstaff, MW; Liu, R; Padera, RF; Schulz, M; Zubris, KA | 1 |
| Li, GT | 1 |
| An, X; Chen, C; Li, YH; Liang, Y; Luo, HY; Wang, FH; Wang, ZQ; Zhang, L | 1 |
| Bafaloukos, D; Christodoulou, C; Fountzilas, G; Gogas, H; Kalogeras, KT; Koutras, AK; Kouvatseas, G; Kronenwett, R; Linardou, H; Pectasides, D; Samantas, E; Wirtz, RM; Zagouri, F | 1 |
| Chu, TQ; Ding, H; Du, WD; Garfield, DH; Gu, AQ; Han, BH; Pei, J | 1 |
| Fujii, S; Matsubara, N; Mukai, H; Wada, N | 1 |
| Godoy, HE; Lele, SB; Odunsi, K; Olawaiye, AB; Rauh-Hain, JA; Shahzad, MM | 1 |
| He, J; Huang, J; Mao, Y; Qu, T; Quan, L; Sun, Y; Wang, J; Xing, P; Xu, N; Zhang, H; Zhou, Y; Zhu, H | 1 |
| Beukema, JC; Burgerhof, JG; Hospers, GA; Langendijk, JA; Muijs, CT; Mul, VE; Muller, K; Paardekooper, G; Plukker, JT; Smit, JK; Timmer, PR; van Dijk, BA; Woutersen, D | 1 |
| Birnbaum, A; Dipetrillo, T; Follett, N; Joyce, D; Khurshid, H; Luppe, D; Merriam, P; Puthawala, Y; Rathore, R; Safran, H; Sio, TT; Thomas, A; Wanebo, H | 1 |
| Cai, RG; Fan, Y; Ma, F; Ma, WY; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yuan, P; Zhang, BL; Zhang, P; Zheng, S | 1 |
| Antsaklis, A; Bamia, C; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Thomakos, N; Vlahos, G; Zagouri, F | 1 |
| Tew, WP | 1 |
| Brenner, A; Castaigne, JP; Drappatz, J; Eichler, A; Elian, K; Fielding, RM; Groves, MD; Kelsey, S; Lawrence, B; Meyers, CA; Mikkelsen, T; Rosenfeld, S; Sarantopoulos, J; Schiff, D; Shing, M; Wang, X; Wen, PY; Wong, ET | 1 |
| Bonomi, PD; Katz, TL; Lee, HJ; Mace, J; Mandanas, RA; Min, M; Olsen, M; Sheth, G; Youssoufian, H | 1 |
| Glisson, BS | 1 |
| Baur, M; DeSantis, M; Dittrich, C; Gerber, E; Hudec, M; Kienzer, HR; Pont, J; Schratter-Sehn, AU; Schweiger, J; Wicke, W | 1 |
| Kalabova, R; Nekulova, M; Pecen, L; Pikner, R; Simickova, M; Topolcan, O; Valik, D; Vondracek, V | 1 |
| Degendorfer, P; Furlan, M; McCarthy, JS; Panzarella, T; Siu, LL; Tannock, IF | 1 |
| Alvarez Castelo, L; Blanco Díez, A; Fernández Rosado, E; González Martín, M; Rodríguez Gómez, I; Sánchez Rodríguez Losada, J; Suárez Pascual, G | 1 |
| Adjei, AA; Baron, AT; Geeraerts, L; Hatfield, AK; Ingle, JN; Kugler, JW; Kuross, SA; Lafky, JM; Maihle, N; Michalak, JC; Perez, EA; Suman, VJ | 1 |
| Petrylak, DP | 2 |
| Matsui, H; Nagai, Y; Seki, K; Sekiya, S; Suzuka, K; Tanaka, N | 1 |
| Balbi, C; Balbi, G; Cardone, A; Cassese, E; Di Prisco, L; Menditto, A; Musone, R | 1 |
| Batist, G; Campos, S; Charpentier, D; Ette, E; Fuller, A; Garg, V; Harding, MW; Matulonis, U; Rose, P; Seiden, MV; Swenerton, KD | 1 |
| Bang, YJ; Boudraa, Y; Daglish, B; Heo, DS; Jacques, C; Kang, WK; Kang, YK; Kim, HC; Kim, NK; Kim, WS; Zuber, E | 1 |
| Herzog, TJ | 1 |
| Hyodo, I; Katsu, K; Mitachi, Y; Miyata, Y; Ohtsu, A; Sairenji, M; Saitoh, S; Sakata, Y; Sato, T; Suwa, T | 1 |
| Bu, CF; Chang, KJ; Chao, TY; Chen, MM; Cheng, AL; Hsu, C; Huang, CS; Lu, YS | 1 |
| De Leonardis, F; Muggeo, P; Rigillo, N; Surico, G | 1 |
| Fukuda, K; Kimura, F; Kokufu, I; Tanei, T; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Blohmer, JU; Breidenbach, M; Göhring, UJ; König, E; Kurbacher, CM; Mallmann, P; Rein, DT; Schmidt, T; Schöndorf, T | 1 |
| Baranzelli, MC; Barnouin, L; Bay, JO; Bui, NB; Chevreau, C; Cupissol, D; Eymard, JC; Lortholary, A; Mita, M; Pivot, X; Savary, J; Thyss, A | 1 |
| Fossella, FV; Lynch, T; Shepherd, FA | 1 |
| Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Ushio, J; Yamamoto, W | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Ong, NC; Ostör, AG | 1 |
| Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
| Chapman, W; Davis, AJ; Hedley, DW; Oza, AM; Tannock, IF | 1 |
| Alvarez, AA; Berchuck, A; Carney, ME; Clarke-Pearson, DL; Havrilesky, LJ; Lancaster, JM; Rodriguez, GC; Sayer, RA; Soper, JT | 1 |
| Antman, K; Brafman, L; Fine, R; Nelsen, C; Petrylak, DP; Shriberg, L; Talbot, S; Tiersten, AD; Troxel, A; Vahdat, L | 1 |
| Ito, T; Kitagawa, T; Kurihara, Y; Morimoto, Y; Nakai, S; Nishimura, J; Tanaka, Y; Yamamoto, S | 1 |
| Iwasa, T; Kanai, T; Koike, S; Komatsu, D; Nakamura, T; Shimizu, T | 1 |
| Fukuda, K; Hosono, M; Kimura, F; Kokufu, I; Tamaoka, K; Tanei, T; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Fujiyoshi, K; Ishimatsu, J; Kawagoe, H; Kawata, T; Nishio, S; Shimomura, T; Tsunawaki, A | 1 |
| Chaplen, R; Gadgeel, SM; Heilbrun, LK; Labadidi, S; Philip, PA; Shields, AF; Zalupski, M | 1 |
| Kamura, T; Kawagoe, H; Kumagai, S; Matsuo, G; Nishida, T; Nishio, S; Ota, S; Sugiyama, T; Ushijima, K | 1 |
| Aoki, Y; Fujita, K; Kurata, H; Matsushita, H; Obata, H; Tanaka, K; Watanabe, M; Yahata, T | 1 |
| Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC | 1 |
| Baayen, HC; Barkhof, F; Boogerd, W; Castelijns, JA; Elkhuizen, PH; Heimans, JJ; Postma, TJ; Uitdehaag, BM; Vos, MJ | 1 |
| Blessing, JA; Lee, RB; Lincoln, S; Rocereto, TF | 1 |
| Airoldi, M; Bumma, C; Cortesina, G; Gabriele, P; Giordano, C; Pedani, F | 1 |
| Chapman, J; Drisko, JA; Hunter, VJ | 1 |
| Kruczek, A; Markowska, J; Skasko, E; Steffen, J; Wojciechowska-Lacka, A | 1 |
| Andersen, W; Blessing, JA; Gallup, DG; Morgan, MA | 1 |
| Enomoto, K; Fukuda, M; Haga, S; Iino, Y; Ikeda, T; Shimizu, T; Taguchi, T | 1 |
| Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T | 1 |
| Colburn, DE; Giles, FJ; Thomas, DA | 1 |
| Coldman, BJ; Fossella, FV; Glisson, BS; Komaki, R; Kurie, JM; Lee, JS; Lu, C; Palmer, JL; Pisters, KM; Shin, DM | 1 |
| Arbuck, SG; Averette, HE; Brady, MF; Delmore, JE; Long, HJ; Look, KY; Omura, GA; Spiegel, G; Wadler, S | 1 |
| Heimans, JJ; Hoekman, K; Postma, TJ; Verstappen, CC | 1 |
| Kaye, SB | 1 |
| Colombo, N; Delaloye, JF; du Bois, A; Floriani, I; Jayson, G; Kristensen, GB; Lamont, A; Ledermann, JA; Parmar, MK; Qian, W; Swart, AM; Torri, V; Tropé, C; Wheeler, S | 1 |
| Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 2 |
| Emoto, T; Fujii, M; Fujikawa, M; Komaki, T; Maeda, S; Naka, Y; Nezu, R; Yoshikawa, K; Yoshioka, Y | 1 |
| Aravantinos, G; Bafaloukos, D; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Papadimitriou, C; Pavlidis, N | 1 |
| Heys, SD; Hutcheon, AW; Sarkar, TK | 1 |
| Adelstein, DJ; Blackstone, EH; Chidel, MA; DeCamp, MM; Murthy, SC; Rice, TW; Rybicki, LA | 1 |
| Aotani, E; Fujiwara, K; Fujiwara, M; Kato, H; Katsumata, N; Kigawa, J; Kohno, I; Numa, F; Oishi, T; Terakawa, N | 1 |
| Gascón, P; Mármol, M; Mellado, B; Montagut, C; Ordi, J; Pahissa, J; Rey, V; Rovirosa, A | 1 |
| Anderson, P; Fields, A; Goldberg, G; Guha, C; Gupta, S; Jones, J; Khabele, D; Runowicz, C; Sood, BM; Vikram, B | 1 |
| Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C | 1 |
| Ahiskali, R; Celikel, T; Ceyhan, BB; Duman, D; Duman, DG | 1 |
| Bessho, A; Eguchi, K; Harada, M; Harita, S; Hiraki, S; Hiraki, Y; Kamei, H; Kiura, K; Okimoto, N; Segawa, Y; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y | 1 |
| Bratengeier, K; Flentje, M; Hagen, R; Helms, J; Hoppe, F; Pfreundner, L; Preisler, V; Willner, J | 1 |
| Buzdar, AU; Hortobagyi, GN | 1 |
| Bell, J; Blessing, JA; Lentz, SS; Olt, G; Thigpen, JT | 1 |
| Aotani, E; Fujiwara, K; Kohno, I; Koshida, T; Maehata, K; Nishiya, M; Sakuragi, N; Sawai, H; Suzuki, S; Yoshida, N | 1 |
| Hanibuchi, M; Hirano, H; Ito, M; Maeda, H; Nakagawa, M; Okumura, Y; Sawabata, Y; Takeda, S; Uematsu, K | 1 |
| Emi, Y; Ezaki, T; Ikegami, T; Ishida, T; Iwanami, T; Kido, A; Kohso, H; Okazaki, J; Tomiyasu, M | 1 |
| Ito, K; Koizumi, T; Niikura, H; Okamura, K; Yaegashi, N | 1 |
| Hirai, K; Kawahara, S; Ushigome, T | 1 |
| Kawaguchi, Y; Saji, S; Sugiyama, Y | 1 |
| Aghajanian, C; Anderson, S; Dizon, DS; Dupont, J; Hummer, A; Sabbatini, P; Spriggs, D | 1 |
| Lane, SR; Ross, GA; ten Bokkel Huinink, W | 1 |
| Bains, MS; Brenner, B; Gonen, M; Ilson, DH; Kelsen, DP; Minsky, BD; Tong, W | 1 |
| Egli, F; Jost, L; Moosmann, P; Stahel, RA | 1 |
| Argiris, A; Forastiere, AA; Langer, CJ; Li, Y; Murphy, BA | 1 |
| Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C; Høgdall, EV | 1 |
| Adamowicz, R; Eltabbakh, GH; Yildirim, Z | 1 |
| Brafman, LB; Hershman, DL; Resnik, EE; Selleck, MJ; Shriberg, L; Smith, D; Tiersten, AD; Troxel, AB | 1 |
| Inoue, H; Kikuchi, Y; Kita, T; Kudoh, K; Oogi, S; Yamamoto, K | 1 |
| Eltabbakh, GH | 1 |
| Inoue, H; Kikuchi, Y; Kita, T; Konno, R; Oowada, M; Seto, H; Shimizu, K; Suzuki, M; Takano, M; Yamamoto, K; Yamamoto, T | 1 |
| Ajarim, DS; Al-Malik, OA; Al-Shabanah, M; Ezzat, AA; Ibrahim, EM; Rahal, MM; Raja, MA; Sorbris, R; Tulbah, AM | 1 |
| Adamo, V; Alafaci, E; Ferraro, G; Laudani, A; Pergolizzi, S; Scimone, A; Sergi, C; Settineri, N; Spano, F; Spitaleri, G | 1 |
| Pfisterer, J | 1 |
| Faibel, M; Hadani, M; Jonas, T; Lidar, Z; Mardor, Y; Nass, D; Pfeffer, R; Ram, Z | 1 |
| Date, K; Egawa, M; Fujitou, N; Fujiwara, H; Mizunoe, T; Sakashita, T; Ueda, K; Urabe, S; Urabe, T | 1 |
| Fuller, AF; Glyptis, T; Goodman, A; Oliva, E; Penson, RT; Seiden, MV; Skates, SJ | 1 |
| Aghajanian, C; Ben-Porat, L; Chi, DS; Hensley, ML; Hoppe, B; Prasad, M; Sabbatini, P | 1 |
| Bergh, J; Linderholm, B | 1 |
| Burke, T; Cooper, J; Fontenesci, J; Greven, K; Underhill, K; Winter, K | 1 |
| Demura, T; Harabayashi, T; Ishikawa, R; Koyanagi, T; Mitsuhashi, K; Murakumo, M; Seki, H; Shinohara, N; Suzuki, S; Toyota, H | 1 |
| Chou, H; Fujita, Y; Kawakami, S; Ogaki, M; Shiomi, A; Takashina, K | 1 |
| Fujiwara, Y; Kimura, Y; Makari, Y; Monden, M; Takiguchi, S; Yano, M; Yasuda, T | 1 |
| Hamanaka, K; Miyagawa, Y; Munakata, Y; Nishimura, H; Ohno, Y; Sakai, H; Seki, H | 1 |
| Buda, A; Colombo, N; Conte, PF; Floriani, I; Fossati, R; Mangioni, C; Ravaioli, A; Rossi, R; Torri, V | 1 |
| Ajani, JA; Cohen, DS; Faust, J; Komaki, R; Lynch, PM; Morris, J; Nivers, R; Putnam, JB; Roth, JA; Smythe, R; Swisher, SG; Vaporciyan, A; Walsh, G; Wu, TT | 1 |
| Adams, D; Anderson, E; Chao, NJ; DeCastro, C; Foster, T; Gasparetto, C; Gockerman, JP; Long, GD; McGaughey, D; Moore, JO; Niedzwiecki, D; Rizzieri, DA; Sand, GJ; Toaso, B; Vredenburgh, JJ | 1 |
| Anagnostopoulos, A; Aravantinos, G; Bafaloukos, D; Daniilidis, J; Dimopoulos, MA; Fountzilas, G; Janinis, J; Kalofonos, HP; Kalogera-Fountzila, A; Makatsoris, T; Nikolaidis, P; Rigatos, SK; Samantas, E; Stathopoulos, GP; Tolis, C | 1 |
| Amsalhem, P; Boaziz, C; Bouillet, T; Breau, JL; Brunel, P; Brunet-Pommeyrol, A; Hennebelle, F; Kanoui, A; Morere, JF; Morin, F; Piperno-Neumann, S; Spano, JP | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Daraï, E; Dormont, D; Madelenat, P; Zylberberg, B | 1 |
| Fabbro, M; Gourgou, S; Gutowski, M; Plaisant, N; Quenet, F; Rouanet, P; Saint-Aubert, B | 1 |
| Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D | 1 |
| Jassem, J; Senkus-Konefka, E | 1 |
| Doi, M; Egawa, T; Hayashi, S; Kitajima, M; Kitano, M; Kubota, T; Nagashima, A; Saikawa, Y; Yoshii, H | 1 |
| Fujimoto, M; Furukawa, J; Higaki, J; Hoashi, T; Ikeda, N; Inui, N; Kogire, M; Matsunami, T; Nakano, K; Nishi, T; Nomura, T; Ogino, N; Takagaki, K; Takeda, C; Tanaka, H; Uenishi, M; Yamada, S; Yamanaka, E; Yamasaki, M; Yamauchi, E; Yayoi, E | 1 |
| Horiguchi, J; Iijima, K; Iino, Y; Kanoh, T; Kikuchi, M; Koibuchi, Y; Morishita, Y; Oyama, T; Takata, D; Yoshida, M; Yoshida, T | 1 |
| Ghaheri, BA; Grecula, JC; Malone, JP; Rhoades, CA; Schuller, DE; Stephens, JA | 1 |
| Agnes Pradelli, B; Battaini, A; Capretti, G; Capretti, PG; Lovotti, D; Rosato, S; Simonetti, A; Zeppieri, MC | 1 |
| Gibb, RK; Herzog, TJ; Horowitz, NS; Hua, J; Mutch, DG | 1 |
| Bellone, S; Cannon, MJ; O'Brien, TJ; Pecorelli, S; Roman, JJ; Santin, AD | 1 |
| Christensen, IJ; Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C | 1 |
| Hasumi, K; Hatae, M; Hirai, Y; Kuramoto, H; Kuzuya, K; Noda, K; Nozawa, S; Ochiai, K; Onose, R | 1 |
| Wu, SX; Xie, CY; Zhang, P | 2 |
| Dvorák, J; Filip, S; Melichar, B; Odrázka, K; Petera, J; Zoul, Z | 1 |
| Akahira, J; Ito, K; Matsunaga, G; Niikura, H; Tase, T; Toyoshima, M; Yaegashi, N | 1 |
| Covens, A; Gerulath, A; Merchandani, DE; Mirchandani, D; Osborne, R | 1 |
| Ino, K; Kajiyama, H; Kikkawa, F; Kondo, C; Mizokami, Y; Mizutani, S; Nomura, S; Shibata, K | 1 |
| Argenta, PA; Boente, MP; Carson, LF; Downs, LS; Judson, PL | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kang, WK; Kim, DW; Kim, HK; Kim, HT; Kim, NK; Kim, TY; Oh, DY; Park, SR; Suh, JH | 1 |
| Edwards, RP; Gallion, HH; Kelley, JL; Kunschner, AJ; Sit, AS | 1 |
| Cole, C; Greystoke, A; Harries, M; Judson, I; Kaye, S; O'Donnell, A; Reade, S; Scurr, M; Twelves, C | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, C; Kosmidis, P; Linardou, H; Papadimitriou, C; Papakostas, P; Skarlos, D | 1 |
| Cai, SM; Huang, X; Li, ZT; Tang, J; Zang, RY | 1 |
| Hirabayashi, K; Ito, J; Ito, T; Kobayashi, M; Numa, F | 1 |
| Enomoto, T; Fujita, M; Murata, Y; Nakashima, R | 1 |
| Kakinoki, S; Takizawa, K | 1 |
| Ochiai, K | 1 |
| Hatae, M; Nakamura, T; Onishi, Y | 1 |
| Cooney, MM; Dowlati, A; Hoppel, CL; Ingalls, ST; Ivy, P; Ksenich, P; Lavertu, P; Makar, V; McCrae, K; McPeak, RJ; Overmoyer, B; Remick, S; Tserng, KY | 1 |
| Aghajanian, C; Anderson, S; Brown, JV; Dizon, D; Dupont, J; Eisenfeld, AJ; Jacobs, A; Mehdi, A; Peters, WA; Rivkin, S; Sabbatini, P; Spriggs, D | 1 |
| Bogart, J; Fitzgerald, TJ; Henderson, IC; Laurie, F; Norton, L; Peterson, BL; Sartor, CI; Turrisi, AJ; Woolf, S | 1 |
| Ebisui, C; Fujimoto, T; Fukuchi, N; Hasuike, Y; Hayashi, N; Izawa, H; Sakita, I; Souma, I; Yoshida, T | 1 |
| Fujiwara, Y; Miyata, H; Monden, M; Takiguchi, S; Yano, M; Yasuda, T | 1 |
| Ledermann, JA; Wheeler, S | 1 |
| Barone, C; Bertetto, O; Birocco, N; Colantonio, I; Dongiovanni, D; Numico, G; Schena, M | 1 |
| González-Martín, AJ | 1 |
| Cohen, RB; DeConti, RC; Forastiere, AA; Jennings, T; Langer, CJ; Li, Y; Nair, S | 1 |
| Christensen, IJ; Gronlund, B; Høgdall, C; Knudsen, JB; Lundvall, L | 1 |
| Biron, P; Bui, B; Caty, A; Culine, S; Curé, H; De Revel, T; Delva, R; Droz, JP; Duclos, B; Fizazi, K; Gligorov, J; Gomez, F; Gravis, G; Guillemaut, S; Lotz, JP; Peny, J; Provent, S; Ségura, C; Théodore, C; Viens, P | 1 |
| Choi, M; Fogoros, S; Griffith, KA; Hu, YY; Liu, JR; Lucas, PC; Williams, J | 1 |
| Fusco, N; Rose, PG; Smrekar, M | 1 |
| Kamata, S; Kotanagi, H; Kumagai, Y; Ouchi, S; Sakusabe, M; Seki, H | 1 |
| Acimovic, L; Jeremic, B; Milicic, B; Milisavljevic, S | 1 |
| Babb, JS; Cheng, J; Cohen, RB; Damsker, JA; Feigenberg, SJ; Horwitz, EM; Kramer, NM; Langer, CJ; Nicolaou, N; Ridge, JA; Sherman, EJ | 1 |
| Alberts, DS; Hallum, AV; Hannigan, EV; Jiang, C; Liu, PY; Markman, M; Scudder, SA; Smith, GB; Smith, HO; Wilczynski, SP | 1 |
| Geisler, JP; Manahan, KJ; Wiemann, MC | 1 |
| Cromwell, LD; Fadul, CE; Kingman, LS; McDonnell, CE; Meyer, LP; Pipas, JM; Rhodes, CH; Rigas, JR | 1 |
| Conzen, SD; Fleming, GF; Heimann, R; Jaskowiak, NT; Kao, J; Masters, GA; Recant, W; Singh, R; Song, DH | 1 |
| Argiris, A; Haraf, DJ; Kao, J; Milano, MT; Mittal, BB; Salama, JK; Stenson, KM; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Atabekoglu, C; Berker, B; Bilgin, T; Dunder, I | 1 |
| Gershanovich, ML; Gulo, EI; Livshits, ME; Makhnova, EV | 1 |
| Bailey, HH; Jumonville, A; Kahl, BS; Kim, KM; Longo, WL; McGovern, J; Smith, EP; Smith, J; Turman, N; Werndli, J; Williams, EC | 1 |
| Bast, RC; Clark, EA; Cliby, WA; Damokosh, AI; Gershenson, D; Hartmann, LC; Hoersch, S; Iartchouk, N; Kalli, KR; Kaufmann, SH; Lillie, J; Linette, GP; Lu, KH; Ross, JS; Shridhar, V; Smith, DI; Stec, J | 1 |
| Italiano, A; Michiels, JF; Otto, J; Peyrade, F; Sirvent, N; Thyss, A | 1 |
| Adrover, E; Arcusa, A; Balañá, C; Bover, I; Calvo, E; Casado, A; Cervantes, A; Godes, MJ; González-Martín, AJ; Herrero, A; Martínez, E; Moyano, A; Ojeda, B; Pardo, B; Rifá, J; Rubio, MJ | 1 |
| Hlavatá, Z; Koza, I; Mardiak, J; Mego, M; Obertová, J; Recková, M; Sálek, T; Sycová-Milá, Z | 2 |
| Gildehaus, FJ; Goldbrunner, R; Holtmannspötter, M; Kreth, FW; Pöpperl, G; Tanner, P; Tatsch, K; Tonn, JC | 1 |
| Bower, M; Dhillon, T; Stebbing, J | 1 |
| Hoskins, PJ; Le, N | 1 |
| Akram, T; Fanning, J; Maseelall, P | 1 |
| Bhagat, K; Hoskins, PJ; Swenerton, KD; Tinker, AV | 1 |
| Kobayashi, Y; Moritake, T; Nagashima, T; Ogura, H; Seiki, T; Terauchi, F; Yamamoto, Y | 1 |
| Agulnik, M; Feldman, LE; Mundt, AJ; Rhee, EN; Yao, M | 1 |
| Harman, EM; Keene, KS; Knauf, DG; McCarley, D; Zlotecki, RA | 1 |
| Iwabuchi, S; Kashiwagi, H; Takahashi, N; Yamazaki, Y; Yanaga, K | 1 |
| Altundag, K; Altundag, MB; Altundag, O; Boruban, C; Turen, S | 1 |
| Kulp, B; Markman, M; Michener, CM; Peterson, G; Webster, KD | 1 |
| Araki, K; Hirabayashi, N; Kataoka, M; Kobayashi, M; Kojima, H; Kondo, K; Matsui, T; Miyashita, Y; Nakao, A; Nakazato, H; Sakamoto, J; Takiyama, W | 1 |
| Asai, S; Dokoh, J; Ishikawa, M; Komiyama, S; Mikami, M; Tsuji, H | 1 |
| Arquette, M; Azarnia, N; Dicke, K; Herbst, RS; Hong, WK; Kies, MS; Shin, DM; Vokes, EE | 1 |
| Biel, MA; El-Naggar, AK; Machtay, M; Rosenthal, DI; Sinard, RJ; Weber, RS; Yom, SS | 1 |
| Chou, W; Lee, N; Puri, DR | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Kuo, SH; Li, SJ; Lin, JF; Lu, YS; Yeh, KH | 1 |
| Bloching, M; Dunst, J; Haensgen, G; Koesling, S; Kuhnt, T; Mueller, AC; Pelz, T; Schubert, J | 1 |
| Byun, JR; Cho, SH; Chung, IJ; Kim, HJ; Kim, YK; Lee, JJ; Na, KJ; Song, SY; Yang, DH | 1 |
| Fujita, S; Hirota, M; Inoue, Y; Nomura, M; Ohshima, M; Sakao, J; Souda, S | 1 |
| Kiwit, JC; Reszka, R; von Eckardstein, KL | 1 |
| Bae, SH; Chun, SH; Do, YR; Hyun, MS; Kim, KO; Kim, MK; Kwon, KY; Lee, KH; Ryoo, HM; Shin, SJ; Song, HS | 1 |
| Akizuki, S; Andoh, M; Fujiwara, Y; Katsumata, N; Watanabe, T; Yamanaka, Y | 1 |
| Ichikawa, D; Kakihara, N; Koizumi, K; Kurioka, H; Morii, J; Morita, S; Nakamura, K; Nishiyama, M; Sakamoto, J; Shimotsuma, M; Takenaka, A; Ueda, Y; Yamagishi, H; Yamashita, T | 1 |
| Cibull, M; Cohn, D; DePriest, PD; Dietrich, CS; Gehrig, P; Giesler, J; Higgins, RV; Huh, W; Hunter, J; Kryscio, R; Manahan, K; Merritt, W; Modesitt, SC; Pavlik, EJ; Powell, M; Puls, L; Reedy, MB; Slomovitz, B; Ueland, FR; van Nagell, JR; Wilder, J | 1 |
| Alwindi, AA; Elhabbash, M | 1 |
| Bacik, J; Bajorin, D; Bosl, GJ; Donadio, A; Kondagunta, GV; Marion, S; Motzer, RJ; Sheinfeld, J | 1 |
| Belani, CP; Bhatnagar, A; Flickinger, JC; Greenberger, JS; Ramalingam, S; Wolski, MJ | 1 |
| Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Tsubono, M; Yasumizu, R | 1 |
| Borghaei, H; Smith, M | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Forkert, R; Fronhoffs, S; Ko, Y; Koll, C; Neuhaus, T; Stier, S; Tuohimaa, A; Vetter, H | 1 |
| Birk, CL; Brown, JV; Goldstein, BH; Micha, JP; Rettenmaier, MA | 1 |
| Adelstein, DJ | 1 |
| Antón, A; Belón, J; Carles, J; Cervantes, A; Chaib, C; Cortés-Funes, H; Escrig, V; Hitt, R; Isla, D; Lobo, F; López-Pousa, A; Martí, JL; Martínez-Trufero, J; Pallarés, C; Pastor, P; Paz-Ares, L; Rizo, A; Sánchez, MA; Valentí, V; Vega, ME | 1 |
| Belinson, JL; Michener, CM | 1 |
| Futagami, M; Mizunuma, H; Shigeto, T; Yokoyama, Y | 1 |
| Du Bois, A; Pfisterer, J | 1 |
| Banba, T; Hatakeyama, K; Kanda, T; Kosugi, S; Ohashi, M; Tanabe, T; Yajima, K | 1 |
| Endo, W; Fukunaga, H; Hojo, S; Maeura, Y; Ota, H; Yamazaki, K; Yoshioka, S | 1 |
| Marutaka, M; Miyake, M; Suguri, T; Yoshimura, K | 1 |
| Al Hayki, M; Baines, KA; Hopkins, L; Kee Fung, MF; Le, T; Rambout, L | 1 |
| Bamias, A; Bozas, GT; Dimopoulos, MA; Kastritis, E; Markaki, S; Papadimitriou, CA; Rodolakis, A; Vlahos, G | 1 |
| Albers, P; Fechner, G; Kobalz, L; Reimann, M; Siener, R | 1 |
| Demura, T; Harabayashi, T; Matsuyama, H; Mitsuhashi, K; Murakumo, M; Nagamori, S; Nagao, K; Naito, K; Nonomura, K; Seki, H; Shinohara, N; Suzuki, S | 1 |
| Boccardo, F; Boni, L; Bruzzone, M; Centurioni, MG; Cosso, M; Ferrarini, M; Franzone, P; Miglietta, L; Tacchini, L | 1 |
| Adamo, V; Altavilla, G; Cascinu, S; Ferraù, F; Girlando, A; Maisano, R; Numico, G; Palazzolo, C; Pergolizzi, S; Russi, E; Santacaterina, A; Settineri, N; Spadaro, P | 1 |
| Boku, N; Fukutomi, A | 1 |
| Biancamano, JD; Gahbauer, RA; Grecula, JC; Jatana, KR; Lang, JC; Schuller, DE; Wang, D | 1 |
| Forastiere, AA; Gilbert, J; Jennings, T; Kies, MS; Li, Y; Pinto, HA; Silverman, P | 1 |
| Kojima, T; Kubo, Y; Mimae, T; Ninomiya, M; Sasaki, H; Takakura, N; Umeoka, T | 1 |
| Baba, H; Emi, Y; Kakeji, Y; Maehara, Y; Oki, E; Takahashi, I; Tokunaga, E; Ushiro, S; Watanabe, M | 1 |
| Cohn, DE; Copeland, LJ; Eaton, LA; Fowler, JM; Resnick, KE; Valmadre, S | 1 |
| Hatanaka, N; Hiraoka, K; Mizutani, S; Nakahara, M; Nakao, K; Okuma, K; Oyama, T; Sueyoshi, K; Taira, M; Takahashi, H; Tori, M; Uchikoshi, F; Ueshima, S; Yamagami, Y; Yoshidome, K | 1 |
| Amadori, D; Benasso, M; Boni, L; Capaccetti, B; Cavallo, G; Grossi, F; Merlano, M; Numico, G; Ponzanelli, A; Ricci, I; Rosso, R; Taveggia, P; Vigo, V | 1 |
| Alberts, DS; Brady, M; Liu, PY; Markman, M; Monk, BJ; Rothenberg, ML | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Onozawa, Y; Yoshino, T; Zenda, S | 1 |
| Chetrit, A; Golan, A; Levy, T; Menczer, J; Sadetzki, S | 1 |
| Huang, HF; Jin, Y; Lang, JH; Pan, LY; Shen, K; Wu, M; Yang, JX | 1 |
| Armstrong, DK; Bailey, HH; Fleming, GF; Markman, M | 1 |
| Gotoh, M; Katsu, K; Kawabe, S; Kii, T; Kuwakado, S; Nishitani, H; Ohta, S; Takiuchi, H; Tanaka, T | 1 |
| Bădulescu, A; Bădulescu, F; Popescu, CF; Schenker, M; Stoica, Z | 1 |
| Odicino, F; Pasinetti, B; Pecorelli, S; Tisi, G | 1 |
| Ledermann, JA; Pfisterer, J | 1 |
| Bhoola, S; Hoskins, WJ | 1 |
| Li, Y; Machtay, M; Wong, SJ | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Clark, JI; Dakhil, SR; Ensley, J; Hussain, MH; Moon, J; Samlowski, W; Urba, SG; Williamson, S; Worden, FP | 1 |
| Hirama, M; Isonishi, S; Saitou, M; Tanaka, T; Yasuda, M | 1 |
| Bell, J; Brady, MF; Lage, J; Look, KY; Rose, GS; Spirtos, NM; Walker, JL; Young, RC | 1 |
| Isayeva, T; Ponnazhagan, S; Ren, C | 1 |
| Hatori, S; Imada, T; Kunisaki, C; Ohshima, T; Ono, H; Otsuka, Y; Rino, Y; Sato, T; Yamada, R | 1 |
| Inoue, K; Nagamoto, N; Nakahara, O; Ohsako, T; Yoshida, Y | 1 |
| Fangusaro, J; Finlay, J; Rook, J; Rosser, T | 1 |
| Arimoto, T; Kawana, K; Nakagawa, S; Taketani, Y; Yano, T; Yasugi, T; Yoshikawa, H | 1 |
| Breidenbach, M; Hille, S; Kurbacher, CM; Neumann, R; Pfützner, A; Rein, DT; Riffelmann, M; Sartorius, J; Schöndorf, T | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Papadimitriou, C; Rodolakis, A; Vlahos, G; Voulgaris, Z | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Grønlund, B | 1 |
| Kamiyama, Y; Kano, Y; Kodama, T; Kondo, T; Mori, K | 1 |
| Bentzen, JD; Hansen, HS | 1 |
| Aravantinos, G; Christodoulou, Ch; Malamos, NA; Rigatos, S; Skarlos, D; Stathopoulos, GP; Stathopoulos, J | 1 |
| Abramson, N; Carlson, RW; Davidson, NE; Goldstein, LJ; O'Neill, AM; Sikic, BI; Stewart, JA; Wood, WC | 1 |
| Aihara, R; Asao, T; Haga, N; Kamiyama, Y; Kuwano, H; Mochiki, E; Nakabayashi, T; Nakamura, J; Ohno, T; Ohsawa, H; Ojima, H; Takeuchi, K | 1 |
| Canales Ugarte, S; Cassinello Espinosa, J | 1 |
| Akizuki, K; Itoh, T; Kageyama, H; Minami, H; Nishida, T; Nishiyama, N; Ozaki, I; Ozuno, I; Shoji, S; Yamamoto, A; Yamamoto, K | 1 |
| Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Kondo, M; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M; Yamamoto, K | 1 |
| Chandrasekharan, S; Clouth, B; Davidson, N; Inwang, R; Sauven, P; Smith, S | 1 |
| Coleman, RL; Crotzer, DR; Gershenson, DM; Levenback, CF; Sun, CC; Wolf, JK | 1 |
| Hisada, T; Ishizuka, T; Kaira, K; Mori, M; Sunaga, N; Yanagitani, N | 1 |
| Armstrong, DK; Giuntoli, RL; Gold, MA; Herzog, TJ; Lewin, S; Moore, KN; Rocconi, RP; Spannuth, WA | 1 |
| Aydiner, A; Karagol, H; Kucucuk, S; Saip, P; Topuz, E; Uygun, K | 1 |
| Hanazaki, K; Kobayashi, M; Kondo, K; Nagata, N; Namikawa, T; Oba, K; Okabayashi, T; Sakamoto, J | 1 |
| Ansell, W; Berney, D; Mutsvangwa, K; Oliver, T; Powles, T; Shamash, J; Stebbing, J; Walsh, E; Wilson, P | 1 |
| Abu-Rustum, NR; Aghajanian, C; Bowes, RJ; Jhamb, N; Khoury-Collado, F | 1 |
| Berchuck, A; Carney, ME; Clarke-Pearson, DL; Havrilesky, LJ; Rodriguez, GC; Secord, AA; Soper, JT | 1 |
| Dakhil, S; Dy, GK; Geoffroy, FJ; Jett, JR; Krewer, KD; Krook, J; Kugler, J; Kutteh, L; Mailliard, J; Maurer, M; Rowland, K; Tazelaar, H; Wender, D | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Han, W; Heo, DS; Im, SA; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Noh, DY; Oh, DY; Park, IA | 1 |
| Choomchuay, N; Leelahakorn, S; Manusirivithaya, S; Pataradool, K; Suekwatana, P; Tangjitgamol, S; Thawaramara, T | 1 |
| Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Yasuda, Y; Yokoyama, T; Zuiki, T | 1 |
| Clegg, AJ; Jones, J; Loveman, E; Takeda, AL; Tan, SC | 1 |
| Amant, F; Cadron, I; Leunen, K; Neven, P; Van Gorp, T; Vergote, I | 1 |
| Bhuta, S; Head, CS; Nabili, V; Sercarz, JA; Tan, JW | 1 |
| Filiaci, VL; Fleming, GF; Gallion, HH; McMeekin, DS; Rodgers, WH; Thigpen, JT | 1 |
| Baba, H; Maehara, Y; Matsui, T; Morita, S; Sakamoto, J; Takiuchi, H; Tsuburaya, A | 1 |
| Hamai, Y; Oue, N; Sentani, K; Suzuki, T; Wada, Y; Yasui, W; Yoshida, K | 1 |
| Aghajanian, C; Gore, ME; Harrison, ML; Hensley, M; Iasonos, A; Kaye, S; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
| Byrd, L; Clamp, A; Hasan, J; Jayson, GC; Thistlethwaite, FC; Ton, C | 1 |
| Imai, S; Jitsuko, A; Nishikawa, H; Otoshi, M; Takahara, S; Tsubono, M; Wada, Y | 1 |
| Akhtar, MS; Chougule, PB; Kennedy, T; Koness, J; McRae, R; Nigri, P; Radie-Keane, K; Rathore, R; Ready, N; Wanebo, HJ | 1 |
| Ames, MM; Horton, TM; Krailo, MD; Mosher, R; Pendergrass, T; Reaman, GH; Reid, JM; Seibel, NL | 1 |
| Masuda, N | 1 |
| Kato, N; Osawa, R; Yamane, N; Yanagi, T | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Tsai, YC; Yang, CH; Yeh, KH | 1 |
| Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H | 1 |
| Havrilesky, LJ; Kulasingam, S; Myers, E; Secord, AA | 1 |
| Davis, S; Hind, D; Rees, A; Simpson, E; Ward, S; Wilkinson, A | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Ellard, S; Hoskins, PJ; Le, N; Lee, U; Martin, LA; Swenerton, KD; Tinker, AV | 1 |
| Bae, SN; Jung, SG; Kim, CJ; Kim, SJ; Lee, C; Na, YJ | 1 |
| Filiaci, VL; Fleming, GF; Grushko, TA; Mundt, AJ; Olopade, OI; Ridderstråle, K | 1 |
| Ang, K; Curran, W; Harris, J; Horwitz, EM; Kies, M; Langer, CJ; Nicolaou, N; Wong, S | 1 |
| Jin, ML; Li, J; Li, Y; Shen, L; Zhang, XD; Zhang, XT | 1 |
| Eisele, DW; Glastonbury, CM; Lin, D; Rafaelian, O; Wang, SJ | 1 |
| Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K | 1 |
| Chu, CY; Hsiao, CH; Lee, HC | 1 |
| Begossi, G; Belliveau, J; DiSiena, M; Gustafson, E; Wanebo, HJ | 1 |
| de Bruijn, P; Fieren, MW; Heijns, JB; Loos, WJ; van der Burg, ME; van der Gaast, A; van Gelder, T | 1 |
| Barbachano, Y; Gore, M; Hook, J; Kaye, SB; Linch, M; Stavridi, F | 1 |
| Cetnar, JP; Malkowicz, SB; Palmer, SC; Vaughn, DJ; Wein, AJ | 1 |
| Fujitani, K; Furukawa, H; Goto, M; Imamoto, H; Imamura, H; Imano, M; Ishida, H; Kimura, Y; Narahara, H; Shimokawa, T; Takiuchi, H | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C | 1 |
| Economopoulos, T; Fountzilas, G; Gaglia, A; Gouveris, P; Kassanos, D; Koumarianou, A; Panayiotidis, J; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N | 1 |
| Antonia, S; Bepler, G; Boulware, D; Burton, M; Chiappori, AA; Haura, E; Kapoor, R; Lush, R; Neuger, AM; Padilla, B; Rodriguez, FA; Simon, G; Sullivan, DM; Williams, C | 1 |
| Graziani, SR; Hegg, R; Maranhão, RC; Pires, LA; Rodrigues, DG; Valduga, CJ | 1 |
| Jin, M; Li, J; Li, Y; Shen, L; Zhang, X | 1 |
| Fukunari, H; Hatano, T; Hayashi, T; Inada, S; Kawauchi, Y; Nikkuni, K; Nishimura, A; Sato, T; Shimizu, T; Sugita, M; Takahashi, S; Tomidokoro, T; Yanagi, M; Yoshida, H | 1 |
| Chang, YL; Cheng, JC; Hsu, CH; Hsu, FM; Lee, JM; Lee, YC; Lin, CC; Tsai, YC | 1 |
| Lindsay, I; Newlands, ES; Savage, PM; Schmid, P; Sebire, NJ; Seckl, MJ; Short, D; Wang, J | 1 |
| Amirifeli, S; Azouz, SM; Colson, YL; Grinstaff, MW; Taylor, KN; Walpole, J | 1 |
| Aydiner, A; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
| Fukumoto, M; Iida, K; Ishibashi, M; Katagiri, A; Miyazaki, K; Nakayama, K; Nakayama, N; Yeasmin, S | 1 |
| Benner, SE; Hong, WK; Huber, MH; Lippman, SM | 1 |
| Haraf, DJ; Levin, J; Malone, D; Stenson, K; Stupp, R; Vokes, EE; Weichselbaum, RR | 1 |
| Adamo, DO; Bicher, A; Christian, M; Davis, P; Kohn, EC; Link, C; Ognibene, FP; Rothenberg, M; Sarosy, G; Steinberg, SM | 1 |
| Reed, E | 1 |
| Green, MR; Lilenbaum, RC; MacManus, DA | 1 |
| Calvert, AH; Earl, H; Gore, ME; Levy, V; Perren, T; Rustin, G; Thompson, JM | 1 |
| Asbury, R; Boros, L; Chang, AY; Garrow, G | 1 |
| Chamberlain, MC; Kormanik, P | 2 |
| Adamo, DO; Bicher, A; Chabner, BA; Davis, P; Jacob, J; Kohn, E; Reed, E; Sarosy, G | 1 |
| Forastiere, AA | 2 |
| Beller, U; Hornreich, G; McDaniel, C; Peretz, T; Shacter, J; Sulkes, A; Winograd, B | 1 |
| Benner, S; Calayag, M; Chasen, M; Fossella, FV; Glisson, B; Lee, JS; Lippman, SM; Murphy, WK; Pang, A; Shin, DM | 1 |
| Johnston, CM; Pearl, ML; Reynolds, RK; Roberts, JA; Yashar, CM | 1 |
| Abe, R; Enomoto, K; Fujita, M; Hamano, K; Hasegawa, K; Mori, S; Morishita, Y; Sasaki, Y; Tabei, T; Taguchi, T | 1 |
| Buser, K; Colombo, N; Eisenhauer, EA; Gianni, L; Kerr, I; Myles, J; Swenerton, KD; ten Bokkel Huinink, WW; van der Burg, ME; Vermorken, JB | 1 |
| Khansur, T; Thigpen, JT; Vance, RB | 1 |
| Bishop, J; Evans, B; Fitzharris, B; Friedlander, M; Joughin, J; McCrystal, M; Olver, I; Phillips, KA; Smith, J | 1 |
| Adachi, I; Aoyama, H; Horikoshi, N; Narabayashi, M; Taguchi, T; Takashima, S; Watanabe, T | 1 |
| Bochtler, H; Diergarten, K; Hanauske, AR; Heinrich, B; Herzog, M; Kau, R; Quasthoff, S; Rastetter, J; Schilling, T | 1 |
| Busse, PM; Clark, JR; Costello, R; Dreyfuss, AI; Lucarini, JW; Norris, CM; Posner, MR; Poulin, MD; Rossi, RM; Thornhill, L | 1 |
| Balcerzak, SP; Benedetti, J; Natale, RB; Weiss, GR | 1 |
| Christian, M; Davis, P; Goldspiel, B; Jacob, J; Kohn, E; Link, CJ; Maher, M; Reed, E; Sarosy, G | 1 |
| Baselga, J; Currie, V; Fennelly, D; Gilewski, T; Hudis, CA; Lebwohl, D; Moynahan, ME; Raptis, G; Seidman, AD; Sklarin, N | 1 |
| Greco, FA; Hainsworth, JD | 1 |
| Berger, MS; Chang, SM; Fulton, D; Gilbert, MR; Kuhn, J; Lamborn, K; McAllister, LD; Mehta, MP; Prados, MD; Rector, DJ; Schold, SC; Spence, AM | 1 |
| Chang, C; Imamura, K; Nishimura, H | 1 |
| Edwards, CL; Ende, K; Fishman, A; Freedman, RS; Kaplan, A; Kavanagh, JJ; Kieback, DG; Kudelka, AP; Levy, T; Mante, R; Steger, M; Verschraegen, CF | 1 |
| Ilson, DH; Kelsen, DP | 1 |
| Cairncross, G; Eisenhauer, E; Forsyth, P; Goodyear, M; Stewart, D; Wainman, N | 1 |
| Blom, R; Palm, N; Simonsen, E | 1 |
| Goldberg, JM; Hempling, RE; Piver, MS; Recio, FO | 1 |
| Schrijvers, D; van Dam, P; van Oosterom, A | 1 |
| Edwards, CL; Kavanagh, JJ; Kudelka, AP; Loyer, E; Piamsomboon, S; Termrungruanglert, W; Verschraegen, CF | 1 |
| Aghajanian, C; Fennelly, D; McKenzie, M; Norton, L; O'Connor, C; O'Flaherty, C; Shapiro, F; Spriggs, D; Tong, W | 1 |
| Khansur, T; Malamud, F; Thigpen, T; Vance, R | 1 |
| Athanassiadis, A; Bacoyiannis, H; Daniilidis, J; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Nikolaou, A; Samantas, E; Skarlos, D; Stathopoulos, G | 1 |
| Haraf, DJ; List, M; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Dobkin, J; Fracasso, PM; Luker, GD; Piwnica-Worms, D | 1 |
| Davison, JD; Francis, PA; Ganju, V; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC | 1 |
| Dunton, CJ | 1 |
| Oliver, RT | 1 |
| Glick, JH; Goldstein, LJ; Neuberg, D; Robert, NJ; Sledge, GW; Sparano, JA; Wood, W | 1 |
| Aloe, A; Atlante, G; Calabresi, F; Cognetti, F; De Marco, S; Iacovelli, A; Nardi, M | 1 |
| Gannett, DE; Hamilton, AJ; Hill, D; Stea, B | 1 |
| Bolis, G; Broom, C; Carmichael, J; Coleman, R; Davidson, N; Fields, SC; Gordon, A; Gore, M; Heron, JF; Hudson, I; Malfetano, J; Malmström, H; Scarabelli, C; Spanczynski, M; ten Bokkel Huinink, W | 1 |
| Fossella, FV; Hong, WK; Lee, JS | 1 |
| Elbendary, A; Herzog, TJ; Mutch, DG; Rader, JS; Swisher, EM | 1 |
| du Bois, A; Lück, HJ; Meerpohl, HG | 1 |
| Kristensen, G; Tropé, C | 1 |
| Curé, H; Diéras, V; Guastalla, JP; Jacquin, JP; Leduc, B; Mignot, L; Mousseau, M; Orfeuvre, H; Paraïso, D; Pujade-Lauraine, E; Tubiana-Mathieu, N; Viens, P; Vincent, P; Weber, B | 1 |
| Alvarez, AM; Blajman, C; Breier, S; Cazap, E; Cóppola, FS; Ezcurdia, L; Fasce, H; Fein, L; Jovtis, SL; Lewi, D; Luchina, AM; Martínez, CA; Mickiewicz, E; Pasccón, G; Polera, J; Politi, PM; Rondinón, M; Rubio, G; Temperley, G; Triguboff, E; Uranga, G | 1 |
| Abu-Rustum, NR; Aghajanian, C; Barakat, RR; Fennelly, D; Shapiro, F; Spriggs, D | 1 |
| Edwards, RP; Hart, LA; Kelley, JL; Kunschner, AJ; Price, FV | 1 |
| Motzer, RJ | 1 |
| Chamberlain, MC; Kormanik, PA | 1 |
| Gabriele, A; Gorga, G; Landoni, F; Lissoni, A; Mangioni, C; Sessa, C; Tumolo, S | 1 |
| Athanassiades, A; Bacoyiannis, C; Briassoulis, E; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lawhorn, K; Lippman, SM; Shin, DM | 1 |
| Ensley, J; Hussain, M; Kucuk, O; Salwen, W | 1 |
| Benasso, M; Gentile, A; Merlano, M; Numico, G; Ricci, I; Rosso, R | 1 |
| Bulusu, VR | 1 |
| Arbit, E; Lederman, G; Lombardi, E; Odaimi, M; Wronski, M; Wrzolek, M | 1 |
| Ang, KK; Callender, DL; Clayman, GL; Gillenwater, AM; Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lawhorn, K; Lee, JJ; Lippman, SM; Papadimitrakopoulou, V; Shin, DM | 1 |
| Fluellen, L; Fusco, N; Rodriguez, M; Rose, PG | 1 |
| Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G | 2 |
| Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM | 2 |
| Ajani, J; Bhalla, K; Donegan, J; Forastiere, A; Huang, Y; Ilson, DH; Kelsen, DP; Martin, L; Patel, P; Pazdur, R; Reed, C | 1 |
| Diergarten, K; Hanauske, AR; Heinrich, B; Herzog, M; Kau, R; Kemmerich, M; Laubenbacher, C; Quasthoff, S; Theiss, F; Thödtmann, F | 1 |
| Adachi, I; Ando, M; Fujii, H; Igarashi, T; Itoh, K; Katsumata, N; Narabayashi, M; Ohtsu, T; Omuro, Y; Sasaki, Y; Taguchi, T; Tokue, Y; Wakita, H; Watanabe, T; Ying, DF | 1 |
| Graeven, U; König, M; Petrasch, S; Reinacher, A; Schmiegel, W; Welt, A | 1 |
| Bolis, G; Bookman, MA; Fields, SZ; Gordon, A; Krebs, JB; Lissoni, A; Malmström, H | 1 |
| Hirabayashi, N; Kanamaru, R; Kurihara, M; Ota, J; Sakata, Y; Suminaga, M; Taguchi, T | 1 |
| Bradac, GB; Rudà, R; Schiffer, D; Soffietti, R | 1 |
| Dakhil, SR; Downey, G; Edwards, CL; Freedman, RS; Fueger, R; Gacrama, P; Greenberg, H; Kavanagh, JJ; Kudelka, AP; Loyer, E; Rusinkiewicz, J; Winn, R | 1 |
| Tay, SK; Thilagam, MD | 1 |
| Gregornik, D; Meyer, WH; Relling, MV; Shearer, PD; Woo, MH | 1 |
| Baba, S; Ebihara, S; Horiuchi, M; Ichikawa, G; Inuyama, Y; Kamata, S; Kanzaki, J; Kataura, A; Kida, A; Konno, A; Kono, N; Kubota, A; Matsunaga, T; Matsuura, H; Miyake, H; Moriyama, H; Saijo, S; Saito, H; Sakai, M; Sasaki, Y; Satake, B; Taguchi, T; Takeoda, S; Togawa, K; Tsukuda, M | 1 |
| Anagnostopoulos, A; Diakomanolis, E; Dimopoulos, MA; Fountzilas, G; Giannakoulis, N; Gika, D; Moulopoulos, LA; Papadimitriou, CA; Sarris, K; Voulgaris, Z | 1 |
| Catimel, G; Droz, JP; Gras, L; Hanauske, AR; Planting, AS; Schöffski, P; Schrijvers, A; Schrijvers, D; Verweij, J; Wanders, J | 1 |
| Lippman, SM; Shin, DM | 1 |
| Belinson, JL; Kennedy, AW; Markman, M; Webster, KD; Zanotti, KM | 2 |
| Canuti, D; Galli, I; Oliverio, G; Panzini, I; Ravaioli, A; Scarpellini, M; Tononi, A | 1 |
| Adams, LM; Buchbinder, A; Budman, DR; Donahue, L; Lichtman, SM; O'Mara, V; Weiselberg, L | 1 |
| Aritake, N; Fukunaga, M; Gotoh, K; Hasegawa, S; Imamoto, H; Kan, K; Kim, Y; Maruyama, H; Oozato, H; Takatsuka, Y; Touno, T; Yamazaki, K | 1 |
| Ghamande, SA; Piver, MS | 1 |
| Funahashi, H; Hayashi, H; Imai, T; Itoh, T; Kikumori, T; Mase, T; Oiwa, M; Sekiya, M; Shibata, A | 1 |
| Balestrino, M; Fei, F; Gabriele, A; Lissoni, A; Mangioni, C; Parma, G; Zanetta, G | 1 |
| Du, W; Ensley, J; Gadgeel, S; Hussain, M; Kucuk, O; Salwen, W | 1 |
| Eltabbakh, GH; Ghamande, SA; O'Neill-Coppola, C; Piver, MS | 1 |
| Gleave, ME; Miayake, H; Tolcher, A | 1 |
| Boyd, JH; Collins, BT; Dunleavy, T; Dunphy, FR; Fletcher, JW; Hollenbeak, C; Kim, H; Lowe, VJ; Martin, D; Stack, BC | 1 |
| Ansari, R; Einhorn, LH; Gabrys, GT; Gonin, R; Murdock, A; Sciortino, DF; Sonpavde, G; Walker, P | 1 |
| Almagro, M; Fonseca, E; Garcia, J; Pozo, JD; Vasquez, A | 1 |
| King, K; Younes, A | 1 |
| Fei, F; Mangioni, C; Zanetta, G | 1 |
| Shin, DM | 1 |
| Akerman, P; Chen, MH; Cioffi, W; DiPetrillo, T; Hesketh, PJ; Ianitti, D; Koness, J; McAnaw, R; Moore, T; Radie-Keane, K; Safran, H; Wanebo, HJ; Wolf, B | 1 |
| Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yamamiti, N; Yoshimasu, T | 1 |
| Arbit, E; Lederman, G; Lombardi, E; Odaimi, M; Wertheim, S; Wronski, M; Wrzolek, M | 1 |
| Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E | 1 |
| Beretta, P; Donadello, N; Franchi, M; Ghezzi, F; Miglierina, M; Zanaboni, F | 1 |
| Beenen, LF; Heimans, JJ; Hoekstra, OS; Klein, M; Luykx, SA; Postma, TJ; Taphoorn, MJ; van Groeningen, CJ; Vermorken, JB; Zonnenberg, BA | 1 |
| Bacik, J; Bains, M; Bajorin, D; Bosl, GJ; Mariani, T; Mazumdar, M; Motzer, RJ; Sheinfeld, J | 1 |
| Aravantinos, G; Dimopoulos, MA; Georgoulias, V; Gika, D; Karpathios, S; Moulopoulos, LA; Papadimitriou, CA; Stamatelopoulos, S | 1 |
| Finlay, J; Glass, J; Gruber, ML; Hochster, H; Muggia, FM; Nirenberg, A; Rosenthal, MA | 1 |
| Bhatla, N; Gupta, S; Kochupillai, V; Kumar, L; Kumar, S; Shamsunder, S; Singh, R | 1 |
| Baylor, A; Cullen, KJ; Johnston, PG; Langmacher, M; Lee, M; Rasmussen, AA; Shiga, H | 1 |
| Buccheri, G; Ferrigno, D | 1 |
| Austin Seymour, MM; Bellon, JR; Ellis, GK; Gralow, JR; Lindsley, KL; Livingston, RB | 1 |
| Kristopaitis, T; Lee, JM; Petruzzelli, GJ; Thomas, C | 1 |
| Hansen, HS; Larsen, SK; Specht, L | 1 |
| Naito, Y; Oura, S; Tanino, H | 1 |
| Kimura, M; Koida, T; Yanagita, Y | 1 |
| Ajarim, DS; Al-Malik, OA; Bazarbashi, SM; Ezzat, AA; Ibrahim, EM; Kandil, A; Rahal, MM; Raja, MA; Stuart, RK; Tulbah, AM | 1 |
| Fujiyoshi, K; Hirai, N; Kamura, T; Komai, K; Nishida, T; Ota, S; Sugiyama, T; Ushijima, K | 1 |
| Cosio, S; Cristofani, R; Fanucchi, A; Gadducci, A; Iacconi, P; Riccardo Genazzani, A | 1 |
| Pitoniak, RF; Takita, H | 1 |
| Gallagher, CJ; Gupta, RK; Kelsey, S; Lister, TA; Newland, AC; O'Doherty, CA; Oliver, RT; Shamash, J | 1 |
| Barnouin, L; Cals, L; Cupissol, D; Guardiola, E; Guerrier, P; Merad, L; Pivot, X; Savary, J; Schneider, M; Tchiknavorian, X; Thyss, A; Wendling, JL | 1 |
| Balaguer-Martínez, JV; Castillo-Pallarés, FJ; Ferrer Albiach, C; Pallardó-Calatayud, J; Romero-de-Avila, C; Ruiz Hernández, G | 1 |
| Endo, M; Kadou, T; Kotani, Y; Ohbayashi, K; Satouchi, M; Takada, Y | 1 |
| Belani, CP; Calvo, AR | 1 |
| Doihara, H; Hino, M; Ishibe, Y; Nagahiro, I; Ogasawara, Y; Sano, Y; Shimizu, N; Teramoto, A; Yoshitomi, S | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Abbruzzese, JL; Breslin, TM; Cleary, KR; Crane, CH; Dackiw, AP; Evans, DB; Harbison, DB; Hess, KR; Janjan, NA; Jean, ME; Lee, JE; Pisters, PW; Vauthey, JN; Wolff, RA | 1 |
| Broët, P; Delattre, JY; Hoang-Xuan, K; Keime-Guibert, F; Napolitano, M; Sanson, M; Yaya, R | 1 |
| Adolph, A; Biem, S; Khan, K; Le, T | 1 |
| Bolis, G; Carmichael, J; Coleman, R; Davidson, N; Fields, SZ; Gordon, A; Gore, M; Héron, JF; Malfetano, J; Malmström, H; Ross, G; Scarabelli, C; Spaczynski, M; ten Bokkel Huinink, W; Vennin, P | 1 |
| Brockstein, B; Chung, T; Haraf, DJ; Kies, MS; List, M; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, A; Rosen, F; Stenson, K; Vokes, EE; Weichselbaum, R | 1 |
| Ang, KK; Clayman, G; Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Lee, JJ; Lippman, SM; Papadimitrakopoulou, VM; Shin, DM | 1 |
| Avallone, A; Biglietto, M; Caponigro, F; Comella, G; Comella, P; De Lucia, L; Mantovani, G; Manzione, L; Massa, E; Rosati, G; Sganga, P; Sguotti, C | 1 |
| Malik, IA | 1 |
| Antonopoulos, M; Kalofonos, HP; Kosmas, C; Kourelis, T; Malamos, N; Panopoulos, C; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Atkinson, MJ; Campo, MG; Lakusta, CM; Nation, J; Robinson, JW; Taenzer, PA | 1 |
| Beyer, J; Bokemeyer, C; Rick, O; Siegert, W | 1 |
| Beppu, M; Chiba, T; Hiura, M; Kawakami, Y; Nogawa, T; Yokoyama, T | 1 |
| Bednar, M; Chachoua, A; Ferrari, AC; Mandeli, J; Muggia, F; Rosenthal, M; Singh, H; Taneja, S | 1 |
| Aoki, Y; Kazama, JJ; Kurata, H; Tanaka, K; Tomita, M | 1 |
| Brady, MF; Fracasso, PM; Grogan, TM; Letvak, L; McGuire, WP; Moore, DH; Rose, PG; Walker, JL | 1 |
| Ohtsu, A; Yoshida, M | 1 |
| Cohen, JS; Faibel, M; Hadani, M; Jonas, T; Lidar, Z; Maier, SE; Mardor, Y; Nass, D; Orenstein, A; Pfeffer, R; Ram, Z; Roth, Y | 1 |
| Bando, H; Hayashi, K; Kuroi, K; Nagai, S; Tanaka, C; Toi, M | 1 |
| Ajani, JA; Komaki, R; Lahoti, S; Lynch, PM; Martin, FD; Nesbitt, J; Pisters, PW; Putnam, JB; Raijman, I; Roth, JA; Smythe, R; Swisher, S; Vaporciyan, A; Walsh, G | 1 |
| Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T | 1 |
| Hirashima, Y; Kanayama, N; Kobayashi, H; Miura, K; Nishiguchi, T | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Palmer, JL; Preti, HA; Rodriguez, MA; Romaguera, JE; Samuels, BI; Younes, A | 1 |
| Hada, M; Koshizuka, K; Mouri, N; Muto, S; Nakagomi, H; Serizawa, M; Tada, Y; Takano, K | 1 |
| Kashimura, M; Matsuura, Y; Murakami, N; Nagashio, E; Toki, N | 1 |
| Berkowitz, RS; Campos, SM; Cook, S; Fuller, AF; Goodman, A; MacNeill, KM; Matulonis, UA; Penson, RT; Seiden, MV; Supko, JG | 1 |
| Hirai, N; Kamura, T; Komai, K; Kumagai, S; Nishida, T; Ota, S; Sugiyama, T; Ushijima, K | 1 |
| Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C | 2 |
| Avigan, D; Elias, AD; Frei, E; Ibrahim, J; Joyce, R; Levine, J; McCauley, M; McDermott, D; Richardson, P; Warren, D; Wheeler, C | 1 |
| Belette, F; Blaustein, A; Davila, E; Lilenbaum, RC; Schwartz, MA; Seigel, L; Wittlin, FN | 1 |
| Acquino-Parsons, C; Hoskins, PJ; Lee, N; Lim, P; Pike, JA; Swenerton, KD; Wong, F | 1 |
| Asbury, R; Boros, L; Chang, AY; Hui, LF; Rubins, J | 1 |
| Blessing, JA; Curtin, JP; DeGeest, K; Soper, JT | 1 |
| Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M | 1 |
| Bubley, GJ; Ko, YJ; Morganstern, DE; Rajeshkumar, B; Shuster, T; Taplin, ME | 1 |
| Leyland-Jones, B; Smith, I | 1 |
| Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC | 1 |
| Ishikawa, H; Kuzuya, K; Nakanishi, T; Nawa, A; Suzuki, Y | 1 |
| Horowitz, J | 1 |
| Fukuda, K; Kim, Y; Kitano, H; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Bastian, R; Choudhury, A; Clark, JI; Collins, S; Emami, B; Hofmeister, C; Matz, G; Melian, E; Petruzzelli, G | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Calabrò, F; Marini, L; Pizzocaro, G; Schnetzer, S; Sella, A; Sternberg, CN | 1 |
| Bagaméri, A; Lehoczky, O; Pulay, T; Udvary, J | 1 |
| Hitsuda, Y; Kato, K; Kawasaki, Y; Kobayashi, K; Matsumoto, S; Mikami, M; Miyata, M; Saito, S; Shimizu, E; Tokushima, T; Yano, S; Yasuda, K | 1 |
| Ames, FC; Buchholz, TA; Buzdar, AU; Hortobagyi, GN; Hunt, KK; Kuerer, HM; Pusztai, L; Ross, MI; Singletary, SE; Valero, V | 1 |
| Hirano, M; Kikkawa, H; Kikuchi, T; Murakami, N; Nozawa, H; Okuda, T; Oya, J; Uno, Y | 1 |
| Beyer, J; Rick, O; Siegert, W | 1 |
| Demetri, GD; Ette, E; Garg, V; Harding, MW; Overmoyer, B; Pollak, M; Russell, C; Seidman, AD; Tkaczuk, K; Toppmeyer, D; Verma, S | 1 |
| Forastiere, AA; Frenette, G; Glisson, BS; Khuri, FR; Murphy, BA | 1 |
| Inaji, H; Kobayashi, H; Motomura, K; Noguchi, S; Taguchi, T; Takamura, Y | 1 |
| Amamoo, MA; Collichio, FA; Fogleman, J; Graham, M; Griggs, J | 1 |
| Ames, F; Berry, D; Booser, DJ; Buzdar, AU; Frye, DK; Holmes, FA; Hortobagyi, GN; Hoy, E; Hunt, K; Ibrahim, NK; Kau, SW; Manuel, N; McNeese, MD; Rahman, Z; Rivera, E; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Thomas, E; Valero, V; Walters, R | 1 |
| Cavina, R; Cerrotta, A; De Palo, G; Garassino, I; Gardan, G; Musumeci, R; Raspagliesi, F; Stefanon, B; Tana, S | 1 |
| Altun, M; Basaran, M; Bavbek, SE; Demirelli, F; Güllü, I; Onat, H; Sakar, B; Tenekeci, N; Yalçin, S | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Efstathiou, E; Gika, D; Gourgoulis, GM; Kalofonos, C; Papadimitriou, CA; Sarris, K; Skarlos, D | 1 |
| Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Hensley, ML | 1 |
| Kovács, AF; Schiemann, M; Turowski, B | 1 |
| Kudo, R; Sagae, S | 1 |
130 review(s) available for paclitaxel and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Sister Mary Joseph nodule as cutaneous manifestations of metastatic ovarian cancer: A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Agents; CA-125 Antigen; Carboplatin; Female; Gynecologic Surgical Procedures; Humans; Liposomes; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Sister Mary Joseph's Nodule; Skin Neoplasms; Tomography, X-Ray Computed; Umbilicus | 2022 |
The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Feasibility Studies; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2022 |
Optimizing regional chemotherapy for epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2022 |
The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; B7-H1 Antigen; Humans; Immunotherapy; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life | 2022 |
Recurrent or primary metastatic cervical cancer: current and future treatments.
Topics: Bevacizumab; Biomarkers; Cisplatin; Female; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Neoplasm Recurrence, Local; Paclitaxel; Papillomavirus Vaccines; Thromboplastin; Uterine Cervical Neoplasms | 2022 |
Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies | 2022 |
Changing therapeutic landscape in advanced Kaposi sarcoma: Current state and future directions.
Topics: Antineoplastic Agents; Doxorubicin; Humans; Neoplasm Recurrence, Local; Paclitaxel; Sarcoma, Kaposi | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Role of forkhead box proteins in regulation of doxorubicin and paclitaxel responses in tumor cells: A comprehensive review.
Topics: Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Humans; Neoplasm Recurrence, Local; Paclitaxel; Phosphatidylinositol 3-Kinases; Quality of Life | 2023 |
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
Topics: Adjuvants, Immunologic; Anthracyclines; Bevacizumab; Carboplatin; Cyclophosphamide; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Network Meta-Analysis; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Uterine Cervical Neoplasms | 2023 |
Advances in paclitaxel combinations for treating cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Uterine Cervical Neoplasms | 2020 |
Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer.
Topics: Adult; Antineoplastic Agents; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies; Survival Rate; Taiwan; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Pemetrexed; Programmed Cell Death 1 Receptor; Progression-Free Survival; Quality of Life; Review Literature as Topic | 2020 |
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease Progression; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Watchful Waiting | 2020 |
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunotherapy; Irinotecan; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy; Stomach Neoplasms | 2020 |
Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Precision Medicine | 2021 |
[Squamous cell anal carcinoma. What's next ?]
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Contraindications, Drug; DNA, Viral; Fluorouracil; Humans; Immune Checkpoint Inhibitors; Immunity, Cellular; Neoplasm Recurrence, Local; Paclitaxel; Telomerase | 2021 |
Hypersensitivity Reaction to Carboplatin in Gynecologic Cancer: A Case Report and a Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Drug Hypersensitivity; Drug Substitution; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Neoplasms | 2021 |
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2017 |
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2018 |
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nomograms; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; United States | 2019 |
Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.
Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Parenteral; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Standard of Care | 2019 |
Everolimus: a new hope for patients with breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Immunosuppressive Agents; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab | 2014 |
An update on the pharmacotherapy for endometrial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Practice Guidelines as Topic; Radiography; Randomized Controlled Trials as Topic | 2013 |
[Treatment strategies in ovarian cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2013 |
Do we have a new standard in suboptimal debulked disease?
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Chemotherapy, Adjuvant; Female; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel | 2013 |
Update on randomized trials on recurrent disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2013 |
CNS metastases in breast cancer: old challenge, new frontiers.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Central Nervous System Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Radionuclide Imaging; Radiopharmaceuticals; Trastuzumab | 2013 |
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2014 |
Advances in cervical cancer pharmacotherapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms | 2014 |
nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Factors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Early Detection of Cancer; Female; Humans; Infusions, Intravenous; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Evidence-Based Medicine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Prevalence; Risk Factors; Survival Rate; Treatment Outcome | 2014 |
Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Clinical Trials as Topic; Drug Delivery Systems; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 2014 |
Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mass Screening; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Topotecan; Uterine Cervical Neoplasms | 2014 |
Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom | 2015 |
Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2015 |
Secondary breast angiosarcoma and paclitaxel-dependent prolonged disease control: report of two cases and review of the literature.
Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Hemangiosarcoma; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Combined Modality Therapy; Cystadenofibroma; Diagnosis, Differential; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2015 |
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Survivin | 2015 |
Management of patients treated with pertuzumab in the Australian clinical practice setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Bridged-Ring Compounds; Disease Management; Disease Progression; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2016 |
High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Patient Selection; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2017 |
Surgical treatment of recurrent urachal carcinoma with liver metastasis: a case report and literature review.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hepatectomy; Humans; Hysterectomy; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2016 |
Chemotherapy for recurrent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms | 2008 |
Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Ifosfamide; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prognosis; Testicular Neoplasms; Time Factors; Treatment Failure; Urogenital Surgical Procedures; Vinblastine | 2008 |
Emerging drugs for ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Parenteral; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2008 |
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Guidelines as Topic; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2009 |
Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Treatment Failure | 2004 |
Weekly paclitaxel in the treatment of recurrent ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Selection | 2010 |
New advances in ovarian cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Infusions, Parenteral; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Poly Adenosine Diphosphate Ribose; Proteins | 2010 |
Paclitaxel poliglumex for ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Polyglutamic Acid; Solubility; Time Factors; Treatment Outcome | 2011 |
Primary clear cell carcinoma of a paratubal cyst: a case report with literature review.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Keratins; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Parovarian Cyst; Salpingectomy | 2011 |
[High dose chemotherapy and germ cell tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Humans; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy | 2011 |
Surgery for recurrent ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Female; Gynecologic Surgical Procedures; Humans; Medical Oncology; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome | 2011 |
A rational approach to the management of recurrent or persistent ovarian carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Decision Making; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic | 2012 |
An overview of current diagnosis and treatment in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel | 2012 |
Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Salvage Therapy; Testicular Neoplasms; Therapeutic Equipoise | 2012 |
Chemotherapy for metastatic and recurrent cervical cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms; Young Adult | 2012 |
The role of docetaxel in the management of squamous cell cancer of the head and neck.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2002 |
Chemotherapy for androgen-independent prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Prostatic Neoplasms; Taxoids | 2002 |
Update on the role of topotecan in the treatment of recurrent ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Rate; Topotecan | 2002 |
Second line chemotherapy for NSCLC: establishing a gold standard.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Quality of Life; Taxoids; Treatment Outcome | 2002 |
[Weekly administration of paclitaxel with a short course of premedication for advanced or recurrent gastric cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Premedication; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Neoadjuvant docetaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids | 2003 |
Activity of chemotherapy with carboplatin plus paclitaxel in a recurrent mesonephric adenocarcinoma of the uterine corpus.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Mesonephroma; Neoplasm Recurrence, Local; Paclitaxel; Uterine Neoplasms | 2003 |
Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Incidence; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Probability; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Time Factors; Treatment Outcome | 2003 |
Localized pleural malignant mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Mesothelioma; Neoplasm Recurrence, Local; Paclitaxel; Pleural Neoplasms; Radiography, Thoracic; Tomography, X-Ray Computed | 2003 |
Recent advances in the management of women with ovarian cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2004 |
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |
Current treatment options for endometrial cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Differentiation; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Ovariectomy; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Receptor, ErbB-2; Risk Factors; Survival Analysis; Trastuzumab | 2004 |
Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyglutamic Acid; Survival Analysis; Taxoids | 2004 |
[Taxol in advanced cervical cancer].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2004 |
[Activity of paclitaxel, epirubicin and carboplatin in patients with advanced or recurrent endometrial cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Endometrial Neoplasms; Epirubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Postoperative Care; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
[Efficacy of cancer chemotherapy on patients with recurrent endometrial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Risk | 2004 |
[Therapy for ovarian cancer--general review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Female; Gynecologic Surgical Procedures; Humans; Lymph Node Excision; Neoplasm Recurrence, Local; Neoplasm Staging; Omentum; Ovarian Neoplasms; Paclitaxel | 2004 |
[Treatment of platinum-resistant ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Time Factors | 2004 |
First-line therapy for ovarian carcinoma: what's next?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Risk Factors | 2004 |
Medical treatment of epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis | 2004 |
Chemotherapy for ovarian cancer: an evidence-based approach.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Time Factors | 2004 |
Paclitaxel for AIDS-associated Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Algorithms; Anti-Retroviral Agents; Antineoplastic Agents, Phytogenic; Herpesviridae Infections; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Sarcoma, Kaposi | 2005 |
[Pharmacotherapy in ovarian carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Quality of Life; Time Factors | 2005 |
[Activity of Taxanes for advanced and recurrent pancreatic cancer].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2006 |
Systemic therapy for ovarian cancer: current status and new treatments.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Decision Trees; Drug Administration Routes; Female; Humans; Infusions, Parenteral; Medical Oncology; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Optimizing gemcitabine regimens in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Decision Trees; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Management of platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2006 |
Diagnosis and management of epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Injections, Intraperitoneal; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2006 |
Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Failure | 2006 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Denmark; Diagnostic Imaging; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Outcome | 2006 |
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors | 2007 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Docetaxel; Female; Fluorouracil; Humans; Informed Consent; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Patient Care Team; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Silicates; Taxoids; Titanium; Trastuzumab | 2007 |
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Models, Biological; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2007 |
The role of paclitaxel in the treatment of head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Tumor Cells, Cultured | 1995 |
Promising new developments in the systemic treatment of ovarian cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Suramin | 1994 |
Current and future trials of Taxol (paclitaxel) in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Forecasting; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic | 1994 |
Taxol: initial Israeli experience with a novel anticancer agent.
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Israel; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Time Factors | 1994 |
Second-line chemotherapy for recurrent carcinoma of the ovary.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 1993 |
[Chemotherapy for recurrent ovarian cancer].
Topics: Adenocarcinoma, Clear Cell; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 1996 |
Management of esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Esophageal Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Premedication; Radiotherapy, Adjuvant; Vinblastine; Vinorelbine | 1996 |
Remission of recurrent cervical cancer with paclitaxel and carboplatin: a case report and review of literature.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 1996 |
The role of paclitaxel in the management of patients with carcinoma of the cervix.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Female; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
New options for the treatment of advanced ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1997 |
Future trials in germ cell malignancy (GCM) of the testis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical Trials as Topic; Decision Making; Etoposide; Forecasting; Genetic Therapy; Germinoma; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Orchiectomy; Paclitaxel; Patient Participation; Quality of Life; Risk Factors; Safety; Salvage Therapy; Seminoma; Testicular Neoplasms | 1997 |
Management strategies for recurrent non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Failure | 1997 |
[Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Survival Rate | 1997 |
Current status of chemotherapy in gynecologic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel | 1999 |
Taxoids in head and neck cancer: the American approach.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; United States | 1999 |
Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy | 2000 |
Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Salvage Therapy; Taxoids; Uterine Cervical Neoplasms | 2000 |
Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Ifosfamide; Mesna; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2000 |
Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2000 |
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
[Chemosensitivity test of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Taxoids; Tumor Cells, Cultured | 2000 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Salvage chemotherapy in relapsed germ cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Testicular Neoplasms; Vinblastine | 2001 |
[New drugs for unresectable or recurrent gastric cancer--paclitaxel and docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome | 2001 |
Role of Herceptin in primary breast cancer: views from North America and Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Interactions; Europe; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; North America; Paclitaxel; Palliative Care; Pilot Projects; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Safety; Survival Analysis; Tamoxifen; Taxoids; Trastuzumab; Treatment Outcome | 2001 |
Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Genes, p53; Genetic Therapy; Genetic Vectors; Glioblastoma; Head and Neck Neoplasms; Humans; Injections; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasms; Ovarian Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Recombinant Fusion Proteins; Salvage Therapy; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 1999 |
Paclitaxel in the adjuvant setting: results so far are inconclusive.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2001 |
Neoadjuvant gemcitabine therapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
524 trial(s) available for paclitaxel and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Carcinoma, Ovarian Epithelial; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intercellular Signaling Peptides and Proteins; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins | 2021 |
Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Humans; Lung Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel | 2021 |
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Hormones; Humans; Neoplasm Recurrence, Local; Paclitaxel; Phosphatidylinositol 3-Kinases; Piperazines; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Receptor, ErbB-2 | 2022 |
Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2022 |
Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2022 |
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Male; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Testicular Neoplasms; Trastuzumab | 2022 |
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Phthalazines; Piperazines; Quinazolines | 2022 |
A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Canada; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Russia; Therapeutic Equivalency; Treatment Outcome; Ukraine; Young Adult | 2022 |
Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Small Cell Lung Carcinoma | 2022 |
Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cisplatin; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel | 2022 |
DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2022 |
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 tr
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Trastuzumab | 2022 |
Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pyrimidines; RNA; Stomach Neoplasms | 2022 |
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Purines | 2022 |
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydrazines; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel | 2023 |
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Recurrence | 2023 |
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Topics: Breast; Breast Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab | 2023 |
Jetstream Atherectomy with Paclitaxel-Coated Balloons: Two-Year Outcome of the Prospective Randomized JET-RANGER Study.
Topics: Angioplasty, Balloon; Atherectomy; Carcinoma, Renal Cell; Femoral Artery; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2023 |
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Mismatch Repair; Double-Blind Method; Endometrial Neoplasms; Female; Humans; Immune Checkpoint Inhibitors; Microsatellite Instability; Neoplasm Recurrence, Local; Paclitaxel | 2023 |
Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies | 2023 |
Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (J
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 2023 |
Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Breast Neoplasms; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2023 |
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A | 2023 |
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Programmed Cell Death 1 Receptor; Thymoma; Thymus Neoplasms | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Humans; Idiopathic Interstitial Pneumonias; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies | 2023 |
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Platinum; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Survival Analysis | 2023 |
ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results.
Topics: Aged; Drug-Eluting Stents; Femoral Artery; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Stents; Treatment Outcome; Vascular Patency | 2023 |
Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2023 |
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab; United States; Young Adult | 2019 |
A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc st
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Survival Rate; Uterine Cervical Neoplasms | 2020 |
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azepines; Biomarkers; Disease-Free Survival; Double-Blind Method; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pyrimidines; Retrospective Studies; Treatment Outcome | 2020 |
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Prospective Studies | 2019 |
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Reoperation; Survival Analysis | 2019 |
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2020 |
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome | 2020 |
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progression; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; France; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Survival Analysis | 2020 |
[Clinical implications of the PORTEC-3 trial for the treatment of high-risk endometrial cancer].
Topics: Area Under Curve; Brachytherapy; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Risk Factors; Survival Rate | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Prospective Studies; Small Cell Lung Carcinoma | 2020 |
Relapse and Prognosis of Non-Muscle Invasive Bladder Cancer After Combined HOLRBT with Sunitinib and TGC Perfusion Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lasers, Solid-State; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sunitinib; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
Topics: Adolescent; Albumins; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Male; Models, Biological; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Tissue Distribution | 2021 |
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Administration Schedule; Endometrial Neoplasms; Endometrium; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2020 |
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Progression-Free Survival; Randomized Controlled Trials as Topic | 2020 |
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Drug Administration Schedule; Female; Humans; Incidence; Intestinal Fistula; Intestinal Perforation; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Uterine Cervical Neoplasms; Vaginal Fistula; Young Adult | 2020 |
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult | 2020 |
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bevacizumab; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Sex Cord-Gonadal Stromal Tumors | 2020 |
The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2020 |
Neoadjuvant chemotherapy followed by conization in stage IB2-IIA1 cervical cancer larger than 2 cm: a pilot study.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Conization; Disease-Free Survival; Feasibility Studies; Female; Fertility Preservation; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Paclitaxel; Patient Acceptance of Health Care; Pilot Projects; Pregnancy; Pregnancy Rate; Tumor Burden; Uterine Cervical Neoplasms; Young Adult | 2021 |
Intensity-modulated radiation therapy (IMRT)-based concurrent chemoradiotherapy (CCRT) with Endostar in patients with pelvic locoregional recurrence of cervical cancer: Results from a hospital in the Qinghai-Tibet Plateau.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Endostatins; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Intensity-Modulated; Recombinant Proteins; Tibet; Uterine Cervical Neoplasms | 2020 |
Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel | 2021 |
Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Caveolin 1; Dasatinib; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Pilot Projects; Receptor, EphA2; Signal Transduction; Survival Rate | 2021 |
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2021 |
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Topics: Aged; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Dose Fractionation, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiotherapy, Intensity-Modulated; Time Factors; Treatment Failure | 2021 |
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Intention to Treat Analysis; Laparoscopy; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Postoperative Complications; Prospective Studies; Quality of Life; Survival Rate; Thoracoscopy | 2021 |
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Survival Rate | 2021 |
A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2021 |
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind
Topics: Administration, Intravenous; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pharmaceutical Preparations; Platinum; Quality of Life; Randomized Controlled Trials as Topic; Selenium | 2021 |
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2021 |
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2021 |
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction | 2017 |
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2017 |
A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
Topics: Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Incidence; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome | 2017 |
ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life | 2017 |
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Uterine Cervical Neoplasms | 2017 |
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms | 2017 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Hong Kong; Humans; Indoles; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Oligonucleotides; Paclitaxel; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate | 2017 |
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus; Squamous Cell Carcinoma of Head and Neck | 2017 |
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Breast Neoplasms, Male; Carboplatin; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Single-Blind Method; Temozolomide; Young Adult | 2018 |
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Genetic Testing; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2018 |
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Placebos; Progression-Free Survival; Proto-Oncogene Mas; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Stomach Neoplasms; Survival Analysis | 2018 |
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome; Young Adult | 2018 |
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Endometrial Neoplasms; Epothilones; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus | 2018 |
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Signet Ring Cell; Choice Behavior; Decision Support Techniques; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; International Agencies; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Stomach Neoplasms; Survival Rate; Young Adult | 2018 |
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Double-Blind Method; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Receptors, Estrogen; Retrospective Studies; Treatment Outcome | 2018 |
Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Dermatitis; Disease-Free Survival; Drug Resistance, Neoplasm; Electric Stimulation Therapy; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retreatment; Survival Rate | 2018 |
Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2018 |
Validation of Effective Dose as a Better Predictor of Radiation Pneumonitis Risk Than Mean Lung Dose: Secondary Analysis of a Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Bayes Theorem; Carboplatin; Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Female; Humans; Incidence; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Photons; Proton Therapy; Protons; Radiation Pneumonitis; Radiometry; Radiotherapy; Radiotherapy, Intensity-Modulated; Reproducibility of Results; Risk; Scattering, Radiation; Smoking; Young Adult | 2019 |
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azepines; Breast Neoplasms; Disease Progression; Europe; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Pyrimidines; Time Factors; United States | 2019 |
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Time Factors; Triple Negative Breast Neoplasms; United States | 2019 |
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyridines | 2019 |
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.
Topics: Adult; Aged; Cancer Vaccines; Dendritic Cells; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Small Cell Lung Carcinoma; Transfection; Tumor Suppressor Protein p53; Vaccination | 2019 |
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Survival Rate; Trastuzumab; Young Adult | 2019 |
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Estrogen; Survival Rate | 2019 |
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bridged-Ring Compounds; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Stomach Neoplasms; Taxoids | 2019 |
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2019 |
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Follow-Up Studies; Humans; Internationality; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Progression-Free Survival; Quality of Life; Response Evaluation Criteria in Solid Tumors; Survival Rate; Young Adult | 2019 |
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Response Evaluation Criteria in Solid Tumors; Survival Rate; Urologic Neoplasms; Vinblastine | 2019 |
Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2019 |
Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 2019 |
Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Idiopathic Interstitial Pneumonias; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel | 2013 |
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymph Nodes; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Risk Assessment; Survival Analysis; Treatment Outcome | 2013 |
Combination phase II study of weekly paclitaxel and 5'-DFUR for unresectable or recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Floxuridine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Survival Rate | 2013 |
Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks.
Topics: Aged; Carboplatin; Cisplatin; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms | 2013 |
A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Prognosis; Radiotherapy, Intensity-Modulated; Uterine Cervical Neoplasms | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Topics: Adult; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival; Treatment Outcome | 2014 |
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pneumonectomy; Postoperative Care; Survival Rate; Treatment Outcome | 2014 |
[The results of combined treatment for stage III lung cancer including the use of intraoperative radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Intraoperative Care; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome | 2013 |
[ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms; Vincristine | 2013 |
Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Survival; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Uterine Neoplasms; Uterus | 2014 |
Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Risk Factors; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Salvage Therapy; Taxoids | 2014 |
Improved survival with bevacizumab in advanced cervical cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis; Topotecan; Uterine Cervical Neoplasms | 2014 |
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan | 2014 |
Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Combined Modality Therapy; Feasibility Studies; Female; Follow-Up Studies; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis | 2014 |
Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma.
Topics: Adenoviridae; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endostatins; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 2014 |
Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Disease-Free Survival; Doxorubicin; Drug Discovery; Female; Humans; Kinetics; Middle Aged; Models, Statistical; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Treatment Outcome | 2014 |
Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Small Cell; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Early Termination of Clinical Trials; Female; Follow-Up Studies; Humans; Interferon-alpha; Isotretinoin; Leukocytes, Mononuclear; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Severity of Illness Index; Small Cell Lung Carcinoma; Survival Analysis | 2014 |
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2014 |
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Topics: Aged; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Edema; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recombinant Fusion Proteins; Withholding Treatment | 2014 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer: a Korean Gynecologic Oncologic Group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Chemoradiotherapy; Confidence Intervals; Disease-Free Survival; Dose Fractionation, Radiation; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Care; Prospective Studies; Radiation-Sensitizing Agents; Republic of Korea; Survival Analysis | 2014 |
Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome | 2014 |
Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Survival Rate; Young Adult | 2015 |
Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Squamous Cell; Dermatologic Agents; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Isotretinoin; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Recombinant Proteins; Survival Rate; Uterine Cervical Neoplasms | 2014 |
Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Treatment Outcome | 2015 |
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Time Factors; Treatment Outcome; Young Adult | 2015 |
A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2015 |
A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).
Topics: Administration, Oral; Albumins; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Prospective Studies; Quality of Life; Stomach Neoplasms; Treatment Outcome | 2015 |
Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2015 |
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2015 |
Do Cell-Cycle Phase-Specific Markers Predict Disease Grade, Stage, and Outcome in Cervical Carcinoma?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Uterine Cervical Neoplasms; Young Adult | 2015 |
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Quality of Life; Risk Factors; Surveys and Questionnaires; Time Factors; Topotecan; Treatment Outcome; United States; Uterine Cervical Neoplasms | 2015 |
Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Treatment Outcome; Uterine Cervical Neoplasms | 2015 |
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Fusion Proteins | 2015 |
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrimidines; Sulfonamides; Treatment Outcome | 2015 |
A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines | 2015 |
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Survival Analysis; Treatment Outcome | 2015 |
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Small Cell Lung Carcinoma | 2016 |
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Drug Administration Schedule; Epothilones; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2015 |
Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.
Topics: Antineoplastic Agents, Phytogenic; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms | 2015 |
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2015 |
Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2016 |
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Prognosis; Risk Factors; Topotecan; Treatment Outcome | 2015 |
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Biopsy, Needle; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Phthalazines; Piperazines; Proportional Hazards Models; Prospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
[Study on therapy of metastasized or locally advanced urothelial cancer: A phase III randomized clinical trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel or vinflunine in subjects with recurrent or progressive metastatic urothelial cancer (Ke
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Docetaxel; Europe; Germany; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; United States; Vinblastine | 2015 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Radiography; Radionuclide Imaging; Survival Rate; Uterine Cervical Neoplasms | 2015 |
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2016 |
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Retreatment; Treatment Outcome | 2015 |
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines; Uterine Cervical Neoplasms | 2015 |
Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Prospective Studies; Retreatment; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms | 2016 |
Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2016 |
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Placebo Effect; Quality of Life; Recombinant Fusion Proteins; Treatment Outcome | 2016 |
Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2016 |
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2016 |
Concurrent Chemoradiation with Weekly Paclitaxel and Cisplatin for Locally Advanced Cervical Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Iran; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Remission Induction; Uterine Cervical Neoplasms | 2016 |
Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemoradiotherapy, Adjuvant; Cisplatin; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Hysterectomy; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Radiation Injuries; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Receptor, ErbB-2; Survival Rate | 2016 |
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Recombinant Fusion Proteins | 2016 |
Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Hemoglobins; Humans; Karnofsky Performance Status; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platelet Count; Prognosis; Prospective Studies; Uterine Cervical Neoplasms | 2016 |
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-c
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Sulfonamides | 2016 |
Ongoing Clinical Trials in Testicular Cancer: The TIGER Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Internationality; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prevalence; Risk Factors; Salvage Therapy; Survival Analysis | 2016 |
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2016 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan | 2016 |
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Panitumumab; Squamous Cell Carcinoma of Head and Neck | 2016 |
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Hypertension; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Selection; Platinum Compounds; Polyethylene Glycols; Topotecan | 2017 |
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
Topics: Adult; Aged; Benzimidazoles; Carcinoma; Cisplatin; Disease-Free Survival; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Uterine Cervical Neoplasms | 2017 |
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Female; Follow-Up Studies; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organs at Risk; Paclitaxel; Prospective Studies; Radiation Dosage; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Survival Rate | 2017 |
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Risk Factors; Tamoxifen; Tumor Burden | 2017 |
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Double-Blind Method; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; International Agencies; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Survival Rate | 2017 |
Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Albumins; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kaplan-Meier Estimate; Male; Nanoparticles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Programmed Cell Death 1 Receptor; Survival Analysis; Taxoids; Urologic Neoplasms; Urothelium; Vinblastine | 2017 |
Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Radiotherapy, Adjuvant; Survival Rate; Tongue Neoplasms | 2008 |
A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Survival Analysis | 2008 |
A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms | 2008 |
Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Topotecan | 2008 |
Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Floxuridine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis | 2008 |
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Tegafur | 2009 |
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid | 2008 |
Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols | 2009 |
[A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2008 |
Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovariectomy; Paclitaxel; Prognosis; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2007 |
[Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neutropenia; Paclitaxel; Survival Rate; Vomiting; Young Adult | 2008 |
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Female; Humans; Immunotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2009 |
Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Feasibility Studies; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2009 |
Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2008 |
Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Epithelial Cells; Female; Follow-Up Studies; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2009 |
Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life | 2009 |
A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Cisplatin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Radiotherapy; Stomach Neoplasms; Treatment Outcome | 2009 |
A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Follow-Up Studies; Head and Neck Neoplasms; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Treatment Outcome | 2009 |
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekolog
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate; Topotecan | 2009 |
Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Grou
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Vulvar Neoplasms | 2009 |
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Treatment Outcome | 2009 |
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel | 2009 |
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2009 |
Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome | 2010 |
Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0
Topics: Aged; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Pyrimidines; Stomach Neoplasms; Tokyo; Treatment Outcome | 2009 |
Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Dose Fractionation, Radiation; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Treatment Outcome | 2009 |
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2010 |
Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Killer Cells, Natural; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; T-Lymphocytes, Regulatory; Taxoids; Vascular Endothelial Growth Factor A; Young Adult | 2010 |
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms | 2010 |
Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Risk Factors; Survival Rate; Treatment Outcome | 2010 |
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center s
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Thoracotomy; Treatment Outcome; Young Adult | 2010 |
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Survival; Tegafur; Treatment Outcome | 2011 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Tegafur | 2010 |
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Filgrastim; Follow-Up Studies; Gene Amplification; Granulocyte Colony-Stimulating Factor; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Survival Rate; Trastuzumab; Treatment Outcome | 2010 |
Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ribonucleoside Diphosphate Reductase; Survival; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2011 |
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Breast Neoplasms; Disease Progression; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome; Tretinoin | 2011 |
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2011 |
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds | 2011 |
[A prospective comparison between surgery alone and postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Survival Rate | 2010 |
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Confidence Intervals; Disease Progression; Drug Combinations; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2010 |
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy | 2010 |
A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Quality of Life; Risk Factors | 2011 |
A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2010 |
Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Uterine Cervical Neoplasms; Young Adult | 2011 |
Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease Progression; Endpoint Determination; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 2011 |
A phase II study of weekly paclitaxel and doxifluridine combination chemotherapy for advanced/recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Female; Floxuridine; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gamma Rays; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiography, Thoracic; Radiotherapy Dosage; Standard of Care; Survival Rate; Treatment Outcome | 2011 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2012 |
Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Ascites; Ascitic Fluid; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Failure; Treatment Outcome; Waist Circumference | 2011 |
Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Radiotherapy, Adjuvant; Survival Rate; Uterine Cervical Neoplasms | 2011 |
Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Treatment Outcome | 2011 |
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Oligonucleotides; Paclitaxel; Receptor, ErbB-2 | 2011 |
A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms | 2011 |
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Sesquiterpenes; Survival Rate; Treatment Outcome | 2010 |
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2011 |
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Radiotherapy Dosage; Salvage Therapy; Survival Rate | 2012 |
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2011 |
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan | 2012 |
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Drug Hypersensitivity; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2011 |
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Demography; Disease-Free Survival; Female; Humans; Male; Micelles; Middle Aged; Nanoparticles; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Time Factors; Treatment Outcome | 2012 |
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Skin Neoplasms; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; CDC2 Protein Kinase; Cyclin-Dependent Kinase 2; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptors, Steroid; Risk Factors; Treatment Outcome | 2012 |
Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Quality of Life; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Exanthema; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2012 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2011 |
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Fusion Proteins; Survival Analysis | 2012 |
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Greece; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2012 |
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Computer Simulation; Confounding Factors, Epidemiologic; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Models, Biological; Monte Carlo Method; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Recombinant Fusion Proteins; Regression Analysis; Treatment Outcome | 2012 |
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Medication Adherence; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life | 2012 |
A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms | 2012 |
Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies | 2012 |
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Neutropenia; Paclitaxel; Small Cell Lung Carcinoma | 2013 |
Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Prospective Studies; Vulvar Neoplasms | 2012 |
Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2012 |
Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Paclitaxel; Uterine Cervical Neoplasms | 2012 |
Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Carcinosarcoma; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Neoplasms | 2012 |
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Receptor, ErbB-2 | 2012 |
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Hyperglycemia; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Humans; Hydroxamic Acids; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Sulfonamides | 2012 |
Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Sarcoma, Endometrial Stromal; Uterine Neoplasms | 2012 |
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2012 |
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Molybdenum; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Care; Preoperative Care; Prognosis; Remission Induction; Survival Rate | 2013 |
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib | 2013 |
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2013 |
Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 2012 |
Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis | 2013 |
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology G
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Caspases; Double-Blind Method; Endostatins; Endothelium, Vascular; Female; Humans; Keratin-18; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2012 |
A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2013 |
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Paclitaxel; Survival Analysis; Treatment Outcome | 2014 |
[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Large-Core Needle; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Young Adult | 2012 |
Phase I study of GRN1005 in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Peptides | 2013 |
Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2013 |
Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids | 2002 |
Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Palliative Care; Treatment Outcome | 2002 |
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Female; Humans; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Piperidines; Pyridines | 2002 |
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Taxoids; Transferases (Other Substituted Phosphate Groups); Treatment Outcome | 2002 |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Synergism; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 2002 |
Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Sarcoma; Survival Analysis | 2002 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2003 |
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Estramustine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Remission Induction; Survival Analysis; Taxoids | 2003 |
Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Survival Analysis | 2003 |
Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Spleen; Splenic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2003 |
Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2003 |
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Synergism; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Neoplasms | 2003 |
Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Incidence; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids | 2003 |
Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2003 |
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan | 2003 |
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Logistic Models; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Proportional Hazards Models; Recombinant Proteins; Survival Analysis | 2003 |
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2003 |
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Neoadjuvant docetaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids | 2003 |
Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Radiotherapy, Adjuvant; Survival Analysis; Thoracic Surgical Procedures; Time Factors; Treatment Outcome | 2003 |
A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2003 |
Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2003 |
[Paclitaxel for treatment of colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2003 |
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Administration Schedule; Female; Humans; Incidence; Infusions, Intravenous; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Topotecan | 2004 |
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Combined Modality Therapy; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome | 2004 |
Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypopharyngeal Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome | 2003 |
Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Prognosis; Survival Analysis; Treatment Outcome | 2004 |
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Reference Values; Topotecan; Treatment Outcome; World Health Organization | 2004 |
Paclitaxel and carboplatin as second-line therapy in women with platinum-sensitive ovarian carcinoma treated with platinum and paclitaxel as first-line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2004 |
Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2004 |
The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer.
Topics: Adult; Aged; CA-125 Antigen; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2004 |
Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2004 |
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Treatment Outcome | 2004 |
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Convection; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Female; Frontal Lobe; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Parietal Lobe; Prospective Studies; Temporal Lobe | 2004 |
Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Compliance; Radiotherapy Dosage; Radiotherapy, Adjuvant; Recurrence; Survival Analysis | 2004 |
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute,
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Microcirculation; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Salvage Therapy | 2004 |
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2004 |
Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2004 |
First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; France; Humans; Ifosfamide; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
[Efficacy and safety of weekly taxol (TXL) for advanced recurrent breast cancer evaluated in a multi-center cooperative clinical trial].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel | 2004 |
Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2004 |
A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 2004 |
A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2004 |
Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cohort Studies; Disease Progression; Docosahexaenoic Acids; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Time Factors | 2004 |
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Doxorubicin; Female; Histiocytoma, Benign Fibrous; Humans; Leiomyosarcoma; Liposarcoma; Liposomes; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Safety; Sarcoma; Survival Rate; Time Factors; Treatment Outcome | 2004 |
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Head and Neck Neoplasms; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pyrroles | 2005 |
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid; Taxoids | 2004 |
Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Elective Surgical Procedures; Female; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy; Retrospective Studies | 2005 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Vomiting | 2005 |
Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cohort Studies; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2004 |
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Etoposide; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Stem Cell Transplantation; Testicular Neoplasms; Transplantation, Autologous; Treatment Outcome | 2005 |
A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2005 |
Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2005 |
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Follow-Up Studies; Head and Neck Neoplasms; Humans; Nausea; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prospective Studies; Retreatment; Salvage Therapy; Stomatitis; Vomiting | 2005 |
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2005 |
A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Filgrastim; Glioblastoma; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome | 2005 |
Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mammaplasty; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiodermatitis; Wound Healing | 2005 |
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paclitaxel; Radiotherapy Dosage | 2005 |
Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carcinoma, Endometrioid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Radiography; Salvage Therapy; Survival Analysis; Treatment Outcome; Turkey | 2005 |
Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Resistance; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2005 |
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.
Topics: Adult; Aged; Carboplatin; Chemotherapy, Adjuvant; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Probability; Prognosis; Quality of Life; Risk Assessment; Spain; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Germinoma; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Testicular Neoplasms; Treatment Outcome | 2005 |
O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Convection; Drug Delivery Systems; Female; Glioblastoma; Humans; Infusions, Intralesional; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Tyrosine | 2005 |
Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Postoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Female; Follow-Up Studies; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy, High-Energy; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Phase I study of a weekly schedule of fixed-dose paclitaxel and escalating doses of cisplatin for recurrent or unresectable gastric cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Gastrectomy; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Japan; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Treatment Outcome | 2005 |
Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Stomach Neoplasms; Survival Rate | 2005 |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Logistic Models; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diarrhea; Esophageal Neoplasms; Fatigue; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2005 |
The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Safety; Stomach Neoplasms; Treatment Outcome | 2005 |
Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2005 |
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Germinoma; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Selection; Probability; Prognosis; Prospective Studies; Salvage Therapy; Survival Analysis; Testicular Neoplasms; Treatment Outcome | 2005 |
Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Patient Compliance; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Spain; Survival Analysis; Treatment Outcome | 2005 |
Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Germinoma; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Gonadal Tissue; Paclitaxel; Prognosis; Prospective Studies; Retroperitoneal Neoplasms; Salvage Therapy; Testicular Neoplasms; Treatment Outcome | 2005 |
Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2006 |
Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Salvage Therapy; Treatment Outcome; Urologic Neoplasms | 2006 |
A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Treatment Outcome; Uterine Cervical Neoplasms | 2006 |
Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salivary Gland Neoplasms | 2006 |
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Drug Administration Schedule; Female; Headache; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2006 |
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2006 |
A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Delayed-Action Preparations; Female; Humans; Infusions, Parenteral; Microspheres; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2006 |
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2006 |
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Analysis | 2006 |
The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine | 2007 |
Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Rate | 2007 |
Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2007 |
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Remission Induction; Thrombocytopenia; Topotecan; Treatment Outcome | 2007 |
A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2006 |
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; Female; Humans; Intestinal Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2006 |
Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Feasibility Studies; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Stomach Neoplasms | 2007 |
A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Follow-Up Studies; Humans; Irinotecan; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Analysis; Testicular Neoplasms; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome | 2007 |
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Topotecan | 2006 |
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2007 |
A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2007 |
[A phase II study of weekly paclitaxel for advanced or recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Antiemetics; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Female; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ranitidine; Survival Rate | 2007 |
Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Neck Dissection; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy Dosage; Survival Rate | 2008 |
A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infant; Infant, Newborn; Leukemia; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2008 |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2007 |
Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2007 |
[Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fatigue; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Radiotherapy; Radiotherapy, High-Energy; Survival Analysis | 2007 |
Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Estramustine; Feasibility Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Prostatectomy; Prostatic Neoplasms; Risk Factors | 2008 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Tegafur; Thrombocytopenia | 2008 |
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate | 2008 |
Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cholesterol; Drug Carriers; Drug Resistance, Neoplasm; Emulsions; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Receptors, Lipoprotein | 2009 |
A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2008 |
Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2009 |
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Premedication; Prognosis; Radiation Dosage; Radiotherapy, Adjuvant; Treatment Outcome | 2008 |
Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Premedication | 1995 |
Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.
Topics: Adult; Aged; Bone Marrow Diseases; Carcinoma; Drug Administration Schedule; Drug Resistance; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 1994 |
A phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1995 |
Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
Topics: Adolescent; Adult; Aged; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Rate | 1995 |
Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease.
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Remission Induction | 1995 |
Salvage chemotherapy with paclitaxel for recurrent primary brain tumors.
Topics: Adult; Aged; Alopecia; Brain Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Salvage Therapy; Thrombocytopenia | 1995 |
Age does not influence taxol dose intensity in recurrent carcinoma of the ovary.
Topics: Adult; Aged; Aging; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 1993 |
Taxol: initial Israeli experience with a novel anticancer agent.
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Israel; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Time Factors | 1994 |
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids | 1994 |
Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Female; Humans; Middle Aged; Models, Biological; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Regression Analysis; Salvage Therapy; Survival Analysis | 1994 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Asthenia; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
Topics: Adult; Aged; Canada; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Premedication; Quality of Life; Remission Induction; Survival Analysis; Treatment Outcome | 1994 |
Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Australia; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1995 |
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Carcinoma, Papillary; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Toxicity Tests | 1996 |
Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction | 1995 |
Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prospective Studies; Remission Induction; Sarcoma; Thrombocytopenia | 1995 |
A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1996 |
Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Remission Induction | 1995 |
Phase II study of paclitaxel in patients with recurrent malignant glioma.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Canada; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Survival Rate; United States | 1996 |
Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 1996 |
Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Docetaxel; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1996 |
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 1997 |
Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction | 1997 |
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction | 1997 |
Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclosporins; Cystadenocarcinoma; Drug Resistance, Multiple; Female; Humans; Kidney; Liver; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Radionuclide Imaging; Technetium Tc 99m Sestamibi | 1997 |
Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis | 1997 |
Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Salvage Therapy; Treatment Failure | 1997 |
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan | 1997 |
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis; Topotecan; Treatment Outcome | 1997 |
[Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Survival Rate | 1997 |
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cisplatin; Confidence Intervals; Disease Progression; Female; France; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Topics: Adult; Aged; Ambulatory Care; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Argentina; Biomarkers, Tumor; CA-125 Antigen; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Microtubules; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Remission Induction; Survival Rate; Thrombocytopenia; Vomiting | 1997 |
Salvage weekly paclitaxel in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Cohort Studies; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fever; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Remission Induction; Retrospective Studies; Salvage Therapy; Tomography, X-Ray Computed | 1997 |
A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cause of Death; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiography; Remission Induction; Risk Factors; Salvage Therapy; Sensation Disorders; Survival Rate; Thrombocytopenia | 1997 |
Paclitaxel in salvage therapy for germ cell tumors.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Cells; Carboplatin; Cisplatin; Cohort Studies; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Follow-Up Studies; Germinoma; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Testicular Neoplasms; Treatment Outcome | 1997 |
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
Topics: Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Female; Humans; Injections, Intravenous; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Paclitaxel; Procarbazine; Salvage Therapy; Thrombocytopenia; Vincristine | 1997 |
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Immunosuppression Therapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 1997 |
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 1997 |
Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects | 1997 |
Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Hemoglobinometry; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Platelet Count | 1997 |
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids | 1998 |
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 1998 |
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 1998 |
Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 1998 |
A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1998 |
Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 1998 |
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome | 1998 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Fever; Humans; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Taxoids; Vomiting | 1998 |
PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Paclitaxel; Radiotherapy, Adjuvant; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine | 1998 |
Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 1996 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1999 |
Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Survival Analysis; Uterine Cervical Neoplasms | 1999 |
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas.
Topics: Adult; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy | 1999 |
Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life; Treatment Outcome | 1999 |
A phase I study of sequential vinorelbine followed by paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Salvage Therapy; Topotecan | 1999 |
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Paclitaxel; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Uterine Cervical Neoplasms | 1999 |
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix--a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 1999 |
Surveillance for recurrent head and neck cancer using positron emission tomography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; False Positive Reactions; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Tomography, Emission-Computed | 2000 |
Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis | 2000 |
Paclitaxel and concurrent radiation for gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiography; Radiotherapy Dosage; Stomach Neoplasms; Survival Analysis | 2000 |
[Efficacy of docetaxel for recurrent breast cancer: evaluation based on chemosensitivity test and clinical response].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2000 |
Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiosurgery; Survival Analysis; Treatment Outcome | 2000 |
A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma.
Topics: Adult; Affect; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome | 2000 |
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Germinoma; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Taxoids; Testicular Neoplasms; Treatment Outcome | 2000 |
Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study.
Topics: Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2000 |
Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Drug Therapy, Combination; Estramustine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2000 |
Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Taxoids | 2000 |
[Weekly administration of paclitaxel for advanced or metastatic breast cancer--short-course premedications for outpatients].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2000 |
High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Saudi Arabia; Survival Analysis; Treatment Outcome | 2000 |
Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours?
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Taxoids | 2000 |
Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Docetaxel; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2000 |
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cross-Over Studies; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Europe; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate; Topotecan; United States | 2001 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Illinois; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis | 2001 |
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2001 |
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Italy; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Compliance; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dose-Response Relationship, Drug; Estramustine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prostatic Neoplasms; Treatment Outcome | 2001 |
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cyclosporins; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2001 |
[Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Tolerance; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2001 |
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Preoperative Care; Prognosis; Stomach Neoplasms; Survival Analysis | 2001 |
[A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Floxuridine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Topotecan; Treatment Outcome | 2001 |
[Effect of weekly docetaxel in patients with recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 2001 |
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Statistics, Nonparametric; Survival Rate; Topotecan | 2001 |
Weekly 1 hour paclitaxel infusion in patients with recurrent gynecological tumors: a pilot study.
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Quality of Life; Salvage Therapy; Uterine Cervical Neoplasms | 2001 |
Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Remission Induction; Retrospective Studies; Survival Rate | 2001 |
A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Survival Rate; Treatment Failure; Treatment Outcome | 2001 |
Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis | 2001 |
Weekly paclitaxel in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis | 2001 |
Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinosarcoma; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Neoplasms | 2001 |
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds | 2001 |
Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2001 |
3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Predictive Value of Tests; Treatment Outcome | 2001 |
Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2001 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2001 |
[Weekly administration of low-dose paclitaxel for advanced or metastatic breast cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Ranitidine; Vomiting, Anticipatory | 2002 |
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Recurrence, Local; Paclitaxel; Piperidines; Pyridines; Safety; Time Factors; Tissue Distribution; Treatment Outcome | 2002 |
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion Pumps; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis | 2002 |
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fever; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome | 2002 |
Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms | 2002 |
A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2002 |
Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Outpatients; Paclitaxel; Prospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2002 |
Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Docetaxel; Dose Fractionation, Radiation; Drug Tolerance; Feasibility Studies; Female; Humans; Injections, Intra-Arterial; Lymph Node Excision; Male; Middle Aged; Mouth Neoplasms; Neck; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Patient Compliance; Pilot Projects; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Taxoids | 2002 |
693 other study(ies) available for paclitaxel and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Temperature and pH-responsive in situ hydrogels of gelatin derivatives to prevent the reoccurrence of brain tumor.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Liberation; Gelatin; Glioblastoma; Humans; Hydrogels; Hydrogen-Ion Concentration; Mice, Inbred BALB C; Mice, Nude; Neoplasm Recurrence, Local; Paclitaxel; Porosity; Stimuli Responsive Polymers; Sulfamethazine; Temperature; Time Factors; Viscosity; Xenograft Model Antitumor Assays | 2021 |
Cancer microcell initiation and determination.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Count; Cell Line, Tumor; Cell Nucleus; Cell Self Renewal; Cell Survival; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Endosomal Sorting Complexes Required for Transport; Female; Fibroblasts; Green Fluorescent Proteins; HeLa Cells; Humans; Indicators and Reagents; Melanoma; Microscopy, Electron; NADP; Neoplasm Recurrence, Local; Neoplasms; Neutral Red; Paclitaxel; Stress, Physiological; Time-Lapse Imaging; Transcription Factors; Transfection; Uterine Cervical Neoplasms | 2021 |
Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2021 |
Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel | 2021 |
Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Aged; Bridged-Ring Compounds; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2021 |
Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
DEHP mediates drug resistance by directly targeting AhR in human breast cancer.
Topics: Adult; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Breast Neoplasms; Cell Line, Tumor; Diethylhexyl Phthalate; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Mice, Knockout; Neoplasm Recurrence, Local; Paclitaxel; Receptors, Aryl Hydrocarbon; Survival Rate; Tamoxifen; Xenograft Model Antitumor Assays; Zebrafish | 2022 |
The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents.
Topics: Apoptosis Regulatory Proteins; Humans; Microtubules; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Triple Negative Breast Neoplasms | 2021 |
Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Cost-Benefit Analysis; Female; Humans; Immune Checkpoint Inhibitors; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Quality-Adjusted Life Years; Survival Rate; United States; Uterine Cervical Neoplasms | 2022 |
Ovarian high-grade serous carcinoma with elevated β-human chorionic gonadotropin: A case report.
Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Chorionic Gonadotropin; Chorionic Gonadotropin, beta Subunit, Human; Cytoreduction Surgical Procedures; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pregnancy | 2021 |
Conversion surgery for recurrent hepatic angiosarcoma after systemic chemotherapy with paclitaxel.
Topics: Aged; Hemangiosarcoma; Hepatectomy; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel | 2022 |
Risk factors for and prognosis of carboplatin-related hypersensitivity in patients with epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Hypersensitivity; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors | 2022 |
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2022 |
Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Topics: Albumin-Bound Paclitaxel; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Propensity Score; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2022 |
Differences in the Therapeutic Effect of Chemotherapy Regimens for Concurrent Chemoradiotherapy of Locally Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Outcome; Vinorelbine | 2022 |
Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Life Style; Liver Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Receptor, ErbB-2; Trastuzumab | 2022 |
Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory: a case report.
Topics: Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2022 |
Paclitaxel-nanocrystals-loaded network thermosensitive hydrogel for localised postsurgical recurrent of breast cancer after surgical resection.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydrogels; Mice; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Poloxamer | 2022 |
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Frail Elderly; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2022 |
HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel.
Topics: HMGA1a Protein; Humans; Microtubules; Neoplasm Recurrence, Local; Paclitaxel; Stathmin; Triple Negative Breast Neoplasms | 2022 |
H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; p300-CBP Transcription Factors; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, Androgen | 2022 |
Linking unfolded protein response to ovarian cancer cell fusion.
Topics: Carcinoma, Ovarian Epithelial; Cell Fusion; Cell Line, Tumor; Female; Humans; Hypoxia; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyploidy; Unfolded Protein Response | 2022 |
Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies | 2022 |
Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2022 |
Neoadjuvant chemotherapy followed by radical surgery reduces radiation therapy in patients with stage IB2 to IIA2 cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Quality of Life; Retrospective Studies; Uterine Cervical Neoplasms | 2022 |
Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Humans; Mice; Neoplasm Recurrence, Local; Paclitaxel; Sarcoma | 2022 |
Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor.
Topics: Antibodies, Monoclonal, Humanized; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Humans; Mouth Neoplasms; Neoplasm Recurrence, Local; NF-kappa B; Paclitaxel; Proteasome Inhibitors; RNA, Messenger | 2022 |
[Evaluation of Neutropenia and Usages of Antihypertensive Drugs in Patients Treated with Ramucirumab plus Paclitaxel Therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Ramucirumab; Retrospective Studies; Stomach Neoplasms | 2022 |
Exceptional widespread, life threatening lung metastasis in stage IA ovarian endometrioid carcinoma: A case report.
Topics: Carboplatin; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2022 |
Hyaluronidase responsive second near-infrared fluorescent nanocomplex for combined HER2 blockade and chemotherapy of HER2+ breast cancer.
Topics: Animals; Breast Neoplasms; Coloring Agents; Female; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2022 |
The miR-33a-5p/CROT axis mediates ovarian cancer cell behaviors and chemoresistance
Topics: 3' Untranslated Regions; Carnitine; Cell Line, Tumor; DNA, Complementary; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Taxoids; Transforming Growth Factor beta | 2022 |
Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma.
Topics: Antineoplastic Agents; Humans; Neoplasm Recurrence, Local; Paclitaxel; Phenylurea Compounds; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2022 |
Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Serum Albumin; Small Cell Lung Carcinoma | 2022 |
Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report.
Topics: Aged; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Thyroid Gland | 2022 |
The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study.
Topics: Activities of Daily Living; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Geriatric Assessment; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Prognosis | 2023 |
Tislelizumab Combined with Carboplatin-Paclitaxel for Treatment of Metastatic or Recurrent Endometrial Cancer: a Retrospective Clinical Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies | 2022 |
Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Morphine; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Triple Negative Breast Neoplasms | 2022 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cervix Uteri; Cisplatin; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Registries; Retrospective Studies; Topotecan; Uterine Cervical Neoplasms | 2023 |
IFT20 Confers Paclitaxel Resistance by Triggering β-arrestin-1 to Modulate ASK1 Signaling in Breast Cancer.
Topics: Apoptosis; beta-Arrestin 1; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; MAP Kinase Kinase Kinase 5; Neoplasm Recurrence, Local; Paclitaxel | 2023 |
The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cell Line, Tumor; Drug Synergism; Humans; Metformin; Neoplasm Recurrence, Local; Paclitaxel | 2022 |
Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Quality of Life | 2023 |
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
[A Case of Multiple Lung Metastases of Pancreatic Cancer with 50 Months Survival by Sequential Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2022 |
Targeting our efforts: the contribution of an open-access tool to assess geographic distribution of recurrent and metastatic cervical cancer.
Topics: Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cohort Studies; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2023 |
Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme.
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Humans; Hydrogels; Nanocomposites; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Temozolomide | 2023 |
Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Humans; Japan; Lung Diseases, Interstitial; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2023 |
Self-assembling paclitaxel-mediated stimulation of tumor-associated macrophages for postoperative treatment of glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Hydrogels; Immunotherapy; Neoplasm Recurrence, Local; Paclitaxel; Tumor Microenvironment; Tumor-Associated Macrophages | 2023 |
Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activity.
Topics: Carcinoma; Cell Line, Tumor; Curcumin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; NF-kappa B; Ovarian Neoplasms; Paclitaxel; RNA-Binding Proteins | 2023 |
CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Topics: Animals; Antigens, CD; ATP-Binding Cassette Transporters; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; GPI-Linked Proteins; Humans; Mice; Neoplasm Proteins; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Receptor, Notch1; STAT3 Transcription Factor | 2023 |
Comparison of Paclitaxel plus Carboplatin versus Observation in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenoid Cystic; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies | 2023 |
Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2023 |
Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2023 |
Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy
Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Esophagogastric Junction; Febrile Neutropenia; Humans; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Ramucirumab; Retrospective Studies; Stomach Neoplasms | 2023 |
The role of inflammatory factors and T-cell subsets in the diagnosis of recurrence in epithelial ovarian cancer patients and the effect of olaparin treatment on them.
Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Interferon-gamma; Interleukin-6; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; T-Lymphocyte Subsets; Tumor Necrosis Factor-alpha | 2023 |
Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populations.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2023 |
A local combination therapy to inhibit GBM recurrence.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; Glioblastoma; Humans; Hydrogels; Neoplasm Recurrence, Local; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Temozolomide | 2019 |
Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Models, Biological; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Modular Engineering of Targeted Dual-Drug Nanoassemblies for Cancer Chemoimmunotherapy.
Topics: Animals; Antigen Presentation; Apoptosis; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Drug Therapy; Female; Imiquimod; Immunotherapy; Mice, Inbred BALB C; Nanoparticles; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Rats, Sprague-Dawley; Tissue Distribution | 2019 |
[A Case of an Elderly Patient with Multiple Lung Metastases of Postoperative Pancreatic Cancer in Whom Lung Metastases Were Controlled by Biweekly Dose-Down Administration of Gemcitabine].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2019 |
Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Radiotherapy, Intensity-Modulated; Retrospective Studies; Salvage Therapy; Survival Rate | 2019 |
A Novel Scoring System for Pivotal Autophagy-Related Genes Predicts Outcomes after Chemotherapy in Advanced Ovarian Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins; Biomarkers, Tumor; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Nomograms; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2019 |
Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR.
Topics: Antineoplastic Agents; BRCA2 Protein; Carboplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Polymerase Chain Reaction | 2020 |
Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study.
Topics: Adult; Aged; Carboplatin; Chemoradiotherapy; Endosonography; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Positron Emission Tomography Computed Tomography; Postoperative Complications; Propensity Score; Prospective Studies; Reoperation; Watchful Waiting | 2021 |
nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Papillomavirus Infections; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2019 |
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines | 2019 |
Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.
Topics: Animals; Apoptosis; Cell Movement; Cell Proliferation; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Integrin beta1; Mice; Neoplasm Recurrence, Local; Oncogene Protein v-akt; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Signal Transduction | 2020 |
Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Salvage Therapy; Testicular Neoplasms | 2020 |
Diatoms embedded, self-assembled carriers for dual delivery of chemotherapeutics in cancer cell lines.
Topics: Adamantane; Antineoplastic Combined Chemotherapy Protocols; Cyclodextrins; Diatomaceous Earth; Doxorubicin; Drug Antagonism; Drug Carriers; Drug Compounding; Drug Synergism; HeLa Cells; Humans; Nanoparticles; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel | 2020 |
A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Foreign-Body Migration; Humans; Hydronephrosis; Neoplasm Recurrence, Local; Paclitaxel; Rectum; Stents; Ureter; Urinary Bladder Fistula; Urinary Tract Infections; Uterine Cervical Neoplasms | 2019 |
Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study.
Topics: Adult; Aged; Carboplatin; Cohort Studies; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Republic of Korea; Retrospective Studies | 2020 |
Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2020 |
Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2020 |
Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Italy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Drug Resistance, Neoplasm; Evidence-Based Medicine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2020 |
Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Progression-Free Survival; Retrospective Studies | 2020 |
[A Case of Gastrointestinal Perforation in Gastric Cancer during Chemotherapy with Paclitaxel plus Ramucirumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2019 |
[A Case of Recurrent Gastric Cancer with Clinical Complete Response after Ramucirumab plus Paclitaxel Therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Positron Emission Tomography Computed Tomography; Ramucirumab; Stomach Neoplasms; Tegafur | 2019 |
Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Markov Chains; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate | 2020 |
Four versus six chemotherapy cycles in endometrial carcinoma with a high risk of recurrence: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Probability; Retrospective Studies; Risk Factors; Treatment Outcome | 2020 |
[Axillary Arterial Bleeding with Administration of Bevacizumab plus Paclitaxel in a Patient with Recurrent Breast Cancer-A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Bevacizumab; Breast Neoplasms; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2020 |
[Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer].
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2020 |
[A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
Topics: Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Squamous Cell; Epithelial Cells; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel | 2020 |
Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinosarcoma; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salpingo-oophorectomy; Survival Rate; Uterine Neoplasms | 2020 |
Sequential Chemoradiotherapy Compared to Radiotherapy in Endometrial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate | 2020 |
Combined nab-paclitaxel and irradiation for large cutaneous angiosarcoma of the face and scalp with pulmonary metastases.
Topics: Aged; Albumins; Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Facial Neoplasms; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Scalp; Skin Neoplasms | 2020 |
Tailored radical hysterectomy for locally advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Paclitaxel; Peripheral Nerves; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2020 |
[A Thoracic Aortic Dissection Case during Treatment with Ramucirumab plus Nab-Paclitaxel].
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aortic Dissection; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2020 |
Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hyperthermic Intraperitoneal Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Time Factors | 2021 |
Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Carboplatin; Carcinoma; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Female; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Integrin alpha3; Mice; Mice, Inbred BALB C; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2020 |
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Confidence Intervals; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2021 |
[A Case of Male Recurrent Breast Cancer Successfully Treated with Bevacizumab plus Paclitaxel Therapy for Carcinomatous Pericarditis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Humans; Male; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Pericarditis | 2020 |
Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ethmoid Sinus; Humans; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Paclitaxel; Paranasal Sinus Neoplasms; Positron-Emission Tomography | 2021 |
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2021 |
Follicular dendritic cell sarcoma of the uterine cervix: a case report.
Topics: Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Dendritic Cell Sarcoma, Follicular; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Salpingo-oophorectomy; Uterine Cervical Neoplasms | 2020 |
Paclitaxel-eluting silicone airway stent for preventing granulation tissue growth and lung cancer relapse in central airway pathologies.
Topics: Airway Obstruction; Cell Line, Tumor; Granulation Tissue; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Silicones; Stents | 2020 |
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Programmed Cell Death 1 Receptor; Progression-Free Survival; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2020 |
[Combination Therapy of Bevacizumab plus Paclitaxel Was Effective for a Metastatic Choroidal Tumor Secondary to Breast Cancer in a Patient with Ocular Symptoms].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Choroid Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel | 2020 |
Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Off-Label Use; Paclitaxel; Paget Disease, Extramammary; Receptor, ErbB-2; Trastuzumab; Vulvar Neoplasms | 2020 |
SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Topics: Adolescent; Adult; Animals; Breast; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intravital Microscopy; Mastectomy; Mice; Microtubules; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoids; Paclitaxel; Prognosis; Protein Multimerization; RNA-Seq; Triple Negative Breast Neoplasms; Tubulin; Tumor Cells, Cultured; Vesicular Transport Proteins; Young Adult | 2020 |
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Bevacizumab; CA-125 Antigen; Carbamates; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; MAP Kinase Kinase 1; Medroxyprogesterone; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oximes; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Recurrence; Sulfonamides; Tamoxifen; Treatment Outcome; Young Adult | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Sarcoma, Ewing | 2021 |
Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenoid Cystic; Humans; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Prospective Studies; Retrospective Studies | 2021 |
[Patient with Recurrent Breast Cancer Who Developed Radiation Esophagitis with Severe Esophageal Stenosis after Combined Bevacizumab and Paclitaxel Therapy-A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Esophageal Stenosis; Esophagitis; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patients; Positron Emission Tomography Computed Tomography; Radiation | 2020 |
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Unknown Primary; Paclitaxel; Salpingo-oophorectomy | 2021 |
The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium.
Topics: Academic Medical Centers; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Doxorubicin; Female; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Prognosis; Progression-Free Survival; Retrospective Studies; Risk Factors; Skin Neoplasms; Young Adult | 2021 |
Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Markov Chains; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2; Trastuzumab; United States; Uterine Neoplasms | 2021 |
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration | 2020 |
[Nab-Paclitaxel plus Gemcitabine for Patients with Recurrence after Resection for Adenocarcinoma of the Pancreas].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2021 |
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Successfully Treated with Paclitaxel plus Ramucirumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2021 |
[A Case of Chemotherapy with Low-Dose Paclitaxel and Bevacizumab for Elderly Recurrent Breast Cancer Patient].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel | 2020 |
[Laparoscopic Partial Hepatectomy for the Liver Metastasis of Gastric Cancer after Nab-Paclitaxel plus Ramucirumab Combination Therapy-A Case Report].
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Hepatectomy; Humans; Laparoscopy; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2020 |
Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Frailty; Head and Neck Neoplasms; Humans; Malnutrition; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2021 |
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Epothilones; Female; Genes, p53; Humans; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Randomized Controlled Trials as Topic; Sirolimus; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53 | 2021 |
A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Paclitaxel; PC-3 Cells; Tocopherols; Xenograft Model Antitumor Assays | 2021 |
[Successful treatment with paclitaxel of a visceral relapse of post-transplant Kaposi's sarcoma].
Topics: Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Neoplasm Recurrence, Local; Paclitaxel; Sarcoma, Kaposi | 2021 |
Patterns of recurrence following definitive chemoradiation for patients with proximal esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Netherlands; Paclitaxel; Progression-Free Survival; Radiotherapy; Retrospective Studies; Salvage Therapy; Time Factors | 2021 |
Neoadjuvant chemotherapy in pregnant patients with cervical cancer: a Latin-American multicenter study.
Topics: Adult; Antineoplastic Agents; Carboplatin; Cesarean Section; Female; Humans; Latin America; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Retrospective Studies; Uterine Cervical Neoplasms | 2021 |
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Rad51 Recombinase | 2021 |
Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Treatment Outcome | 2021 |
Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Denmark; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2021 |
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cesarean Section; Female; Humans; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Thrombosis; Triple Negative Breast Neoplasms; Vena Cava, Superior | 2022 |
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Confidence Intervals; Disease Progression; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Progression-Free Survival; Propensity Score; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2021 |
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Decision Trees; Drug Costs; Endometrial Neoplasms; Female; Humans; Markov Chains; Microsatellite Instability; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Phenylurea Compounds; Progression-Free Survival; Quality of Life; Quality-Adjusted Life Years; Quinolines | 2021 |
Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
Topics: Biomarkers, Tumor; Datasets as Topic; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genetic Heterogeneity; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Paclitaxel; Protein Interaction Maps; Triple Negative Breast Neoplasms; Up-Regulation | 2021 |
[Primary Peritoneal Carcinoma with Long Term Survival-A Case Report].
Topics: Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Omentum; Paclitaxel; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography | 2021 |
Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms; Vimentin; Zebrafish | 2021 |
Successful Treatment of a Locally Recurrent and Metastatic Malignant Phyllodes Tumor with Accelerated Radiotherapy and Nab-Paclitaxel, Cisplatin, and Liposomal Doxorubicin Chemotherapy.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Phyllodes Tumor; Polyethylene Glycols; Positron Emission Tomography Computed Tomography; Remission Induction | 2021 |
Identifying prognostic factors associated with overall survival in second-line paclitaxel plus ramucirumab treated human epidermal growth factor receptor 2-negative advanced/recurrent gastric cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Ramucirumab; Receptor, ErbB-2; Stomach Neoplasms | 2021 |
[A Case of Pseudopancreatic Cyst Development during Bevacizumab plus Paclitaxel Therapy for Pancreatic Metastasis of Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cysts; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2021 |
Dose-dense Paclitaxel- and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemo-radiotherapy in Cervical Cancer: a Preliminary Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2017 |
Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer.
Topics: Aged; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Perioperative Care; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2017 |
Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cost-Benefit Analysis; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2018 |
Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; New Zealand; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant; Prognosis; Retrospective Studies; Treatment Outcome | 2017 |
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Pilot Projects; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids | 2018 |
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Topotecan | 2017 |
Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Xenograft Model Antitumor Assays | 2017 |
Wilms Tumor NCAM-Expressing Cancer Stem Cells as Potential Therapeutic Target for Polymeric Nanomedicine.
Topics: Cell Differentiation; Cell Self Renewal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Nanoconjugates; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Neural Cell Adhesion Molecules; Paclitaxel; Polymers; Wilms Tumor | 2017 |
Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Uterine Cervical Neoplasms | 2018 |
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2017 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.
Topics: Animals; Antibodies; Cell Line, Tumor; Cytokines; Female; Ganciclovir; Immunologic Surveillance; Killer Cells, Natural; Melanoma, Experimental; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Recurrence, Local; Oncolytic Virotherapy; Paclitaxel; Reoviridae; Skin Neoplasms; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2017 |
Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy, Adjuvant; Eccrine Porocarcinoma; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Sweat Gland Neoplasms | 2018 |
Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Re-Irradiation; Squamous Cell Carcinoma of Head and Neck | 2018 |
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.
Topics: Benzimidazoles; Breast Neoplasms; Carboplatin; Humans; Neoplasm Recurrence, Local; Paclitaxel; Temozolomide | 2018 |
A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Ramucirumab; Retrospective Studies; Stomach Neoplasms | 2018 |
Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2018 |
Clinicopathological characteristics and molecular analysis of primary pulmonary mucoepidermoid carcinoma: Case report and literature review.
Topics: Aged; Carboplatin; Carcinoma, Mucoepidermoid; Disease-Free Survival; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2018 |
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pelvic Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms | 2017 |
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Recurrence, Local; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2018 |
Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies | 2018 |
Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Drug Administration Schedule; Endometrial Neoplasms; Endometrium; Female; Humans; Middle Aged; Mullerian Ducts; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Paclitaxel; Retrospective Studies; Treatment Outcome | 2018 |
The Combination of Gemcitabine, Cisplatin, and Paclitaxel as Salvage Chemotherapy for Advanced Urothelial Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urologic Neoplasms | 2018 |
Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Humans; Hydroxychloroquine; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Sequestosome-1 Protein | 2018 |
PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Topics: Antimicrobial Cationic Peptides; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Nanoparticles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering | 2018 |
[Paclitaxel containing chemotherapeutic regimens in first line and reintroduced palliative treatment of metastatic cervical cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Uterine Cervical Neoplasms | 2018 |
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan | 2017 |
Paclitaxel and Pazopanib in Ovarian Cancer.
Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides | 2018 |
Paclitaxel and Pazopanib in Ovarian Cancer-Reply.
Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides | 2018 |
Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety; Survival Rate; Young Adult | 2019 |
Undifferentiated Endometrial Carcinomas: Clinicopathologic Characteristics and Treatment Outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Lymph Nodes; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate | 2018 |
Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2018 |
A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Carbazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Survivin | 2018 |
Evaluation of intravenous and subcutaneous administration of a novel, excipient-free, nanoparticulate formulation of paclitaxel in dogs with spontaneously occurring neoplasia.
Topics: Animals; Antineoplastic Agents, Phytogenic; Dog Diseases; Dogs; Drug Administration Schedule; Female; Infusions, Intravenous; Injections, Subcutaneous; Male; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel | 2018 |
[Induction Chemoradiotherapy Followed by Surgery in Non-small-cell Lung Cancer;a Retrospective Study].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Retrospective Studies | 2018 |
Recurrent Small Cell Carcinoma of the Uterine Cervix Responding to Combined Therapy with Paclitaxel, Cisplatin, and Bevacizumab: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2018 |
Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Propensity Score; Retrospective Studies; Time Factors; Treatment Outcome | 2018 |
The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Hematologic Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome | 2018 |
Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Retrospective Studies; Treatment Outcome; Vulvar Neoplasms | 2018 |
Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Retrospective Studies; Uterine Cervical Neoplasms | 2018 |
Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2018 |
A Case Report of Recurrent Metastatic Sebaceous Carcinoma Which Showed Favorable Response Tt Non-Fluorouracil Based Chemotherapy.
Topics: Adenocarcinoma, Sebaceous; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Positron Emission Tomography Computed Tomography; Sebaceous Gland Neoplasms; Skin Neoplasms; Treatment Outcome | 2018 |
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Inflammation; Liver Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Topotecan | 2019 |
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
Topics: Clinical Decision-Making; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; United States | 2018 |
Nivolumab therapy for lung cancer with tracheo-parenchymal fistula: A case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bevacizumab; Carboplatin; Chemoradiotherapy; Docetaxel; Fistula; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Treatment Outcome | 2018 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Herpesvirus 4, Human; Humans; Liposomes; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids | 2018 |
A personalized and long-acting local therapeutic platform combining photothermal therapy and chemotherapy for the treatment of multidrug-resistant colon tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Drug Liberation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Elastic Modulus; Gold; Humans; Hydrogels; Hyperthermia, Induced; Inhibitory Concentration 50; Male; Mice, Nude; Micelles; Nanoparticles; Nanotubes; Neoplasm Recurrence, Local; Paclitaxel; Phototherapy; Polyethylene Glycols; Temperature; Time Factors; Vitamin E | 2018 |
Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Republic of Korea; Topotecan | 2019 |
A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2019 |
The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Bridged-Ring Compounds; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oxazines; Paclitaxel; Pyridines; RNA, Small Interfering; Syk Kinase; Taxoids | 2019 |
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Ramucirumab; Stomach Neoplasms; Tegafur | 2018 |
[A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemodialysis].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Renal Dialysis | 2018 |
Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
[Curative Resection of Pancreatic Head Cancer with Liver Metastasis after GEM plus Nab-PTX Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2019 |
Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin- chitosan nanoparticles loading paclitaxel- cholesterol complex.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Chitosan; Cholesterol; Drug Liberation; Endocytosis; Injections, Intralesional; Lecithins; Liver; Lung; Mice, Inbred BALB C; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Particle Size; Polysorbates; Survival Analysis; Treatment Outcome | 2019 |
Poly(d,l-lactide)/polyethylene glycol micro/nanofiber mats as paclitaxel-eluting carriers: preparation and characterization of fibers, in vitro drug release, antiangiogenic activity and tumor recurrence prevention.
Topics: Angiogenesis Inhibitors; Animals; Body Weight; Cell Death; Cell Line, Tumor; Cell Survival; Chickens; Drug Carriers; Drug Liberation; Humans; Male; Mice, Nude; Nanofibers; Neoplasm Recurrence, Local; Paclitaxel; Polyesters; Polyethylene Glycols; Temperature; Tumor Burden; X-Ray Diffraction | 2019 |
Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow; Bone Marrow Cells; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cohort Studies; Datasets as Topic; Disease Models, Animal; Drug Resistance, Neoplasm; F-Box-WD Repeat-Containing Protein 7; Female; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Kaplan-Meier Estimate; MCF-7 Cells; Mice; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2019 |
Radiation-induced angiosarcoma of the parotid gland after postoperative radiotherapy for hypopharyngeal carcinoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Diagnosis, Differential; Female; Hemangiosarcoma; Humans; Hypopharyngeal Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Paclitaxel; Parotid Neoplasms; Radiotherapy, Adjuvant; Squamous Cell Carcinoma of Head and Neck | 2019 |
Platinum sensitive carcinoma of ovary relapsed as pericardial effusion with cardiac tamponade.
Topics: Carboplatin; Cardiac Tamponade; Echocardiography; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Phthalazines; Piperazines; Thoracotomy; Treatment Outcome | 2019 |
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Longitudinal Studies; Models, Statistical; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2019 |
Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Retrospective Studies; Stomach Neoplasms | 2019 |
Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply.
Topics: Azepines; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines | 2019 |
Paclitaxel and Alisertib in Recurrent Ovarian Cancer.
Topics: Azepines; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines | 2019 |
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nivolumab; Oxonic Acid; Paclitaxel; Palliative Care; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Failure | 2020 |
[A Case of Boderline Resectable Pancreatic Cancer Curatively Resected after Chemotherapy with Gemcitabine and Nab-Paclitaxel].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2019 |
[Questionnaire Survey of Secondary Chemotherapy for Gastric Cancer in the Yamaguchi Prefecture].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Paclitaxel; Practice Patterns, Physicians'; Stomach Neoplasms; Surveys and Questionnaires | 2019 |
[Efficacy and Safety of Paclitaxel plus Ramucirumab Therapy for Unresectable or Recurrent Gastric Cancer].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2019 |
[Effect of Hypoalbuminemia on Severe Neutropenia Induced by Paclitaxel Monotherapy and Paclitaxel plus Ramucirumab Combination Therapy in Patients with Gastric Cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Hypoalbuminemia; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2019 |
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult | 2019 |
Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2019 |
Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Combinations; Drug Delivery Systems; Female; Glioblastoma; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Mice, Nude; Neoplasm Recurrence, Local; Paclitaxel; Temozolomide | 2019 |
Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Follow-Up Studies; Humans; Immunologic Factors; Immunotherapy; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Programmed Cell Death 1 Receptor; Retroperitoneal Neoplasms; Treatment Outcome | 2019 |
Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; CD8-Positive T-Lymphocytes; Cohort Studies; Cyclophosphamide; Dendritic Cells; Female; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Lymphocytes, Tumor-Infiltrating; Middle Aged; Mitoxantrone; Monocytes; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Thiotepa; Vinblastine | 2019 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Blotting, Western; Carboplatin; Cystadenocarcinoma, Serous; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Microfilament Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 2013 |
First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: a retrospective analysis of patients treated at Brazilian National Cancer Institute.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Brazil; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms; Young Adult | 2013 |
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors | 2013 |
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2013 |
Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Care; Prospective Studies; Radiotherapy Dosage; Republic of Korea; Survival Rate; Uterine Cervical Neoplasms | 2013 |
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
Comparison of clinical efficacy of three different neoadjuvant approaches (chemotherapy combined vaginal intracavitary irradiation, neoadjuvant chemotherapy alone or radiotherapy) combined with surgery for patients with stage Ib2 and IIa2 cervical cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Body Mass Index; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Postoperative Complications; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vincristine | 2013 |
Gemcitabine with paclitaxel therapy against mesocolic leiomyosarcoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Leiomyosarcoma; Male; Mesocolon; Neoplasm Recurrence, Local; Paclitaxel; Prognosis | 2013 |
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Radiotherapy, Intensity-Modulated; Survival Rate; Tumor Burden | 2014 |
Impact of treatment strategies on local control and survival in uterine carcinosarcomas in Turkey.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carboplatin; Carcinosarcoma; Cross-Linking Reagents; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Turkey; Uterine Neoplasms | 2013 |
Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel | 2013 |
Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Doxorubicin; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Prognosis; Retrospective Studies; Time Factors | 2013 |
Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2013 |
CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.
Topics: AC133 Antigen; Animals; Antibodies, Immobilized; Antigens, CD; Antineoplastic Agents, Phytogenic; Breast; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Peptides | 2013 |
Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Treatment Outcome | 2013 |
[A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
Topics: Adenocarcinoma; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Survival Rate | 2013 |
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Female; Gene Expression; Hormone Antagonists; Humans; Immediate-Early Proteins; Mice; Mice, SCID; Mifepristone; Neoplasm Recurrence, Local; Neoplasm Transplantation; Paclitaxel; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Receptors, Estrogen; Receptors, Glucocorticoid; Signal Transduction; Transplantation, Heterologous; Triple Negative Breast Neoplasms | 2013 |
The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Risk Factors; Survival Rate | 2013 |
The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: survey among Dutch gynecologists and medical oncologists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Data Collection; Female; Gynecology; Humans; Medical Oncology; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Surveys and Questionnaires | 2013 |
Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Ifosfamide; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
[Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer].
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2013 |
Differential effects of drugs targeting cancer stem cell (CSC) and non-CSC populations on lung primary tumors and metastasis.
Topics: Aldehyde Dehydrogenase; Animals; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Flow Cytometry; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Paclitaxel; Pyrans; Real-Time Polymerase Chain Reaction; Receptors, CXCR4; SOXB1 Transcription Factors | 2013 |
[Efficacy of postoperative simple chemotherapy and concurrent chemoradiotherapy in FIGO stage IB2-IIB cervical cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hysterectomy; Ifosfamide; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Uterine Cervical Neoplasms | 2013 |
LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Immunohistochemistry; MCF-7 Cells; Mice; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; RNA, Small Interfering; Tumor Suppressor Proteins | 2014 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2013 |
Detection of recurrence in a surveillance program for epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Odds Ratio; Paclitaxel; Patient Admission; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2014 |
A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prospective Studies; ROC Curve; Survival Analysis; Treatment Outcome | 2014 |
The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model.
Topics: Aged; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 4; Membrane Glycoproteins; Mice; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Paclitaxel; Paracrine Communication; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Triple Negative Breast Neoplasms | 2015 |
Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Esophageal Neoplasms; Female; Follow-Up Studies; Hematologic Tests; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies | 2014 |
Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumo
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cisplatin; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Transplantation, Autologous; Young Adult | 2014 |
Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Humans; Ifosfamide; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Paclitaxel | 2015 |
Rare case of syndrome of inappropriate antidiuretic hormone as the initial presentation of ovarian cancer recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Inappropriate ADH Syndrome; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Tomography, X-Ray Computed | 2015 |
Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Female; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.
Topics: Aged; Aged, 80 and over; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Conformal; Sensitivity and Specificity; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
[Outcomes of treatment of 32 cases of advanced or relapsed post-surgery pulmonary sarcomatoid carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Period; Survival Rate | 2014 |
Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Scalp; Skin Neoplasms; Taxoids; Treatment Outcome | 2014 |
Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Surgical Wound Dehiscence; Thoracic Wall | 2015 |
Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Janus Kinase 2; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Thoracic Neoplasms | 2014 |
Efficacy of taxane-based regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids | 2014 |
Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Consolidation Chemotherapy; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2015 |
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2015 |
Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytodiagnosis; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2015 |
Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Deoxyglucose; Electron Transport Chain Complex Proteins; Female; Glycolysis; Humans; Hyaluronan Receptors; I-kappa B Kinase; Maintenance Chemotherapy; Mice; Mitochondria; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Ovarian Neoplasms; Oxidative Phosphorylation; Paclitaxel; Phenotype; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Ifosfamide; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Para-Aortic Bodies; Pelvic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Polyurethanes; Retrospective Studies; Treatment Outcome | 2014 |
Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Ifosfamide; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2015 |
Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
Topics: Animals; Antibodies; Antigens, CD; Antineoplastic Agents, Phytogenic; Breast Neoplasms; CD4 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Humans; Immunoglobulin Fab Fragments; Immunotherapy; Interferon-gamma; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Recurrence, Local; Oligodeoxyribonucleotides; Orexin Receptors; Paclitaxel; Spleen; Transplantation, Homologous; Tumor Necrosis Factor-alpha | 2014 |
The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Irinotecan; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retroperitoneal Neoplasms; Retrospective Studies; Salvage Therapy; Seminoma; Testicular Neoplasms; Treatment Outcome; Young Adult | 2016 |
Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Paclitaxel; Protein Kinase Inhibitors; Radiation Tolerance; Radiotherapy Dosage; Sex Factors; Vinblastine; Vinorelbine | 2015 |
Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy | 2015 |
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy -a retrospective evaluation. .
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Young Adult | 2014 |
Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tertiary Care Centers | 2014 |
Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Failure | 2015 |
Significance of SALL4 as a drug‑resistant factor in lung cancer.
Topics: Aged; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Paclitaxel; RNA, Small Interfering; Transcription Factors | 2015 |
The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Prognosis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Remission Induction; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2015 |
Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Cisplatin; Disease Progression; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome | 2015 |
Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms | 2015 |
Prolonged response to aflibercept in ovarian cancer relapse: a case report.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Lymphatic Metastasis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Transitional Cell; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Neutrophils; Paclitaxel; Platinum; Vascular Endothelial Growth Factor A | 2015 |
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Small Cell Lung Carcinoma | 2015 |
Targeting the microenvironment in ovarian cancer.
Topics: Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides | 2015 |
Prolonged remission of recurrent cervical carcinoma following paclitaxel and carboplatin chemotherapy with paclitaxel maintenance chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Uterine Cervical Neoplasms | 2015 |
Intensive systemic chemotherapy is effective against recurrent malignant Brenner tumor of the ovary: An analysis of 10 cases within a single center.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brenner Tumor; Carboplatin; Cisplatin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2015 |
Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Gynecologic Surgical Procedures; Humans; Kaplan-Meier Estimate; Laparoscopy; Laparotomy; Length of Stay; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Operative Time; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Population Surveillance; Prospective Studies; Sample Size; Treatment Outcome | 2015 |
Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 2015 |
Nasopharyngeal carcinoma with bone marrow metastasis: positive response to weekly paclitaxel chemotherapy.
Topics: Bone Marrow Neoplasms; Carcinoma; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Risk Factors | 2015 |
Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Obesity; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2015 |
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids | 2015 |
Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Humans; Hyperthermia, Induced; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Catheter Obstruction; Catheters, Indwelling; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Diarrhea; Disease-Free Survival; Female; Humans; Ileus; Infusions, Parenteral; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Risk Factors; Survival Rate; Vomiting; Withholding Treatment | 2015 |
Chemotherapy as Adjuvant Treatment for Intermediate-High Risk Early-Stage Endometrial Cancer: A Pilot Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Prospective Studies; Young Adult | 2015 |
Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
Topics: Abdominal Neoplasms; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Chemoradiotherapy; Cohort Studies; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pelvic Neoplasms; Radiotherapy; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Survival Rate; Tumor Burden | 2017 |
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; United States | 2015 |
Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Proteins; Retrospective Studies; ROC Curve; Survival Rate; Vinblastine; Vinorelbine; WAP Four-Disulfide Core Domain Protein 2 | 2016 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Endometrioid; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitals, University; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Remission Induction; Thailand; Treatment Outcome | 2015 |
A case of recurrent squamous cell carcinoma of the vulva successfully treated by combination therapy with cetuximab and paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Vulvar Neoplasms | 2016 |
Clinical implications for cediranib in advanced cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines; Uterine Cervical Neoplasms | 2015 |
[Clinical efficacy of paclitaxel combined with S-1 in the prevention and treatment of gastric cancer with peritoneal metastasis].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2015 |
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; China; Cisplatin; Class I Phosphatidylinositol 3-Kinases; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genomics; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured | 2016 |
Proteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts.
Topics: Antineoplastic Agents; Antioxidants; Autophagy; Azathioprine; Biomarkers, Tumor; Cell Differentiation; Cells, Cultured; Cellular Senescence; Disease-Free Survival; Fibroblasts; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Proteomics; Stress, Physiological; Tumor Microenvironment | 2015 |
Recurrent Penile Squamous Cell Carcinoma Successfully Treated With Cetuximab, Chemotherapy, and Radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Penile Neoplasms; Radiography; Skin Neoplasms; Treatment Outcome | 2016 |
Efficacy of paclitaxel in the treatment of Kaposi sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Sarcoma, Kaposi; Treatment Outcome | 2015 |
The problem with platinum.
Topics: Antineoplastic Agents; Bevacizumab; Carboplatin; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Tamoxifen | 2015 |
Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cytoreduction Surgical Procedures; Female; Hospitals, High-Volume; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2016 |
Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
Topics: Adenoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; M Phase Cell Cycle Checkpoints; Membrane Proteins; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Tumor Stem Cell Assay | 2016 |
Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Selection; Radiotherapy Dosage; Vinblastine; Vinorelbine | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Systemic Therapy of Endometrial (Uterine) Cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Progestins; Singapore; Sirolimus; Tamoxifen | 2015 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
A Rare Case of Intra-Endometrial Leiomyoma of Uterus Simulating Degenerated Submucosal Leiomyoma Accompanied by a Large Sertoli-Leydig Cell Tumor.
Topics: Adenomyosis; Carboplatin; Female; Humans; Laparoscopy; Leiomyoma; Male; Menorrhagia; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Sertoli-Leydig Cell Tumor; Treatment Outcome; Uterine Neoplasms | 2016 |
A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Prospective Studies; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome; Young Adult | 2016 |
Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Quality of Life; Salvage Therapy; Urologic Neoplasms; Urothelium | 2016 |
ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Resistance, Neoplasm; Epigenomics; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Promoter Regions, Genetic; Survival Rate; Tumor Cells, Cultured | 2016 |
Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Tertiary Care Centers; Thailand; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Adenocarcinoma of the ampulla of Vater metastasising into the right ventricle.
Topics: Adenocarcinoma; Adult; Albumins; Ampulla of Vater; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Neoplasms; Heart Ventricles; Humans; Neoplasm Recurrence, Local; Paclitaxel | 2016 |
Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models | 2016 |
Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Genital Neoplasms, Male; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Retrospective Studies; Risk Assessment; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cohort Studies; Cytoreduction Surgical Procedures; Epirubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2016 |
A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prognosis; Re-Irradiation; Treatment Outcome | 2016 |
A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Humans; Italy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Surveys and Questionnaires | 2016 |
Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab; Treatment Outcome | 2017 |
Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured | 2016 |
Paraaortic node recurrence 25 years after removal of epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Remission Induction; Treatment Outcome | 2016 |
Inactivation of transforming growth factor-β-activated kinase 1 promotes taxol efficacy in ovarian cancer cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Female; Gene Knockdown Techniques; Humans; MAP Kinase Kinase Kinases; Mice; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Treatment Outcome; Xenograft Model Antitumor Assays; Zearalenone | 2016 |
Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Esophagus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2017 |
Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab | 2016 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Young Adult | 2017 |
[Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cost-Benefit Analysis; Female; Fluorouracil; Health Care Costs; Humans; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Otorhinolaryngologic Neoplasms; Paclitaxel; Prognosis; Treatment Outcome | 2017 |
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2017 |
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Retrospective Studies | 2017 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cohort Studies; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies | 2017 |
Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Ginsenosides; Humans; Neoplasm Recurrence, Local; NF-kappa B; Paclitaxel; Panax; Signal Transduction; Triple Negative Breast Neoplasms | 2017 |
The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Proteins; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Paclitaxel; Signal Transduction | 2017 |
[Adjuvant chemotherapy for breast cancer and targeted therapies].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab | 2008 |
FDG positron emission tomography imaging of drug-induced pneumonitis.
Topics: Aged; Anxiety Disorders; Brain Neoplasms; Breast Neoplasms; Dibenzothiazepines; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pneumonia; Positron-Emission Tomography; Quetiapine Fumarate; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2008 |
Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Survival Rate; Uterine Neoplasms | 2008 |
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Preoperative Care; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan | 2008 |
[Comparative study of different chemotherapy approaches for advanced epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phlebitis; Retrospective Studies; Treatment Outcome | 2008 |
[Treatment of advanced penile cancer. Do we need new methods for chemotherapy?].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Disease Progression; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Palliative Care; Penile Neoplasms | 2008 |
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Disease-Free Survival; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Uterine Neoplasms | 2008 |
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Facial Neoplasms; Female; Hemangiosarcoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Scalp; Skin Neoplasms; Soft Tissue Neoplasms; Young Adult | 2008 |
[Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids | 2008 |
Ovarian cancer: front-line standard treatment in 2008.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2008 |
[A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed; Trastuzumab; Treatment Failure | 2008 |
Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Skin Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2008 |
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Tubulin | 2009 |
[Combination chemotherapy with paclitaxel and carboplatin (TC therapy) for endometrial cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel | 2008 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; Humans; Mastectomy, Modified Radical; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab | 2009 |
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Phosphorylation; Polymerase Chain Reaction; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Retrospective Studies; Trastuzumab | 2009 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes | 2009 |
[Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Retrospective Studies; Survival Analysis; Treatment Outcome | 2008 |
Complete response of recurrent squamous cell carcinoma of the lung: dose the dose matter?
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel; Tomography, X-Ray Computed | 2009 |
[Recurrence of skin and lymph nodes from asynchronous breast cancer successfully treated with paclitaxel and toremifene therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lymphatic Metastasis; Mastectomy, Radical; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Toremifene; Ultrasonography | 2008 |
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Cystadenocarcinoma, Serous; Disease Progression; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Neoplasms | 2009 |
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Cystadenocarcinoma, Serous; Feasibility Studies; Female; Humans; Injections, Intraperitoneal; Intraoperative Care; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Treatment Outcome | 2009 |
Systemic therapy developments and their effects regarding the current concept of recurrent ovarian carcinoma as a chronic disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chronic Disease; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2009 |
Response to paclitaxel in a radiotherapy-induced breast angiosarcoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Hemangiosarcoma; Humans; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Paclitaxel; Treatment Outcome | 2009 |
The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salvage Therapy; Uterine Cervical Neoplasms | 2009 |
Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Female; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2009 |
Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Metaplasia; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2009 |
Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel | 2009 |
Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies | 2009 |
Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2009 |
Third S. S. Ratnam memorial lecture 2007. Ovarian cancer: Is there hope for women?
Topics: Adult; CA-125 Antigen; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Laparoscopy; Mass Screening; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Ultrasonography | 2009 |
[Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Topotecan | 2009 |
Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovariectomy; Paclitaxel; Radiotherapy, Adjuvant; Treatment Outcome | 2009 |
Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cheek; Cranial Nerve Neoplasms; Facial Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Trigeminal Nerve Diseases | 2009 |
[Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery].
Topics: Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Paclitaxel; Splenectomy; Stomach Neoplasms; Tegafur | 2009 |
Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Genes, BRCA1; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel; Platinum Compounds | 2009 |
The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Pulmonary Diffusing Capacity; Radiotherapy Dosage; Retrospective Studies | 2009 |
Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 2009 |
Metastatic uterine cervical cancer originating in the lung: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoproteins; CA-125 Antigen; Carboplatin; Female; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Nuclear Proteins; Paclitaxel; Pulmonary Surfactant-Associated Proteins; Thyroglobulin; Thyroid Nuclear Factor 1; Tomography, X-Ray Computed; Transcription Factors; Uterine Cervical Neoplasms | 2009 |
The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2009 |
The impact of hospital type on the efficacy of chemotherapy treatment in ovarian cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cyclophosphamide; Female; Hospitals; Humans; Medical Oncology; Middle Aged; Neoplasm Recurrence, Local; Netherlands; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome; Workforce | 2009 |
Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2009 |
Pemetrexed-induced pneumonitis: a case report.
Topics: Adrenal Cortex Hormones; Aged; Anti-Infective Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Ciprofloxacin; Cisplatin; Drug Hypersensitivity; Drug Therapy, Combination; Dyspnea; Erythema; Glutamates; Guanine; Humans; Lung; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pneumonia; Pulmonary Fibrosis; Recovery of Function; Solitary Pulmonary Nodule | 2009 |
Beyond platinum for metastatic and recurrent carcinoma of the cervix.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Otorhinolaryngologic Neoplasms; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant; Survival Analysis | 2009 |
The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Adhesion; Cisplatin; Comparative Genomic Hybridization; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Paclitaxel; Poly(ADP-ribose) Polymerases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
ABC transporter gene expression in benign and malignant ovarian tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Carboplatin; Cyclophosphamide; Cystadenoma; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Multidrug Resistance-Associated Protein 2; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; ROC Curve; Up-Regulation | 2010 |
[First line chemotherapy of advanced epithelial ovarian cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic | 2009 |
Prevention of local tumor recurrence following surgery using low-dose chemotherapeutic polymer films.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Paclitaxel; Polymers; Tumor Cells, Cultured; Wound Healing | 2010 |
[Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Remission Induction; Retrospective Studies; Survival Rate | 2009 |
Long-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy.
Topics: Adenocarcinoma, Follicular; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Thyroid Neoplasms | 2009 |
[Advanced lung cancer with mediastinal lymph node metastasis and recurrence of brain metastasis completely responsive to combination chemotherapy and gamma knife radiosurgery--a case report].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinum; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiosurgery | 2009 |
[A case of advanced gastric cancer treated with S-1 and S-1/paclitaxel showing complete response twice].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cardia; Drug Combinations; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2009 |
[A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
Topics: Antimetabolites, Antineoplastic; Carnitine O-Palmitoyltransferase; Drug Combinations; Duodenal Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Tegafur | 2009 |
Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2010 |
Increased paclitaxel resistance in recurrent epithelial ovarian cancer: analysis of metachronous tumors.
Topics: Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Time Factors | 2010 |
Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Tumor Lysis Syndrome | 2010 |
The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Synergism; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Salvage Therapy; Topotecan; Uterine Cervical Neoplasms | 2010 |
[Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2010 |
Intraperitoneal chemotherapy for advanced ovarian and peritoneal cancers in patients following interval debulking surgery or primary cytoreductive surgery: Tom Baker Cancer Centre experience from 2006 to 2009.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2010 |
Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Radiation-Sensitizing Agents; Salvage Therapy; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome | 2011 |
Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Risk Factors; Survival Rate; Uterine Cervical Neoplasms | 2010 |
[Application of ATP-tumor chemosensitivity assay in primary epithelial ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2010 |
Failure rates and patterns of recurrence in patients with resected N1 non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Retrospective Studies; SEER Program; Treatment Failure; Vinblastine; Vinorelbine | 2011 |
Chemotherapy: A new standard combination for recurrent ovarian cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Survival Rate | 2010 |
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Doxorubicin; Expert Testimony; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prevalence; Randomized Controlled Trials as Topic; Survival Analysis; Survival Rate; Treatment Outcome | 2010 |
[A case of recurrent invasive thymic cancer showing a stable disease to carboplatin plus paclitaxel].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Thymus Neoplasms | 2010 |
Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Feasibility Studies; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Small Cell Lung Carcinoma; Vascular Endothelial Growth Factor A | 2010 |
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Orotate Phosphoribosyltransferase; Oxonic Acid; Paclitaxel; ROC Curve; Tegafur; Thymidylate Synthase; Treatment Outcome | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan | 2010 |
[Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
Topics: Adult; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Treatment Failure | 2010 |
[Clinical characteristics and prognosis of large cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Tumor Burden; Young Adult | 2010 |
[The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Receptors, Estrogen; Toremifene | 2010 |
[A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Duodenal Neoplasms; Duodenal Obstruction; Duodenum; Fluorouracil; Gastrectomy; Humans; Intestinal Atresia; Jaundice, Obstructive; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms | 2010 |
[A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Lymph Node Excision; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Tamoxifen; Taxoids; Tegafur; Trastuzumab; Uracil | 2010 |
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Introns; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Survival Rate | 2011 |
Primary squamous cell carcinoma associated with ovarian endometriosis: a case report and literature review.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Endometriosis; Female; Humans; Laparotomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms | 2011 |
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2011 |
Complementary and alternative medicine use among women receiving chemotherapy for ovarian cancer in 2 patient populations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Carcinoma, Ovarian Epithelial; Complementary Therapies; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Surveys and Questionnaires; Survival Rate; Treatment Outcome; United Kingdom | 2011 |
Paclitaxel-loaded expansile nanoparticles delay local recurrence in a heterotopic murine non-small cell lung cancer model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Female; Lung Neoplasms; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Time Factors | 2011 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2010 |
Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; Ifosfamide; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2011 |
Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Gamma Rays; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Preservation; Paclitaxel; Remission Induction; Survival Rate; Treatment Outcome | 2011 |
Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Chemoradiotherapy; Cranial Irradiation; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies | 2011 |
Fertility sparing surgery for ovarian tumors in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Chemotherapy, Adjuvant; Child; Cisplatin; Etoposide; Female; Fertility Preservation; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Ovarian Cysts; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prospective Studies; Young Adult | 2012 |
Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2012 |
Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2011 |
Paclitaxel-eluting polymer film reduces locoregional recurrence and improves survival in a recurrent sarcoma model: a novel investigational therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chondrosarcoma; Disease Models, Animal; Female; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Polymers; Survival Rate; Therapies, Investigational; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Endometrial cancer: prognostic significance of risk classification based on pre-intraoperative findings.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovariectomy; Paclitaxel; Predictive Value of Tests; Preoperative Care; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Salpingectomy | 2012 |
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salivary Gland Neoplasms; Treatment Outcome | 2011 |
Expression of ERCC1, p53, and class III β-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endonucleases; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Tubulin; Tumor Suppressor Protein p53 | 2011 |
Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Floxuridine; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Tegafur | 2011 |
Paclitaxel-ifosfamide-carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours.
Topics: Adnexal Diseases; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Mixed Tumor, Malignant; Mixed Tumor, Mullerian; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2011 |
Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Seminoma; Testicular Neoplasms; Young Adult | 2011 |
Role of adjuvant chemotherapy in patients with early stage uterine papillary serous cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; California; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Neoplasms | 2011 |
Measurement of the minimum apparent diffusion coefficient (ADCmin) of the primary tumor and CA125 are predictive of disease recurrence for patients with endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Membrane Proteins; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Predictive Value of Tests | 2012 |
Bevacizumab-induced laryngeal necrosis.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Laryngeal Diseases; Lung Neoplasms; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Tubulin Modulators | 2012 |
A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Trastuzumab; Treatment Outcome | 2011 |
Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Intestinal Obstruction; Lymph Node Excision; Lymphedema; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Complications; Radiotherapy, Adjuvant; Retrospective Studies; Uterine Cervical Neoplasms | 2012 |
Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pennsylvania; Registries; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Taxoids | 2011 |
Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retreatment; Retrospective Studies; Thrombocytopenia | 2012 |
Pneumocystis jiroveci Pneumonia in an Atypical Host.
Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bevacizumab; Breast Neoplasms; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Dexamethasone; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Paclitaxel; Pneumocystis carinii; Pneumonia, Pneumocystis; Quinazolines; Trimethoprim, Sulfamethoxazole Drug Combination | 2012 |
Extraperitoneal metastases from recurrent ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Cisplatin; Combined Modality Therapy; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome | 2012 |
Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain; Breast Neoplasms; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2012 |
A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Risk Factors; Treatment Outcome; Young Adult | 2011 |
Comparison of limited-volume perioperative high-dose-rate brachytherapy and wide-field external irradiation in resected head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy Dosage | 2012 |
[Comparison of pegylated liposomal doxorubicin and carboplatin with paclitaxel and carboplatin in the treatment of patients with late recurrence of platin-sensitive ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2011 |
Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes.
Topics: Carcinoma; Catheter Ablation; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies | 2012 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
Angiosarcoma of the breast: a difficult surgical challenge.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2012 |
Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2012 |
Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors; Stomach Neoplasms; Survival Rate; Young Adult | 2012 |
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome | 2012 |
Carbon ion radiotherapy for recurrent malignant transformation from mature cystic teratoma of the ovary.
Topics: Aged; Antineoplastic Agents; Carbon Radioisotopes; Carboplatin; Cell Transformation, Neoplastic; Combined Modality Therapy; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Paclitaxel; Teratoma; Treatment Outcome | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Uterine carcinosarcoma associated with pelvic radiotherapy for sacral chordoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Chemotherapy, Adjuvant; Chordoma; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Paclitaxel; Sacrococcygeal Region; Uterine Neoplasms | 2012 |
Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Failure | 2012 |
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2012 |
Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cervix Uteri; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Female; Fertility Preservation; Follow-Up Studies; Humans; Ifosfamide; Laparoscopy; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvis; Prospective Studies; Uterine Cervical Neoplasms | 2012 |
Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2012 |
Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2012 |
Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: a Cooperation Task Force (CTF) Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Postoperative Complications; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Failure; Uterine Neoplasms; Young Adult | 2012 |
Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.
Topics: Adenocarcinoma; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Receptor, Notch3; Receptors, Notch; Retrospective Studies; RNA, Small Interfering; Survival Rate | 2012 |
The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2013 |
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nomograms; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Sensitivity and Specificity; Treatment Outcome | 2013 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Protein Structure, Tertiary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Drug Carriers; Ethanol; Female; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasm Recurrence, Local; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Polyethylene Glycols | 2013 |
[Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Routes; Evidence-Based Medicine; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2012 |
Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome | 2013 |
Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doxorubicin; Endometrial Neoplasms; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2012 |
Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Confidence Intervals; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Netherlands; Paclitaxel; Proportional Hazards Models; Radiotherapy Dosage; Survival Rate; Tumor Burden | 2013 |
Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2013 |
Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carboplatin; Cyclophosphamide; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Practice Patterns, Physicians'; Survival; Treatment Outcome | 2013 |
Predicting response of ovarian cancer to paclitaxel treatment based on trend analysis of serum CA125.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Reference Values | 2002 |
[Ureteroplasty using the appendix: apropos of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendix; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Laparotomy; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrostomy, Percutaneous; Paclitaxel; Prostatectomy; Retroperitoneal Space; Transplantation, Autologous; Transplantation, Heterotopic; Ureter; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Impact of maintenance chemotherapy on disease-free survival in patients with stage Ic and II epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Japan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2002 |
New paclitaxel-cisplatin based chemotherapy regimen for advanced stage, recurrent, or refractory neuroblastoma-preliminary report.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Fatal Outcome; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Paclitaxel; Retroperitoneal Neoplasms; Salvage Therapy; Taxoids | 2003 |
[A case of effective weekly paclitaxel administration for metastatic gastric cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms | 2002 |
Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Fatal Outcome; Floxuridine; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Borderline mucinous tumour with mural nodule of signet ring adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Cystadenocarcinoma, Mucinous; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2002 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma; Cell Division; Cell Nucleus; Clone Cells; Drug Resistance, Neoplasm; Female; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects | 2003 |
[Weekly administration of paclitaxel and pirarubicine for recurrent breast cancer].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel | 2003 |
[Two cases of effective weekly paclitaxel administration and concurrent radiation for metastatic breast cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents | 2003 |
[Weekly paclitaxel infusion in patients with recurrent ovarian cancer--a pilot study].
Topics: Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2003 |
Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Evaluation; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pleurodynia, Epidemic; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome; Women's Health | 2003 |
Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Tomography, X-Ray Computed | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplatin; Dacarbazine; Ependymoma; Female; Glioblastoma; Glioma; Humans; Image Enhancement; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Oligodendroglioma; Paclitaxel; Procarbazine; Sensitivity and Specificity; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2003 |
The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Carboplatin; Complementary Therapies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Treatment Outcome; Vitamins | 2003 |
Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Disease Progression; Female; Follow-Up Studies; Genes, BRCA1; Genetic Predisposition to Disease; Humans; Incidence; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Poland; Prospective Studies; Risk Factors; Sampling Studies; Survival Analysis; Treatment Failure | 2003 |
[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Floxuridine; Humans; Leukopenia; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects | 2003 |
Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurologic Examination; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 2003 |
Chemotherapy for recurrent ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2003 |
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure | 2003 |
[Clinical study of weekly paclitaxel administration for metastatic breast cancer based on time to progression (TTP) and survival].
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2003 |
Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Shiga Toxins; Survival Analysis; Treatment Failure; Uterine Neoplasms | 2003 |
Extraorbital sebaceous carcinoma with rapidly developing visceral metastases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Fatal Outcome; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Orbit; Paclitaxel; Sebaceous Gland Neoplasms; Taxoids; Viscera | 2003 |
Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas--a possibility for organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Hypopharyngeal Neoplasms; Imaging, Three-Dimensional; Laryngeal Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiation Injuries; Tomography, X-Ray Computed | 2003 |
First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Second-Look Surgery | 2003 |
[Lung adenocarcinoma with multiple pulmonary metastases completely responsive to combination chemotherapy with carboplatin and weekly paclitaxel--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction | 2003 |
Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Renal Dialysis; Renal Insufficiency; Time Factors | 2003 |
[Cryoimmunological therapy with local injection of OK-432 against advance or recurrent breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cryosurgery; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Injections, Intralesional; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Taxoids | 2003 |
Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2003 |
Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Endometrioid; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Reoperation | 2004 |
Recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
[Recurrent ovarian cancer with cancer peritonitis treated with weekly paclitaxel infusion--a clinicopharmacological study].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritonitis; Quality of Life | 2004 |
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2004 |
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.
Topics: Adolescent; Adult; Aged; Deoxycytidine; Drug Costs; Drug Resistance, Neoplasm; Female; Gemcitabine; Health Care Costs; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Topotecan | 2004 |
Weekly taxanes--a leap forward or a minute progress?
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
[Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Paclitaxel; Survival Rate; Thrombocytopenia; Urologic Neoplasms | 2004 |
[Complete response of gastric cancer with interaorticocaval lymph node recurrence to weekly administration of paclitaxel--a case report].
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Stomach Neoplasms | 2004 |
[Weekly administration of paclitaxel as a second-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Edema; Feasibility Studies; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[Weekly paclitaxel therapy for locoregional lymph node recurrence of estrogen-receptor-negative breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptors, Estrogen | 2004 |
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Survival Rate | 2004 |
[Retrospective analysis on efficacy and toxicity of paclitaxel-containing treatments in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Vomiting, Anticipatory | 2004 |
[Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneum; Survival Rate | 2004 |
Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitors; Biotransformation; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Gene Expression Profiling; Genes, p53; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Paclitaxel; Pharmacogenetics; Tamoxifen; Trastuzumab | 2004 |
[Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ranitidine; Stomach Neoplasms; Survival Analysis | 2004 |
[Metastatic breast cancer treated with trastuzumab and paclitaxel--a case report with clinically complete response].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2004 |
Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Glossectomy; Humans; Intraoperative Care; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Radiotherapy Dosage; Radiotherapy, Adjuvant; Recovery of Function; Tongue Neoplasms; Treatment Outcome | 2004 |
[Radical peritonectomy in 37 patients with stage II and III ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Female; Humans; Infusions, Parenteral; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneum; Retrospective Studies; Second-Look Surgery; Treatment Outcome | 2004 |
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genes, MDR; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Topotecan | 2004 |
Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prognosis; Retrospective Studies; Topotecan | 2004 |
Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Patient Selection; Quality of Life; Treatment Outcome; Uterine Neoplasms | 2004 |
[Efficacy of combined paclitaxel and oxaliplatin therapy in patients with pretreated advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Treatment Outcome | 2004 |
Weekly paclitaxel combined with local hyperthermia in the therapy of breast cancer locally recurrent after mastectomy--a pilot experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Carcinoma, Ductal; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperthermia, Induced; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Palliative Care; Treatment Outcome | 2004 |
Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Neoplasms | 2004 |
Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Salvage Therapy; Uterine Neoplasms | 2004 |
Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Endometrioid; Cell Line, Tumor; Cisplatin; Cystinyl Aminopeptidase; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Transfection | 2004 |
Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Evaluation; Female; Follow-Up Studies; Humans; Life Tables; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
[Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2004 |
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Hydronephrosis; Lymph Node Excision; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Pyridines; Stents; Stomach Neoplasms; Tegafur | 2004 |
[Two cases of advanced and recurrent gastric cancer treated with the combination of chemotherapy and radiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Analysis | 2005 |
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Topotecan; Xenograft Model Antitumor Assays | 2005 |
[A case of effective weekly paclitaxel administration for gastric cancer recurrence with carcinomatous pericarditis].
Topics: Aged; Antineoplastic Agents, Phytogenic; Drainage; Drug Administration Schedule; Gastrectomy; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Pericardial Effusion; Pericarditis; Stomach Neoplasms | 2005 |
[Comparative clinical appraisal of the effectiveness and tolerability of paclitaxel-LANCE and taxol in combination chemotherapy for recurrences and platinum-refractory ovarian carcinoma].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Treatment Outcome | 2004 |
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate | 2005 |
Tumour response to paclitaxel in an adult with relapsed nephroblastoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Female; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Wilms Tumor | 2005 |
Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2005 |
Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2005 |
A pilot study of weekly paclitaxel administration for patients with relapsed cervical cancer after heavy medication.
Topics: Agranulocytosis; Alopecia; Antiemetics; Antineoplastic Agents, Phytogenic; Cimetidine; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hysterectomy; Infusions, Intravenous; Lymph Node Excision; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Survival Rate; Uterine Cervical Neoplasms | 2005 |
Weekly paclitaxel may improve locoregional recurrence by decreasing interstitial fluid pressure in operable node-positive breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Extracellular Fluid; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pressure | 2006 |
Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Outcome | 2005 |
A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Platinum Compounds; Taxoids; Treatment Outcome | 2005 |
Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2005 |
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Laryngoscopy; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Palliative Care; Radiation Dosage; Radiation Injuries; Remission Induction; Retrospective Studies; Salvage Therapy; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Osteoradionecrosis; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2005 |
Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Multivariate Analysis; Necrosis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Prospective Studies; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Inflammation; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Reoperation; Trastuzumab; Treatment Outcome | 2005 |
Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Carriers; Drug Delivery Systems; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Survival Analysis | 2005 |
Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Uterine Neoplasms | 2005 |
Paclitaxel in relapsed high risk anthracycline treated breast cancer patients.
Topics: Adult; Anthracyclines; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Premenopause; Remission Induction; Retrospective Studies; Risk Assessment; Survival Analysis | 2005 |
Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Esophageal Diseases; Follow-Up Studies; Humans; Lung Diseases; Lung Neoplasms; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis | 2005 |
[Experience of weekly paclitaxel combined with orally administered doxifluridine therapy for advanced and recurrent gastric cancer-preliminary study].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Feasibility Studies; Female; Floxuridine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms | 2005 |
Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study," by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Paclitaxel | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Drug Hypersensitivity; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2006 |
Induction redux: once more with taxanes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Remission Induction; Treatment Outcome | 2005 |
Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chronic Disease; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Secondary Prevention; Topotecan | 2005 |
Syndrome of inappropriate secretion of anti-diuretic hormone following carboplatin-paclitaxel administration in a patient with recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Diagnosis, Differential; Female; Humans; Inappropriate ADH Syndrome; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2005 |
[Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[Two patients of recurrent breast cancer with carcinomatous pleurisy well controlled pleural effusion].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drainage; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Pleural Effusion, Malignant; Pleurisy | 2005 |
[A paclitaxel-resistant case of recurrent breast cancer responded to combination therapy of capecitabine and trastuzumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lung; Lymphatic Metastasis; Lymphatic System; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab | 2005 |
Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clavicle; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Survival Analysis | 2006 |
p16 gene alterations in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; Female; Gene Expression Regulation, Neoplastic; Genes, p16; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2006 |
[A case of recurrent gastric cancer with improvement of obstructive symptoms caused by carcinomatous peritonitis and prolonged survival by chemotherapy with combined use of Paclitaxel and 5-FU].
Topics: Adenocarcinoma, Scirrhous; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Gastrectomy; Humans; Ileus; Male; Neoplasm Recurrence, Local; Paclitaxel; Pancreaticoduodenectomy; Parenteral Nutrition, Home Total; Peritonitis; Stomach Neoplasms | 2006 |
Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Taxoids | 2006 |
[Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Floxuridine; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2006 |
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Analysis | 2006 |
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2006 |
Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Physical Examination | 2006 |
Treatment options for patients with recurrent ovarian cancer: a review of 54 cases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Reoperation; Survival Rate | 2006 |
[Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2006 |
The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Topics: CA-125 Antigen; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan; Treatment Outcome | 2005 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Primary chemotherapy-associated effect of second-line chemotherapy on survival of patients with advanced ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Analysis | 2006 |
Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Ascitic Fluid; Combined Modality Therapy; Dependovirus; Drug Resistance, Neoplasm; Endostatins; Female; Gene Expression; Genetic Therapy; Genetic Vectors; Inhibitor of Apoptosis Proteins; Injections, Intraperitoneal; Mice; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Survival Rate; Survivin; Vascular Endothelial Growth Factor A | 2007 |
[Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
Topics: Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan | 2008 |
Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2007 |
Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cisplatin; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; RNA, Messenger | 2006 |
Cerebral and parotid metachronous metastases from an ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Anticonvulsants; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Parotid Neoplasms; Supratentorial Neoplasms; Topotecan | 2006 |
[Metastatic lung tumor from uterine leiomyosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Female; Humans; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pneumonectomy; Uterine Neoplasms | 2006 |
[A case of complete remission of carcinomatous ascites refractory for TS-1 monotherapy treated with TS-1 plus paclitaxel combined therapy for gastric cancer].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-19-9 Antigen; Female; Gastrectomy; Humans; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2007 |
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids | 2007 |
Effective combination chemotherapy of carboplatin and paclitaxel in the treatment of a recurrent small-cell lung cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2007 |
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2007 |
Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Uterine Cervical Neoplasms | 2007 |
Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinosarcoma; Disease-Free Survival; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; North Carolina; Paclitaxel; Pilot Projects; Treatment Outcome; Utah; Uterine Cervical Neoplasms | 2007 |
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Ki-67 Antigen; Lymph Node Excision; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-bcl-2; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Tumor Suppressor Protein p53 | 2007 |
Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Fatal Outcome; Female; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Ovariectomy; Paclitaxel; Uterine Cervical Neoplasms | 2007 |
Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1.
Topics: Abdominal Neoplasms; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Japan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Silicates; Stomach Neoplasms; Survival Analysis; Time Factors; Titanium; Treatment Outcome; Tumor Burden | 2007 |
The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2007 |
Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Facial Paralysis; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Receptor, ErbB-2; Retrospective Studies; Salivary Gland Neoplasms; Trastuzumab | 2007 |
Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Melanoma-Specific Antigens; Neoplasm Proteins; Neoplasm Recurrence, Local; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Stomach Neoplasms; Taxoids; Transfection | 2007 |
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Clinical Trials as Topic; Disease-Free Survival; Endpoint Determination; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Remission Induction; Retrospective Studies | 2007 |
Weekly paclitaxel in the treatment of recurrent ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome | 2007 |
Clearance of recurrent, classical Kaposi's sarcoma using multiple paclitaxel treatments.
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Sarcoma, Kaposi; Skin Neoplasms | 2007 |
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Costs; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Uterine Neoplasms | 2008 |
Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Dactinomycin; Etoposide; Female; Humans; Hydatidiform Mole; Korea; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Prospective Studies; Registries; Retrospective Studies; Risk Factors; Salvage Therapy; Severity of Illness Index; Uterine Neoplasms | 2007 |
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Membrane; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2 | 2008 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2007 |
Carbon beam therapy in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy | 2008 |
Carcinoma erysipeloides from ovarian clear-cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Female; Gynecologic Surgical Procedures; Humans; Lower Extremity; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Skin Neoplasms | 2007 |
Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Rectal Neoplasms | 2008 |
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Dialysis, Continuous Ambulatory; Renal Insufficiency; Treatment Outcome | 2008 |
Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2008 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Monitoring; Estrogens; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Progesterone; Prognosis; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2008 |
[Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Female; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Particle Accelerators; Radiotherapy Dosage; Radiotherapy, High-Energy; Remission Induction; Survival Rate; Thrombocytopenia | 2007 |
Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Gestational Trophoblastic Disease; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis | 2008 |
Prevention of local tumor growth with paclitaxel-loaded microspheres.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Feasibility Studies; Female; Lung Neoplasms; Mice; Mice, Inbred C57BL; Microspheres; Neoplasm Recurrence, Local; Paclitaxel | 2008 |
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols | 2008 |
A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polymerase Chain Reaction; Repressor Proteins; Retrospective Studies | 2008 |
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Admission; Pilot Projects; Radiotherapy, Adjuvant | 1995 |
Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Analysis; Treatment Outcome | 1996 |
Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 1996 |
CA 125: a misleading tumor marker?
Topics: Antineoplastic Agents, Phytogenic; CA-125 Antigen; Cystadenocarcinoma, Mucinous; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 1996 |
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pleural Effusion; Taxoids; Treatment Failure; Treatment Outcome | 1997 |
Paclitaxel as a radiosensitizer combined with fractionated stereotactic radiotherapy in the treatment of recurrent medulloblastoma.
Topics: Adult; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Humans; Magnetic Resonance Imaging; Male; Medulloblastoma; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Quality of Life; Radiation-Sensitizing Agents; Radiosurgery; Radiotherapy Dosage | 1997 |
Paclitaxel in recurrent ovarian cancer: better upfront? Comments on: A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study. Eur J Cancer 1977, 33, 160-163.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 1997 |
Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Radiosurgery | 1998 |
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Treatment Outcome | 1998 |
[Breast cancer with liver metastasis responsive to docetaxel: case report].
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1998 |
Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy--experience in an Asian population.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Singapore; Time Factors; Treatment Outcome | 1998 |
Pharmacokinetics of paclitaxel in an anephric patient.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Child; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Renal Dialysis; Wilms Tumor | 1999 |
The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Survival Rate; Uterine Neoplasms | 1999 |
[Pharmacological study of weekly docetaxel in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report].
Topics: Aged; Alendronate; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
[Administration of docetaxel in cases of recurrent breast carcinoma with malignant pleural effusion controlled by intrapleural administration of OK-432].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Pleura; Pleural Effusion, Malignant; Taxoids | 1999 |
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2000 |
Nail alterations secondary to pactitaxel [corrected] therapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Lymphatic Metastasis; Middle Aged; Nail Diseases; Neoplasm Recurrence, Local; Paclitaxel; Pigmentation Disorders | 2000 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Leucovorin; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Taxoids | 2000 |
Microlaparoscopy: a new approach to the reassessment of ovarian cancer patients.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biopsy; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Laparoscopy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Reoperation; Videotape Recording | 2000 |
Chemotherapy in recurrent epithelial ovarian cancer (EOC): an analysis of prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2000 |
Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate | 2000 |
Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2000 |
Malignant craniopharyngioma.
Topics: Adult; Carboplatin; Carcinoma, Squamous Cell; Craniopharyngioma; Female; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Paclitaxel; Pituitary Neoplasms; Radiotherapy; Tumor Suppressor Protein p53 | 2000 |
Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2000 |
Successful treatment of two patients with recurrent endometrial cancer by weekly paclitaxel.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2000 |
Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
Induction chemotherapy for locoregional lung cancer using paclitaxel combination. A preliminary report.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2000 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Fatal Outcome; Follow-Up Studies; Gallium Radioisotopes; Gastrectomy; Gastroscopy; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Methylprednisolone; Mitoxantrone; Neoplasm Recurrence, Local; Paclitaxel; Prednisone; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Adjuvant; Stomach Neoplasms; Stomach Ulcer; Tomography, X-Ray Computed; Vincristine | 2001 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
[Two cases of advanced and metastatic breast cancers treated by docetaxel in combination with intra-arterial infusion of adriamycin].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2001 |
Recurrent metastatic fallopian tube carcinoma in pregnancy.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Salvage Therapy | 2001 |
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prospective Studies; Topotecan | 2001 |
Quality of life in ovarian cancer patients receiving chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2001 |
[Weekly paclitaxel and cisplatin in recurrent ovarian cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2001 |
Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cystadenocarcinoma, Papillary; Female; Humans; Kidney Failure, Chronic; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Renal Dialysis; Thrombocytopenia | 2001 |
Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Convection; Diffusion; Drug Delivery Systems; Glioma; Humans; Magnetic Resonance Imaging; Monitoring, Physiologic; Neoplasm Recurrence, Local; Paclitaxel; Water | 2001 |
A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoembryonic Antigen; Carcinoma, Squamous Cell; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2001 |
Glassy cell carcinoma of the uterine cervix: combination chemotherapy with paclitaxel and carboplatin in recurrent tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cell Nucleolus; Cell Nucleus; Combined Modality Therapy; Cytoplasm; Fallopian Tubes; Female; Humans; Hysterectomy; Lymph Node Excision; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Ovariectomy; Paclitaxel; Radiotherapy; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2001 |
[Two cases of effective weekly paclitaxel administration for metastatic breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2001 |
[Second-line chemotherapy with paclitaxel for ovarian cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2001 |
[Successful treatment of weekly paclitaxel for a patient with recurrent lung cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life | 2002 |
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Care Planning; Prospective Studies; Ultrasonography | 2001 |
Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Etoposide; Germinoma; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2001 |
Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Collagen; Cyclophosphamide; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Gels; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Taxoids | 2002 |
Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
Topics: Age Factors; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Topotecan | 2002 |
[Treatment of recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infusions, Parenteral; Lymph Node Excision; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovariectomy; Paclitaxel | 1992 |